Indolines as PROTAC Compounds

PROTAC molecules targeting PMS2 protein degradation offer a novel approach to treat MMR-deficient cancers by restoring MMR function and enhancing immune activation, addressing the limitations of current treatments.

JP2024541578AInactive Publication Date: 2024-11-08NEOPHORE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024531698
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-28
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for cancers with mismatch repair (MMR) deficiencies, such as Lynch syndrome and congenital mismatch repair disorder (CMMRD), are limited in efficacy due to the lack of targeted therapies that can effectively degrade the PMS2 protein, a critical component of the MMR pathway, which is essential for restoring anti-tumor immune responses.

Method used

Development of PROTAC molecules that specifically bind to and degrade the PMS2 protein, potentially combined with immunotherapeutic agents and DNA damage response pathway modulators, to restore MMR function and enhance immune activation against cancer cells.

Benefits of technology

The PROTAC molecules effectively reduce PMS2 protein levels, thereby enhancing anti-tumor immune responses and providing a therapeutic avenue for MMR-deficient cancers, including improved response to immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541578000001_ABST
    Figure 2024541578000001_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) that target PMS2, a component of DNA mismatch repair (MMR). [Formula 1] JPEG2024541578000101.jpg56170[where, R 2 , R 4 , R 6 , A1, A2, A4, L and Q are each as defined herein. The invention also relates to methods for the preparation of these compounds, pharmaceutical compositions containing them, and their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PMS2 is implicated.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] preface The present invention relates to several compounds that function as modulators of PMS2 protein activity. In particular, the compounds of the present invention can be used as binding agents for PMS2 protein and decomposing it. Thus, the compounds of the present invention can be used to treat diseases or conditions mediated, at least in part, by inappropriate PMS2 activity, such as cancer. The present invention further relates to the use of the compounds and pharmaceutical compositions containing them. [Background technology]

[0002] Cancer is caused by alterations in cell proliferation. What exactly causes cells to become malignant and grow in an uncontrolled and unregulated manner has been the focus of intensive research over the past few decades. Such research has identified the most important pathways and associated molecular targets that enable such malignancies.

[0003] Mismatch repair (MMR) is a highly conserved DNA repair pathway that plays a major role during DNA replication, repair, and recombination, as well as during meiosis in eukaryotes and immunoglobulin maturation / diversification in mammals. MMR promotes genome stability in all organisms by correcting DNA base mismatches and insertion / deletion (indel) loops that can occasionally occur during the normal DNA replication process. Base pair mismatches occur when an incorrect nucleotide is inserted into a newly synthesized DNA strand and circumvents the proofreading function of DNA polymerase. Indel loops commonly occur in association with microsatellites, which are highly polymorphic short, repetitive DNA sequences distributed throughout prokaryotic and eukaryotic genomes. Normally, in microsatellites, the template and primer strands are prone to slippage (dissociation and reannealing) during replication, which can generate loop structures and discordant numbers of repeat units between the template and newly synthesized strands.

[0004] DNA mismatch repair is a bidirectional excision and resynthesis system that initiates at a defined strand break on either the 3'- or 5'-side of the mismatch; the excision tract extends just beyond the mismatch. MMR can be divided into four steps: 1) mismatch recognition by MSH proteins; 2) recruitment of MLH / PMS proteins that link the mismatch recognition signal to the initiation site of the DNA strand break; 3) excision of the erroneous DNA strand; and 4) resynthesis of the excision gap using the remaining DNA strand as a template [1]. MMR is a highly conserved biological pathway. In humans, the MMR pathway is initiated by mismatch recognition by hMutSα (MSH2-MSH6) or hMutSβ (MSH2-MSH3). Binding of hMutSα or hMutSβ to the mismatch site leads to the recruitment of MutLα (MLH1-PMS2) to form a ternary complex whose protein-protein, protein-DNA interactions, and exonuclease activity are modulated by ATP / ADP cofactors. Proliferating cell nuclear antigen (PCNA) may play a role in recruiting MMR proteins to the vicinity of replication forks [1]. PCNA can also activate the latent endonuclease activity of eukaryotic MutLα proteins. After DNA cleavage, exonuclease 1 (EXO1) is recruited, which excises the newly synthesized DNA strand, and the DNA excision gap is resynthesized by DNA polymerase δ (Pol δ). If DNA resynthesis is complete, the remaining nick is ligated by DNA ligase, restoring double-strand integrity [2]. Consistent with this function, MMR is an important tumor suppressor pathway that reduces sporadic cancers by up to 40%. Furthermore, individuals with germline mutations in MMR genes develop a cancer predisposing state.

[0005] Lynch syndrome (LS, formerly named hereditary nonpolyposis colorectal cancer) is the most common cause of hereditary colorectal cancer (CRC), accounting for 2–5% of all cases. LS is also characterized by an increased risk of malignant lesions at several extracolonic sites, including the endometrium, ovaries, stomach, and small intestine, among others. [3] LS has an autosomal dominant inheritance pattern and is caused by germline mutations in the MMR genes MLH1, MSH2, MSH6, or PMS2. Gene expression from one wild-type allele is sufficient for adequate MMR activity until a second hit inactivates the wild-type allele, resulting in MMR deficiency.

[0006] Congenital mismatch repair disorder (CMMRD) syndromes are distinct childhood cancer predisposition syndromes that result from biallelic germline mutations in one of four MMR genes: MLH1, MSH2, MSH6, or PMS2. Patients can have homozygous biallelic alterations or heterozygous alterations in the MMR genes.

[0007] MMR-abnormal cancers are generally characterized by the accumulation of DNA mutations at a rate faster than normal cells and other tumors; for example, CMMRD tumors typically have a hypermutated phenotype (>250 substitution mutations / Mb) [4]. MMR deficiency also results in an increase or decrease in microsatellite repeat length, termed microsatellite instability (MSI). Cancers with greater than 40% microsatellite mutations (positive for two or more of five routinely tested microsatellite markers) are described as MSI-high (MSI-H). Tumors lacking MSI are microsatellite stable (MSS), while those with less than 40% microsatellite mutations (positive for one of the five markers indicating microsatellite instability) are MSI-low (MSI-L) [5]. MSI analysis is a widely used diagnostic biomarker for MMR-deficient tumors, and MSI status is associated with a high prevalence of frameshift (FS) mutations, which can occur due to insertions / deletions within coding microsatellites. In addition to altering downstream protein functions, FS creates new amino acid sequences that act as substrates for antigen processing and presentation [6], stimulating CD8+ T cell activation (class I) and CD4+ T cell "helper" function (class II).

[0008] Cancers with a higher number of neoantigens are more prone to immune surveillance and are more likely to respond to immunotherapy [7]; a higher neoantigen load is associated with higher total lymphocyte infiltration, TILs, memory T cells, and survival in colorectal cancer [8, 9]. This characteristic supports the rationale for immunotherapy-based therapeutic strategies [6]. Consistent with this concept, immune checkpoint inhibitors now represent an important therapeutic advance in the treatment of MMR-abnormal cancers. PD-1 inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have been approved by the US Food and Drug Administration (FDA) for patients with MMR-D or MSI-H metastatic CRC based on their significant survival benefit. The CTLA-4 inhibitor ipilimumab (Yervoy) has been approved for use in combination with nivolumab for the treatment of patients with MMR-D or MSI-H CRC previously treated with chemotherapy. Importantly, the FDA approved the use of pembrolizumab in MMR-D / MSI-H cancers, regardless of histological tumor type

[10] .

[0009] It is now accepted that clinical response to immune checkpoint inhibitors requires the presence of tumor neoantigens and the infiltration of T cells that recognize these neoantigens. Higher neoantigen burden is associated with a better response to CTLA-4 and PD-1 blockade in patients with melanoma and non-small cell lung cancer [11, 12, 13]. The number of neoantigens is associated with tumor mutational burden (TMB), and several large-scale studies have confirmed that high TMB correlates with enhanced checkpoint inhibitor response and improved overall survival in several tumor types, such as urothelial carcinoma

[14] , non-small cell lung cancer [15-18], and small cell lung cancer

[19] .

[0010] Germano et al. recently proposed that MMR inactivation by silencing MLH1 increases TMB, resulting in a "dynamic mutational profile" and persistent neoantigen regeneration in vitro and in vivo. This induces immune surveillance and leads to tumor growth control, particularly in combination with immune checkpoint blockade in mouse models

[20] . Similar results have been observed with silencing MSH2

[21] .

[0011] Guan et al. and Lu et al. reported that MLH1 deficiency leads to cytosolic DNA release, activation of the cGAS-STING pathway, and IFN-β production. Guan et al. demonstrated that loss of MLH1 leads to DNA hyperexcision, RPA depletion, chromosomal instability, and cytosolic DNA accumulation

[22] . Lu et al. reported that cytosolic DNA sensing by the cGAS-STING pathway contributes to the clinical benefit of immunotherapy in patients with MMR-deficient tumors

[23] . Together, these reports suggest that suppressing MMR activity can induce beneficial immune activation by activating the cGAS-STING pathway.

[0012] MLH1 and PMS2 generally form heterodimers; loss of the MLH1 protein typically results in the concomitant loss of the PMS2 protein, suggesting that one or both of the proteins may be essential for MMR function and cGAS / STING pathway regulation.

[0013] Thus, there is biological and clinical evidence that highlights the need for agents that target and degrade the PMS2 protein, a key component of DNA MMR, to restore anti-tumor immune responses.

[0014] Thus, the present invention provides PROTAC molecules that bind to and promote the degradation of the DNA MMR component PMS2, and provides methods for the treatment of cancer by using these PROTAC molecules, optionally in combination with immunotherapeutics, other DNA damage response pathway modulators and / or standard of care chemotherapeutics.

[0015] Outside of the cancer field, triplet repeat disorders include more than 30 human neurodegenerative and neuromuscular genetic disorders, such as Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar ataxias (SCAs). Such disorders are characterized by the expansion of simple repeats in genomic DNA. These unstable repeats are generally found in different regions of several genes, and their expansions can cause disease through various loss-of-function and gain-of-function pathways, for example, by interfering with the expression or characteristics of gene products or by affecting splicing or antisense regulation. Several mechanisms have been proposed to contribute to repeat instability, including errors during DNA replication, meiotic recombination, transcription, DNA repair, and chromatin remodeling, which can occur at various stages of the cell cycle. There is evidence that a functional MMR pathway is required to maintain the stability of microsatellite sequences: for example, Msh2- / - transgenic mice carrying a copy of human HD exon 1 (containing a CAG repeat) show a reduced expansion of the introduced (CAG)n repeat when compared to their Msh2+ / +HD exon 1 mouse counterparts

[24] .

[0016] Thus, there is a further need for compounds that target components of the DNA MMR process, including PMS2, for the treatment of triplet repeat disorders.The present invention was made with the foregoing in mind. (References) 1. Martin-Lopez, J.V. and R. Fishel, The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam Cancer, 2013. 12(2): p. 159-68. 2. Liu, D., G. Keijzers, and L.J. Rasmussen, DNA mismatch repair and its many roles in eukaryotic cells. Mutat Res, 2017. 773: p. 174-187. 3. Lynch, H.T., et al., Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet, 2009. 76(1): p. 1-18. 4. Shlien, A., et al., Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet, 2015. 47(3): p. 257-62 5. Sehgal, R., et al., Lynch syndrome: an updated review. Genes (Basel), 2014. 5(3): p. 497-507 6. Willis, J.A., et al., Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res, 2019. 7. Gubin, M.M. and R.D. Schreiber, CANCER. The odds of immunotherapy success.Science, 2015. 350(6257): p. 158-9. 8. Kloor, M. and M. von Knebel Doeberitz, The Immune Biology of Microsatellite-Unstable Cancer. Trends Cancer, 2016. 2(3): p. 121-133. 9. Giannakis, M., et al., Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.Cell Rep, 2016. 17(4): p. 1206. 10. Lemery, S., P. Keegan, and R. Pazdur, First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med, 2017. 377(15): p. 1409-1412. 11. Le, D.T., et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 2015. 372(26): p. 2509-20. 12. Rizvi, N.A., et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015. 348(6230): p. 124-8. 13. Van Allen, E.M., et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015. 350(6257): p. 207-211. 14. Rosenberg, J.E., et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet, 2016. 387(10031): p. 1909-20. 15. Hellmann, M.D., et al., Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 843-852 e4. 16. Rizvi, H., et al., Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol, 2018. 36(7): p. 633-641. 17. Carbone, D.P., et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 376(25): p. 2415-2426. 18. Hellmann, M.D., et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med, 2018. 378(22): p. 2093-2104. 19. Hellmann, M.D., et al., Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 853-861 e4. 20. Germano, G., et al., Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017. 552(7683): p. 116-120. 21. Mandal, R., et al., Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science, 2019. 364(6439): p. 485-491. 22. Guan J., et al., MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021, 39 (1), 109 - 121. 23. Lu, C., et al. DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell. 2021, 39 (1), 96 - 108. 24. Manley, K., et al., Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet, 1999. 23(4): p. 471-3. Summary of the Invention

[0017] According to a first aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0018] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0019] According to a further aspect of the present invention there is provided a method of reducing PMS2 protein levels and / or inhibiting PMS2 activity in vitro or in vivo, said method comprising the step of contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0020] According to a further aspect of the present invention there is provided a method of treating a disease or disorder in which PMS2 activity is associated in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0021] According to a further aspect of the present invention there is provided a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0022] According to a further aspect of the present invention there is provided a method of treating cancer in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0023] According to a further aspect of the present invention, there is provided a method of treating a triplet repeat disorder (e.g., Huntington's disease (HD), myotonic dystrophy type 1 (DM1), Fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar ataxias (SCAs)) in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0024] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.

[0025] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use as a medicament.

[0026] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative disorder.

[0027] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, for use in the treatment of cancer. In particular embodiments, the cancer is a human cancer.

[0028] According to a further aspect of the present invention, there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in treating a triplet repeat disorder. In particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0029] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in reducing PMS2 protein levels and / or inhibiting PMS2 activity.

[0030] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder associated with PMS2 activity.

[0031] According to a further aspect of the invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0032] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of cancer.

[0033] According to a further aspect of the present invention, there is provided use of a compound defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition defined herein, in the manufacture of a medicament for the treatment of a triplet repeat disorder. In particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0034] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for reducing PMS2 protein levels and / or inhibiting PMS2 activity.

[0035] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a disease or disorder associated with PMS2 activity.

[0036] According to a further aspect of the present invention there is provided a process for preparing a compound defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0037] According to a further aspect of the present invention there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by or obtained by or directly by a process for preparing a compound as defined herein.

[0038] According to a further aspect of the present invention there is provided a novel intermediate, as defined herein, suitable for use in any one of the synthetic methods described herein.

[0039] In the above-outlined aspects of the invention, the proliferative disorder is suitably cancer, and the cancer is suitably a human cancer. In particular, the compounds of the invention are useful in the treatment of any cancer in which mismatch repair inhibition and / or cGAS / STING pathway activation is beneficial. Any suitable cancer can be targeted (e.g., adenoid cystic carcinoma, adrenal tumor, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer (cholangiocarcinoma), Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, Carney complex, central nervous system tumor, cervical cancer, colorectal cancer, Cowden disease, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing's sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial non-VHL clear cell renal cell carcinoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor -GIST, germ cell tumors, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary mixed polyposis syndrome, hereditary pancreatitis, hereditary papillary renal cell carcinoma, juvenile polyposis syndrome, kidney cancer, lacrimal gland tumors, laryngeal and hypopharyngeal cancer, leukemia (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia Disease, hairy cell leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic T-cell lymphocytic leukemia, eosinophilic leukemia), Li-Fraumeni syndrome, liver cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (Hodgkin, non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, melanoma, meningioma, mesothelioma, multiple endocrine neoplasia type 1 and type 2, multiple myeloma, MUTYH (or MYH)-associated polyposis, myelodysplastic syndrome (MDS), nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine tumors (e.g., of the gastrointestinal tract, lung, or pancreas), neurofibromatosis types 1 and 2, nevoid basal cell carcinoma syndrome, oral or oropharyngeal cancer, osteosarcoma, ovarian / fallopian tube / peritoneal cancer, pancreatic cancer, parathyroid cancer, penile cancer, Peutz-Jeghers syndrome, pheochromocytoma, paraganglioma , pituitary tumors, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma (e.g., Kaposi's or soft tissue), skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, tuberous sclerosis, uterine cancer, vaginal cancer, von Hippel-Lindau syndrome, vulvar cancer, Waldenström's macroglobulinemia, Werner's syndrome, Wilms' tumor, and xeroderma pigmentosum). Particular cancers of interest include hematological cancers, such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma (BL), and angioimmunoblastic T-cell lymphoma (AITL)), leukemias (including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, endometrial cancer, gastro-esophageal cancer, neuroendocrine cancer, osteosarcoma, prostate cancer, pancreatic cancer, small intestine cancer, bladder cancer, rectal cancer, cholangiocarcinoma, CNS cancer, thyroid cancer, head and neck cancer, esophageal cancer, and ovarian cancer.

[0040] Features, including optional, suitable and preferred features, with respect to one aspect of the invention may also be features, including optional, suitable and preferred features, with respect to any other aspect of the invention. DETAILED DESCRIPTION OF THE INVENTION

[0041] definition Unless otherwise stated, the following terms used in the specification and claims have the following meanings, as set forth below.

[0042] References to "treating" or "treatment" shall be understood to include prevention as well as the alleviation of established symptoms of a condition. Thus, "treating" a situation, disorder, or condition or "treatment" of a situation, disorder, or condition includes (1) preventing or delaying the appearance of clinical symptoms of the situation, disorder, or condition occurring in a person who may be afflicted with or predisposed to the situation, disorder, or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the situation, disorder, or condition; (2) inhibiting the situation, disorder, or condition, i.e., (in the case of maintenance treatment) arresting, reducing, or delaying the onset of the disease or its recurrence or at least one of its clinical or subclinical symptoms; or (3) relieving or attenuating the disease, i.e., causing regression of the situation, disorder, or condition or at least one of its clinical or subclinical symptoms.

[0043] "Therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" varies depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated. For example, in humans or other mammals, it should be understood that a therapeutically effective amount can be determined experimentally in a laboratory or clinical setting, or the therapeutically effective amount can be the amount required by the guidelines of the U.S. Food and Drug Administration (FDA) or a corresponding foreign regulatory agency for a particular disease and subject to be treated. It should be understood that the determination of appropriate dosage forms, dosage amounts, and administration routes is within the level of ordinary skill in the pharmaceutical and medical fields.

[0044] As used herein, alone or in combination with one or more other terms, "subject(s)" and "patient(s)" refer to animals (e.g., mammals), particularly humans. Suitably, "subject(s)" and "patient(s)" may be non-human animals (e.g., livestock or household pets) or humans.

[0045] As used herein, alone or in combination with one or more other terms, "pharmaceutically acceptable" generally refers to a material that is chemically and / or physically compatible with other ingredients (e.g., as with respect to a formulation), and / or generally physiologically compatible with its recipient (e.g., a subject, etc.).

[0046] As used herein, the term "alkyl" includes straight-chain and branched-chain alkyl groups. Reference to a particular alkyl group, e.g., "propyl," is specific for the straight-chain version only, and reference to a particular branched-chain alkyl group, e.g., "isopropyl," is specific for the branched-chain version only. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl, and t-butyl.

[0047] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms.

[0048] An "alkylene" group is an alkyl group that is positioned between and serves to connect two other chemical groups. Thus, "(1-6C)alkylene" means a straight-chain saturated divalent hydrocarbon group of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon group of 3 to 6 carbon atoms, such as methylene (-CH-), the ethylene isomers (-CH(CH)- and -CHCH-), the propylene isomers (-CH(CH)CH-, -CH(CHCH)-, -C(CH)-, and -CHCHCH-), pentylene (-CHCHCHCHCHCH-), and the like.

[0049] The term "alkyenyl" refers to straight- and branched-chain alkyl groups containing two or more carbon atoms and at least one carbon-carbon double bond is present within the group. Examples of alkenyl groups include ethenyl, propenyl, and but-2,3-enyl, including all possible geometric (E / Z) isomers.

[0050] The term "alkynyl" refers to straight- and branched-chain alkyl groups containing two or more carbon atoms and at least one carbon-carbon triple bond is present within the group. Examples of alkynyl groups include acetylenyl and propynyl.

[0051] "(m-nC)cycloalkyl" means a saturated hydrocarbon ring system containing m to n carbon atoms. Exemplary cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and bicyclo[2.2.1]heptyl.

[0052] The term "alkoxy" refers to O-linked straight and branched chain alkyl groups. Examples of alkoxy groups include methoxy, ethoxy, and t-butoxy.

[0053] The term "haloalkyl," as used herein, refers to an alkyl group in which one or more hydrogen atoms have been replaced by halogen (e.g., fluorine) atoms. Examples of haloalkyl groups include -CHF, -CHF, and -CF.

[0054] The term "halo" or "halogeno" refers to fluoro, chloro, bromo and iodo, suitably fluoro, chloro and bromo, more suitably fluoro and chloro.

[0055] The terms "carbocyclyl," "carbocyclic," or "carbocycle" mean a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic carbon-containing ring system(s). Monocyclic carbocyclic rings contain about 3 to 12 (suitably 3 to 7) ring atoms. Bicyclic carbocyclic rings contain 6 to 17 member atoms, suitably 7 to 12 member atoms in the ring. Bicyclic carbocyclic ring(s) can be fused, spiro, or bridged ring systems. Examples of carbocyclic groups include cyclopropyl, cyclobutyl, cyclohexyl, cyclohexenyl, and spiro[3.3]heptanyl.

[0056] The terms "heterocyclyl," "heterocyclic," or "heterocycle" refer to a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain about 3 to 12 (suitably 3 to 7) ring atoms, with 1 to 5 (suitably 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur in the ring. Bicyclic heterocyclic rings contain 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic ring(s) can be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers, such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Nitrogen-containing heterocycles include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Typical sulfur-containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepin. Other heterocycles include dihydrooxathiolyl, tetrahydrooxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. In the case of sulfur-containing heterocycles, sulfur-oxide heterocycles containing SO or SO groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl, such as tetrahydrothienyl 1,1-dioxide and thiomorpholinyl 1,1-dioxide, etc. The heterocycle can contain one or two oxo (=O) or thioxo (=S) substituents.Suitable values ​​for a heterocyclyl group bearing one or two oxo (=O) or thioxo (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3- to 7-membered heterocyclyls containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl, or homopiperazinyl. As would be understood by one skilled in the art, any heterocycle can be linked to another group by any suitable atom, for example, a carbon or nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1-yl or morpholin-4-yl ring linked by the ring nitrogen.

[0057] The phrase "bridged ring system" means a ring system in which two rings share two or more atoms, see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, and quinuclidine.

[0058] By the term "spiro bicyclic ring system," we mean that the two ring systems share one common spiro carbon atom, i.e., the heterocyclic ring is linked to an additional carbocyclic or heterocyclic ring by a single common spiro carbon atom. Examples of spiro ring systems include 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7-azaspiro[3.5]nonane, and 2-oxa-6-azaspiro[3.5]nonane.

[0059] As used herein, alone or in combination with another term or terms, "aromatic" refers to monocyclic and polycyclic ring systems containing 4n+2 π-electrons, where n is an integer. Aromatic should be understood to refer to and include ring systems containing only carbon atoms (i.e., "aryl") as well as ring systems containing at least one heteroatom selected from N, O, or S (i.e., "heteroaromatic" or "heteroaryl"). Aromatic ring systems may be substituted or unsubstituted.

[0060] As used herein, alone or in combination with another term or terms, "non-aromatic" refers to a monocyclic or polycyclic ring system having at least one double bond that is not part of an extended conjugated π system. As used herein, non-aromatic refers to and includes ring systems containing only carbon atoms as well as ring systems containing at least one heteroatom selected from N, O, or S. Non-aromatic ring systems may be substituted or unsubstituted.

[0061] The term "heteroaryl" or "aromatic heterocycle" refers to an aromatic monocyclic, bicyclic, or polycyclic ring incorporating one or more (e.g., 1 to 4, particularly 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur. The term heteroaryl includes monovalent and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, more usually 5 to 10 ring members. A heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring, e.g., a 5- and 6-membered fused ring or a bicyclic structure formed from two 6-membered fused rings. Each ring can contain up to about four heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, a heteroaryl ring contains up to three heteroatoms, more usually up to two, e.g., a single heteroatom. In one embodiment, a heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl ring can be basic, as in the case of an imidazole or pyridine, or essentially non-basic, as in the case of an indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in a heteroaryl group, including any amino group substituents on the ring, will be fewer than five.

[0062] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolyl. nyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, and imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also encompasses partially aromatic bicyclic or polycyclic ring systems in which at least one ring is aromatic and one or more of the other ring(s) is non-aromatic, saturated or partially saturated, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of partially aromatic heteroaryl groups include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.

[0063] Examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl groups.

[0064] Examples of 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.

[0065] Bicyclic heteroaryl groups include, for example: a benzene ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a furan ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered aromatic heterocycle containing 1, 2, or 3 ring heteroatoms; and The group may be a group selected from a cyclopentyl ring fused to a 5- or 6-membered aromatic heterocycle containing 1, 2, or 3 ring heteroatoms.

[0066] Particular examples of bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring include, but are not limited to, benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl, and pyrazolopyridinyl groups.

[0067] Particular examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.

[0068] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. In a particular embodiment, the aryl is phenyl.

[0069] This specification also uses some compound terms to describe groups containing two or more functional groups. Such terms are understood by those skilled in the art. For example, (3-6C)cycloalkyl(m-nC)alkyl includes (m-nC)alkyl substituted with (3-6C)cycloalkyl.

[0070] The term "optionally substituted" refers to groups, structures, or molecules that are substituted and to groups, structures, or molecules that are not substituted. 1 "One / any CH, CH, CH group or heteroatom (i.e., NH) within the group is optionally substituted" means that R 1 Suitably, it means that one (any) of the hydrogen radicals of the group is replaced by the associated defined group.

[0071] When an optional substituent is selected from "one or more" groups, it is to be understood that this definition includes all substituents selected from one of the specified groups or substituents selected from two or more of the specified groups. In some embodiments, one or more refers to one, two, or three. In other embodiments, one or more refers to one or two. In particular embodiments, one or more refers to one.

[0072] The phrase "compounds of the invention" means, both generically and specifically, the compounds disclosed herein.

[0073] When used herein in connection with a measurable value, such as an amount or duration, "about" is meant to encompass a reasonable variation of the value, for example, allowing for experimental error in determining said value.

[0074] compound

[0075] In one aspect, the present invention provides a compound of structural formula (I), shown below: [ka] [In the formula, R 2 is hydrogen or fluoro; R 4is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl, (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl, wherein said (1-6C)alkyl is selected from the group consisting of one or more R 5a and the (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b each R 5a are independently selected from halogen or (1-4C)alkoxy; and each R 5b are independently selected from the group consisting of halogen, (1-4C) alkyl, and (1-4C) alkoxy; R 6 is a (1-6C)alkyl, (3-8C)cycloalkyl, or 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or a group having a structure according to formula (A) shown below: [ka] (In the formula, R 7 is hydrogen or (1-3C) alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; A1 is N, CH or CR 11 Selected from; A2 is N, CH or CR 12 Selected from; A4 is N, CH or CR 14 Selected from; provided that only one or two of A1, A2 or A4 may be N; R 11 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 11 is -(CHR o ) h -Z 11 (In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 , -NR 16 R 17 , -C(O)NR 16 R 17 or -NR 18 C(O)R 19 and; R 15 is (1-4C) alkyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-7C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-7C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j-[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 16 and R 17 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 6-membered heterocyclic ring; R 18 is hydrogen or (1-2C) alkyl; R 19 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-7C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R l is hydrogen or methyl, and k is 0 or 1; R 15 , R 16 , R 17 , R 18 Or R 19 or R 16 and R 17 Each of any rings formed when R are linked may contain one or more R a (optionally substituted with ); R 12 is fluoro; R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14is -(CHR k ) m -Z 14 (In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 6-membered heterocyclic ring; R 33is hydrogen or (1-2C) alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a (optionally substituted with ); Each R a are independently selected from the group consisting of oxo, halogen, cyano, hydroxy, or (1-4C)alkyl; L is a linker; Q is an E3 ubiquitin ligase-binding moiety, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0076] Certain compounds of the present invention include, for example, compounds of formula (I), or pharmaceutically acceptable salts, hydrates and / or solvates thereof, unless otherwise indicated, wherein R 2 , R 4 , R 6 Each of A1, A2, A4, L and Q, and any associated substituents, has any of the meanings defined above or in any of the following paragraphs (1) to (90): (1)R 2 is fluoro. (2)R 2is hydrogen. (3)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C)alkyl, (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl, wherein said (1-4C)alkyl is selected from the group consisting of one or more R 5a and the (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b optionally substituted with R 5a and R 5b are each as defined herein. (4)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C) alkyl, (3-5C) cycloalkyl and (3-5C) cycloalkyl(1-2C) alkyl, wherein said (1-4C) alkyl is selected from the group consisting of one, two or three R 5a and the (3-5C)cycloalkyl and (3-5C)cycloalkyl(1-2C)alkyl groups are optionally substituted with one, two or three R 5b optionally substituted by R 5a and R 5b are each as defined herein. (5)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C) alkyl, (3-5C) cycloalkyl and (3-5C) cycloalkyl(1C) alkyl, wherein said (1-4C) alkyl is selected from the group consisting of one, two or three R 5a and the (3-5C)cycloalkyl and (3-5C)cycloalkyl(1C)alkyl groups are optionally substituted with one, two or three R 5b optionally substituted by R 5a and R 5b are each as defined herein. (6)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C) alkyl and (3-5C) cycloalkyl, wherein said (1-4C) alkyl is selected from the group consisting of one or two R 5aand the (3-5C)cycloalkyl group is optionally substituted with one or two R 5b optionally substituted by R 5a and R 5b are each as defined herein. (7)R 4 is selected from the group consisting of hydrogen, fluoro, chloro, (1-4C)alkyl, cyclopropyl, and cyclobutyl, wherein said (1-4C)alkyl is selected from the group consisting of one R 5a and the cyclopropyl and cyclobutyl groups are optionally substituted with one R 5b optionally substituted by R 5a and R 5b are each as defined herein. (8)R 4 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, and cyclobutyl. (9)R 4 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl, and cyclobutyl. (10)R 4 is selected from the group consisting of hydrogen, methyl, ethyl and cyclopropyl. (11)R 4 is selected from the group consisting of hydrogen and methyl. (12)R 4 is methyl. (13)Each R 5a are independently selected from halogen or (1-3C)alkoxy. (14)Each R 5a is independently selected from fluoro, chloro or (1-2C)alkoxy. (15)Each R 5a is independently selected from fluoro, chloro or methoxy. (16)Each R 5b are independently selected from the group consisting of halogen, (1-3C)alkyl and (1-3C)alkoxy. (17)Each R 5bare independently selected from the group consisting of halogen, (1-2C) alkyl and (1-2C) alkoxy. (18)Each R 5b is independently selected from the group consisting of fluoro, chloro, (1-2C)alkyl and (1-2C)alkoxy. (19)Each R 5b is independently selected from the group consisting of fluoro, chloro, methyl and methoxy. (20)R 6 is a (1-6C)alkyl, (3-6C)cycloalkyl, or 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (21)R 6 is a (1-4C)alkyl or a 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (22)R 6 is a (1-3C)alkyl or a 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (23)R 6 is a 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (24)R 6 is a 5- or 6-membered heterocyclyl ring containing one heteroatom selected from O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (25)R 6 is tetrahydrofuran, tetrahydropyran, or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (26)R 6 is a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein. (27)R 7 is hydrogen or (1-2C) alkyl. (28)R 7 is hydrogen or methyl. (29)R 7 is hydrogen. (30)n is 2. (31)n is 1. (32)R 8 is (3-8C)cycloalkyl, aryl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is selected from one or more R 9 and each R 9 is as defined herein. (33)R 8 is (3-8C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is selected from one or more R 9 and each R 9 is as defined herein. (34)R 8 is (3-6C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is selected from one or more R 9 and each R 9 is as defined herein. (35)R 8 is a 5- or 6-membered cycloalkyl, phenyl, 5- or 6-membered heterocyclyl, or 6-membered heteroaryl, each of which is selected from one or more R 9 and each R 9 is as defined herein. (36)R 8 is cyclohexyl, phenyl, 6-membered heterocyclyl, or 6-membered heteroaryl, each of which is selected from one or more R 9 and each R 9 is as defined herein. (37)R 8 is cyclohexyl, phenyl, 6-membered heterocyclyl, or pyridyl, each of which may be selected from one or more R9 and each R 9 is as defined herein. (38)R 8 has the following structure: [ka] [In the formula, each R 9 is as defined herein]. (39)R 8 is cyclohexyl or phenyl. (40)Each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy. (41)Each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. (42)Each R 9 is independently selected from the group consisting of halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. (43)Each R 9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy. (44)Each R 9 is independently selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy. (45) A1 is CH or C R11 is selected from. (46) A1 is CH. (47) A2 is CH or C R12 is selected from. (48) A2 is CH. (49) A4 is CH or C R14 is selected from. (50) A4 is CH. (51) A1 is N, CH or CR 11 Selected from; A2 is N, CH or CR 12 Selected from; A4 is N, CH or CR 14 Selected from; However, only one of A1, A2 or A4 can be N. (52) A1 is N, CH or CR 11 Selected from; A2 is N, CH or CR 12 Selected from; A4 is selected from N or CH; However, only one of A1, A2 or A4 can be N. (53) A1 is selected from N or CH; A2 is N, CH or CR 12 Selected from; A4 is selected from N or CH; However, only one of A2, A3 or A4 can be N. (54) A1 is N, CH, or CR 11 Selected from; A2 is selected from N or CH; A4 is selected from N or CH; However, only one of A1, A2 or A4 can be N. (55) A1 is CH; A2 is CH; A4 is CH. (56) A1 is CH; A2 is CH or CR 12 and; A4 is CH. (57) A1 is CH or CR 11 Selected from; A2 is CH; A4 is CH. (58) A1 is CH; A2 is CH; A4 is CH or CR 14 is. (59) A1, A2, and A4 are all CH. (60)R 11 is selected from cyano, halo, or (1-2C)alkyl, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 , -NR 16 R 17 , -C(O)NR 16 R 17 or -NR 18 C(O)R 19 and; R 15 is (1-4C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-6C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-6C)cycloalkyl, -(CHR m )j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 16 and R 17 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 6-membered heterocyclic ring; R 18 is hydrogen or (1-2C) alkyl; R 19 is (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-6C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R l is hydrogen or methyl, and k is 0 or 1; R 15 , R 16 , R 17 , R 18 Or R 19 or R 16 and R 17 Each of any rings formed when R are linked may contain one or more R a optionally replaced by; R a is as defined anywhere herein. (61)R 11is selected from cyano, fluoro, chloro or (1-2C)alkyl, wherein any (1-2C)alkyl moiety is optionally substituted with one or more fluoro, chloro or (1-2C)alkoxy; or R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 , -NR 16 R 17 , -C(O)NR 16 R 17 or -NR 18 C(O)R 19 and; R 15 is (1-4C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-6C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 16 and R 17 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 6-membered heterocyclic ring; R 18 is hydrogen or (1-2C) alkyl; R 19 is (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, or -(CHR l ) k -(3-6C)cycloalkyl, and R l is hydrogen or methyl, and k is 0 or 1; R 15 , R 16 , R 17 , R 18 Or R 19 or R 16 and R 17 Each of any rings formed when R are linked may contain one or more R a optionally replaced by; R a is as defined anywhere herein. (62)R 11 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 , -NR 16 R17 , or -C(O)NR 16 R 17 and; R 15 is (1-4C) alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR n ) i -[4- to 6-membered heterocyclyl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C) alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR m ) j -[4- to 6-membered heterocyclyl]; R m is hydrogen or methyl, and j is 0 or 1; or R 16 and R 17 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 8-membered heterocyclic ring; R 15 , R 16 , R 17 or R 16 and R 17 Each of any rings formed when R are linked may contain one or more R a optionally replaced by; R a is as anywhere in the specification. (63)R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 , -NR 16 R 17 or -NR 18 C(O)R 19 and; R 15is (3-6C)cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 is hydrogen and R 17 is hydrogen, (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl], and R m is hydrogen or methyl, and j is 0 or 1; or R 16 and R 17 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 6-membered heterocyclic ring; R 18 is hydrogen or (1-2C) alkyl; R 19 is (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl or 5- or 6-membered heteroaryl; R 15 , R 16 , R 17 , R 18 Or R 19 or R 16 and R 17 Each of any rings formed when R are linked may contain one or more R a optionally replaced by; Ra is as defined anywhere herein. (64)R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 -OR 15 or -NR 16 R 17 and; R 15 is (3-6C)cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-6C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 16 is hydrogen and R 17 is hydrogen, (1-6C) alkyl, (3-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl], and R m is hydrogen or methyl, and j is 0 or 1; R 15 or R 17Each of the a optionally replaced by; R a is as defined anywhere herein. (65)R 11 is -(CHR o ) h -Z 11 [In the formula, R o is hydrogen; h is 0 or 1; Z 11 is -NR 16 R 17 and; R 16 is hydrogen and R 17 is (3-6C)cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl], and R m is hydrogen or methyl, and j is 0 or 1; R 17 is one or more R a optionally replaced by; R a is as defined anywhere herein. (66)R 12 is fluoro. (67)R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k )m -Z 14 [In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen or (1-2C) alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a optionally replaced by; R a is as defined anywhere herein. (68)R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 [In the formula, R k is hydrogen; m is 0 or 1; Z 12 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, -(CHR j ) o -(3-7C)cycloalkyl, or -(CHR j ) o -[4- to 6-membered heterocyclyl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, -(CHR i ) p -(3-7C)cycloalkyl, or -(CHR i ) p -[4- to 6-membered heterocyclyl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen or methyl; R 34 is (1-6C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, -(CHR h ) q -(3-7C)cycloalkyl, or -(CHR h ) q -[4- to 6-membered heterocyclyl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a optionally replaced by; R ais as defined anywhere herein. (69)R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 [In the formula, R k is hydrogen; m is 0 or 1; Z 12 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR j ) o -[4- to 6-membered heterocyclyl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR i ) p -[4- to 6-membered heterocyclyl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are linked so that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen; R 34is (1-6C) alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR h ) q -[4- to 6-membered heterocyclyl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a optionally replaced by; R a is as defined anywhere herein. (70)R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy. (71)Each R a is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, or (1-4C)alkyl. (72)Each R a is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, or (1-2C)alkyl. (73)Each R a is independently selected from the group consisting of oxo, chloro, fluoro, cyano, hydroxy, or (1-2C)alkyl. (74)Each R a is independently selected from the group consisting of oxo, chloro, fluoro, cyano, hydroxy, or methyl. (75) L is a linker containing 3–40 chain atoms. (76) L is a linker containing 5–30 chain atoms. (77) L is a linker containing 10–25 chain atoms. (78) L is a linker containing 13–23 chain atoms. (79) L is a group of the formula: -X L1 -A L1 -R L1 -X L2 -A L2 -X L3 -R L2 -A L3 -X L4 - * [ka] [In the formula, * represents the connection point with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-15C) alkylene, -(CH2) a1 -[O-CH2CH2] a2 -or-[O-CH2CH2] a2 -(CH2) a1 - and R L1 does not exist, or: [ka] (In the formula, Y L1 is CH or N; R L3 and R L4 is selected from H or methyl, or R L3 and R L4 are linked to form a piperidinyl or piperazinyl ring optionally substituted with halo; X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -You can choose from; or Y L1 If CH, then X L2-O-, NR XL2 , -C(O)-, -C(O)NR XL2 or -NR XL2 C(O)- can be selected from; R XL2 is hydrogen or methyl; A L2 is absent, or (1-15C) alkylene, -(CH2) a3 -[O-CH2CH2] a4 -or-[O-CH2CH2] a4 -(CH2) a3 - and X L3 is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: [ka] (In the formula, Y L2 and Y L3 are each independently CH or N; R L3 and R L4 is selected from H or methyl, or R L3 and R L4 are linked to form a piperidinyl or piperazinyl ring optionally substituted with halo; A L3 is absent, or (1-15C) alkylene, -(CH2) a5 -[O-CH2CH2] a6 -or-[O-CH2CH2] a6 -(CH2) a5 - and X L4 is absent, or -O-, -C(O)-, or -C(O)NR XL4 -or-NR XL4 C(O)- or (2-4C)alkynyl; R XL4is hydrogen or methyl; Integers a1, a3, and a5 are each independently 1 to 4; and the integers a2, a4, and a6 are each independently 1 to 7. (80) L is a group having the formula: -X L1 -A L1 -R L1 -X L2 -A L2 -X L3 -R L2 -A L3 -X L4- * [In the formula, * represents the connection point with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-10C) alkylene, -(CH2) a1 -[O-CH2CH2] a2 -or-[O-CH2CH2] a2 -(CH2) a1 - and R L1 does not exist, or: [ka] (In the formula, Y L1 is CH or N); X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -You can choose from; or Y L1 If CH, then X L2 -O-, NR XL2 , -C(O)-, -C(O)NR XL2 or -NRXL2 C(O)- can be selected from; R XL2 is hydrogen or methyl; A L2 is absent, or (1-10C) alkylene, -(CH2) a3 -[O-CH2CH2] a4 -or-[O-CH2CH2] a4 -(CH2) a3 - and X L3 is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: [ka] (In the formula, Y L2 and Y L3 are each independently CH or N; A L3 is absent, or (1-10C) alkylene, -(CH2) a5 -[O-CH2CH2] a6 -or-[O-CH2CH2] a6 -(CH2) a5 - and X L4 is absent, or -O-, -C(O)-, or -C(O)NR XL4 -or-NR XL4 C(O)- or (2-4C)alkynyl; R XL4 is hydrogen or methyl; Integers a1, a3, and a5 are each independently 1 to 3; and the integers a2, a4, and a6 are each independently 1 to 6. (81) L is a group having the formula: -X L1 -A L1 -R L1 -X L2-A L2 -X L3 -R L2 - * [In the formula, * represents the connection point with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-10C) alkylene, -(CH2) a1 -[O-CH2CH2] a2 -or-[O-CH2CH2] a2 -(CH2) a1 - and R L1 does not exist, or: [ka] (In the formula, Y L1 is CH or N); X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -You can choose from; or Y L1 If CH, then X L2 -O-, NR XL2 , -C(O)-, -C(O)NR XL2 or -NR XL2 C(O)- can be selected from; R XL2 is hydrogen or methyl; A L2 is absent, or (1-10C) alkylene, -(CH2) a3 -[O-CH2CH2] a4 -or-[O-CH2CH2] a4 -(CH2) a3 - and X L3is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: [ka] (In the formula, Y L2 and Y L3 are each independently CH or N; Integers a1 and a3 are each independently 1 to 3; and the integers a2 and a4 are each independently 1 to 6. (82) Q is a small molecule or peptide E3 ubiquitin ligase-binding moiety. (83) Q is a small molecule E3 ubiquitin ligase-binding moiety. (84)Q is: von Hippel-Lindau (VHL); cereblon, XIAP, E3A; MDM2; anaphase-promoting complex; EIBR5(EDDI); SOCS / BC-box / eloBC / CUL5 / RING; LNXp80; CBX4; CBLL1; HACE1; HECTD1; HECTD2; HECTD3; HECW1; HECW2; HERC1; HERC2; HERC3; HERC4; HUWE1; ITCH; NEDD4; NEDD4L; PPIL2; PRPF19; PIAS1; PIAS2; PIAS3; PIAS4; RANBP2; RNF4; RBX1; SMURF 1; SMURF2; STUB1; TOPORS; TRIP 12;UBE3A;UBE3B;UBE3C;UBE4A;UBE4B;UBOXS;UBR5;WWP1;WWP2;Parkin;A20 / TNFAIP3;AMFR / gp78;ARA54;Beta-TrCPl / BTRC;BRCA1;CBL;CHIP / STUB 1;E6;E6AP / UBE3A;F-box protein 15 / FBX015;FBXW7 / Cdc4;GR AIL / RNF 128;HOIP / RNF31;cIAP-l / HIAP-2;cIAP-2 / HIAP-l;cIAP(pan);ITCH / AIP4;KAP1;MARCH8, Mind Bomb 1 / MIB1;Mind Bomb 2 / MIB2;MuRF and an E3 ubiquitin ligase-binding moiety capable of binding an E3 ubiquitin ligase selected from the group consisting of: 1 / TRIM63; NDFIP1; NEDD4; NleL; Parkin; RNF2; RNF4; RNF8; RNF168; RNF43; SART1; Skp2; SMURF2; TRAF-1; TRAF-2; TRAF-3; TRAF-4; TRAF-5; TRAF-6; TRIMS; TRIM21; TRIM32; UBR5; and ZNRF3. (85) Q is an E3 ubiquitin ligase-binding moiety capable of binding an E3 ubiquitin ligase selected from the group consisting of: von Hippel-Lindau (VHL); or cereblon. (86)Q is the E3 ubiquitin ligase-binding moiety that can bind the E3 ubiquitin ligase of cereblon. (87) Q is selected from thalidomide, pomalidomide, lenalidomide, a VHL ligand, methyl-bestatin, or nutlin. (88) Q is selected from thalidomide, pomalidomide, lenalidomide, or a VHL ligand. (89)Q is: [ka] [ka] [In the formula, [ka] represents the connection point with L; R q is hydrogen or fluoro; R VHL is cyclopropyl optionally substituted with fluoro; X2 is selected from -CH2- or -C(O)-. (90)Q is: [ka] [ka] [In the formula, [ka] represents the connection point with L; R q is hydrogen or fluoro; R VHL is cyclopropyl optionally substituted with fluoro; X2 is selected from -CH2- or -C(O)-.

[0077] Appropriately, R 2 is as defined in numbered paragraph (1). Most suitably, R 2is as defined in numbered paragraph (2).

[0078] Appropriately, R 4 is as defined in any one of numbered paragraphs (5) to (12). More suitably, R 4 is as defined in any one of numbered paragraphs (8) to (12). Most suitably, R 4 is as defined in any one of numbered paragraphs (10) to (12).

[0079] Appropriately, R 5a is as defined in any one of numbered paragraphs (13) to (15). Most suitably, R 5a is as defined in numbered paragraph (14) or (15).

[0080] Appropriately, R 5b is as defined in any one of numbered paragraphs (16) to (19). Most suitably, R 5b is as defined in numbered paragraph (18) or (19).

[0081] Appropriately, R 6 is as defined in any one of numbered paragraphs (20) to (26). More suitably, R 6 is as defined in any one of numbered paragraphs (22) to (26). Most suitably, R 6 is as defined in any one of numbered paragraphs (24) to (26).

[0082] Appropriately, R 7 is as defined in any one of numbered paragraphs (27) to (29). Most suitably, R 7 is as defined in numbered paragraph (28) or (29).

[0083] Suitably, n is as defined in numbered paragraph (30) or (31). Most suitably, n is as defined in numbered paragraph (31).

[0084] Appropriately, R 8 is as defined in any one of numbered paragraphs (32) to (39). More suitably, R 8 is as defined in any one of numbered paragraphs (35) to (39). Most suitably, R 8 is as defined in any one of the numbered paragraphs (37) to (39).

[0085] Appropriately, R 9 is as defined in any one of numbered paragraphs (40) to (44). Most suitably, R 9 is as defined in numbered paragraph (43) or (44).

[0086] Suitably, A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59). More suitably, A1, A2 and A4 are as defined in any one of numbered paragraphs (55) to (59). Most suitably, A1, A2 and A4 are as defined in numbered paragraph (59).

[0087] Appropriately, R 11 is as defined in any one of numbered paragraphs (60) to (65). Most suitably, R 11 is as defined in any one of numbered paragraphs (63) to (65).

[0088] Appropriately, R 12 is as defined in numbered paragraph (66).

[0089] Appropriately, R14 is as defined in any one of numbered paragraphs (67) to (70). Most suitably, R 14 is as defined in numbered paragraph (69) or (70).

[0090] Appropriately, R a is as defined in any one of numbered paragraphs (71) to (74). Most suitably, R a is as defined in numbered paragraph (73) or (74).

[0091] Linker group L The linker, L, is a group that serves to connect Q to the rest of the molecule. Any suitable linker known in the PROTAC field may be used in the compounds of the present invention.

[0092] In one embodiment, the linker is a carbon chain optionally containing one, two, three, or more heteroatoms selected from N, O, and S. In one embodiment, the carbon chain contains only saturated chain carbon atoms. In another embodiment, the carbon chain optionally contains two or more unsaturated chain carbon atoms. In one embodiment, one or more chain carbon atoms in the carbon chain are optionally substituted with one or more substituents including, but not limited to, oxo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-3C)alkoxy, OH, halogen, deuterium, N(1-3C)alkyl, N[(1-3C)alkyl)]2, CN, (3-8C)cycloalkyl, heterocyclyl, phenyl, and heteroaryl.

[0093] In one embodiment, the linker comprises at least 5 chain atoms selected from C, O, N, and S atoms. In one embodiment, the linker comprises fewer than 40 chain atoms selected from C, O, N, and S atoms. In one embodiment, the linker comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 chain atoms selected from C, O, N, and S atoms. In one embodiment, the linker comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 chain atoms selected from C, O, N, and S atoms. In one embodiment, the linker comprises 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 chain atoms selected from C, O, N, and S atoms. In one embodiment, the linker comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 20, 21, 22, 23, 24, or 25 chain atoms selected from C, O, N, and S atoms.

[0094] It is understood that the term "chain atom" is understood to mean an atom that separates Q from the rest of the molecule (i.e., a bridging atom between Q and the rest of the molecule). It is understood that the number of bond lengths in the "chain atom" portion is n+1, where n is the number of "chain atoms." Thus, when L is as defined in numbered paragraph (75), the number of bond lengths can be envisioned to be between 4 and 41 bond lengths. It is understood that L can be defined in terms of "bond lengths" and "chain atoms."

[0095] In further embodiments, the linker group is selected from the group consisting of one or more of the following carbon atoms: -O-, -NH-, -N(CH3)-, CO, [ka] and each of the alkylene groups is a straight-chain alkylene group having 3 to 40, 5 to 30, 10 to 25, or 13 to 23 carbon atoms, each of which is substituted by a group independently selected from the group consisting of:

[0096] In further embodiments, the linker group is selected from the group consisting of one or more of the following carbon atoms: -O-, -NH-, -N(CH3)-, CO, [ka] and each of the alkylene groups is a straight-chain alkylene group having 3 to 40, 5 to 30, 10 to 25, or 13 to 23 carbon atoms, each of which is substituted by a group independently selected from the group consisting of:

[0097] In further embodiments, the linker group is one in which one or more carbon atoms are: -O-, -NH-, CO, [ka] and each of the alkylene groups is a straight-chain alkylene group having 3 to 40, 5 to 30, 10 to 25, or 13 to 23 carbon atoms, each of which is substituted by a group independently selected from the group consisting of:

[0098] Suitably, L is as defined in any one of numbered paragraphs (75) to (81). More suitably, L is as defined in any one of numbered paragraphs (77) to (81). Most suitably, L is as defined in any one of numbered paragraphs (79) to (81).

[0099] E3 ubiquitin ligase-binding domain Q The E3 ubiquitin ligase-binding moiety Q can be any suitable E3 ubiquitin ligase-binding moiety known in the art.

[0100] In one embodiment, Q is a small molecule or peptide E3 ubiquitin ligase-binding moiety. In a particular embodiment, Q is a small molecule E3 ubiquitin ligase-binding moiety.

[0101] Suitably, Q is as defined in any one of numbered paragraphs (82) to (90). More suitably, Q is as defined in any one of numbered paragraphs (84) to (90). Most suitably, Q is as defined in any one of numbered paragraphs (87) to (90).

[0102] In one particular group of compounds of the invention, the compound has formula II, I-II, I-III, I-IV, or IV (which are sub-definitions of formula I): [ka] [ka] [In the formula, R 4 , R 6 , A1, A2, A4, L, Q and any related subgroups are as defined in any of the numbered paragraphs appearing hereinabove], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0103] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0104] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (12); R 6 is as defined in any one of numbered paragraphs (22) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (55) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0105] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 6 is as defined in any one of numbered paragraphs (24) to (26); R 7 is as defined in any one of numbered paragraphs (27) to (29); n is as defined in numbered paragraph (30) or (31); R 8is as defined in any one of numbered paragraphs (32) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0106] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0107] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); R 11 is as defined in any one of numbered paragraphs (60) to (65); R 12 is as defined in numbered paragraph (66); R 14 is as defined in any one of numbered paragraphs (67) to (70); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0108] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0109] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0110] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0111] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 6 is as defined in any one of numbered paragraphs (24) to (26); R 7 is as defined in any one of numbered paragraphs (27) to (29); n is as defined in numbered paragraph (30) or (31); R 8 is as defined in any one of numbered paragraphs (32) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0112] In one embodiment of the compound of Formula II, I-II, I-III, I-IV or IV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0113] In one particular group of compounds of the invention, the compound has formula I-VI, I-VII, I-VIII, I-IX or IX (which are sub-definitions of formula I): [ka] [ka] [In the formula, R 6 , A1, A2, A4, L, Q and any related subgroups are as defined in any of the numbered paragraphs appearing hereinabove], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0114] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0115] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (22) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (55) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0116] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (24) to (26); R 7 is as defined in any one of numbered paragraphs (27) to (29); n is as defined in numbered paragraph (30) or (31); R 8 is as defined in any one of numbered paragraphs (32) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0117] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0118] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); R 11 is as defined in any one of numbered paragraphs (60) to (65); R 12 is as defined in numbered paragraph (66); R 14 is as defined in any one of numbered paragraphs (67) to (70); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0119] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0120] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0121] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (20) to (26); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0122] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in any one of numbered paragraphs (24) to (26); R 7 is as defined in any one of numbered paragraphs (27) to (29); n is as defined in numbered paragraph (30) or (31); R 8 is as defined in any one of numbered paragraphs (32) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0123] In one embodiment of the compound of Formula I-VI, I-VII, I-VIII, I-IX or IX, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0124] In one particular group of compounds of the invention, the compound has formula I-XI, I-XII, I-XIII, I-XIV or I-XV (which are sub-definitions of formula I): [ka] [ka] [In the formula, R 4, R 8 , A1, A2, A4, L, Q and any related subgroups are as defined in any of the numbered paragraphs appearing hereinabove], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0125] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 8 is as defined in any one of numbered paragraphs (32) to (39); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0126] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (12); R 8 is as defined in any one of numbered paragraphs (35) to (39); A1, A2 and A4 are as defined in any one of numbered paragraphs (55) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0127] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 8 is as defined in any one of numbered paragraphs (37) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0128] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 8is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0129] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 8 is as defined in any one of numbered paragraphs (32) to (39); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); R 11 is as defined in any one of numbered paragraphs (60) to (65); R 12 is as defined in numbered paragraph (66); R 14 is as defined in any one of numbered paragraphs (67) to (70); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0130] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 8 is as defined in any one of numbered paragraphs (32) to (39); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (75) to (81); Q is as defined in any one of numbered paragraphs (82) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0131] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 8 is as defined in any one of numbered paragraphs (32) to (39); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0132] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (3) to (12); R 8 is as defined in any one of numbered paragraphs (32) to (39); A1, A2 and A4 are as defined in any one of numbered paragraphs (51) to (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0133] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 8 is as defined in any one of numbered paragraphs (35) to (39); R 9 is as defined in any one of numbered paragraphs (40) to (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in any one of numbered paragraphs (77) to (81); Q is as defined in any one of numbered paragraphs (84) to (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0134] In one embodiment of the compound of Formula I-XI, I-XII, I-XIII, I-XIV or I-XV, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (10) to (12); R 8 is as defined in numbered paragraph (38) or (39); R 9 is as defined in numbered paragraph (43) or (44); A1, A2 and A4 are as defined in numbered paragraph (59); L is as defined in numbered paragraph (80) or (81); Q is as defined in numbered paragraph (89) or (90); All other groups are as defined in any of the numbered paragraphs appearing hereinabove.

[0135] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 2 is as defined in paragraph (2) above.

[0136] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (9) above.

[0137] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (10) above.

[0138] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (11) above.

[0139] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (12) above.

[0140] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (22) above.

[0141] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (23) above.

[0142] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (24) above.

[0143] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (25) above.

[0144] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above.

[0145] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (32) above.

[0146] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (28) above, n is as defined in paragraph (31) above, and R 8is as defined in paragraph (32) above.

[0147] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (29) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (32) above.

[0148] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (33) above.

[0149] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined above in paragraph (34).

[0150] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (35) above.

[0151] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (36) above.

[0152] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (37) above.

[0153] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (38) above.

[0154] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (39) above.

[0155] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2 and A4 are as defined in paragraph (51) above, and R 11 is as defined above in paragraph (60), and R 12 is as defined in paragraph (66) above, and R 14 is as defined in paragraph (67) above.

[0156] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2 and A4 are as defined in paragraph (52) above, and R 11 is as defined above in paragraph (60), and R 12 is as defined in paragraph (66) above.

[0157] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2 and A4 are as defined in paragraph (53) above, and R 12is as defined in paragraph (66) above.

[0158] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2 and A4 are as defined in paragraph (54) above, and R 11 is as defined above in paragraph (60).

[0159] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2 and A4 are as defined in paragraph (59) above.

[0160] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (75) above.

[0161] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (76) above.

[0162] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (77) above.

[0163] In one embodiment of a compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (78) above.

[0164] In one embodiment of a compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (79) above.

[0165] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (80) above.

[0166] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, L is as defined in paragraph (81) above.

[0167] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined in paragraph (82) above.

[0168] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined above in paragraph (83).

[0169] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined above in paragraph (84).

[0170] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined in paragraph (85) above.

[0171] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined in paragraph (86) above.

[0172] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined above in paragraph (87).

[0173] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined above in paragraph (88).

[0174] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined in paragraph (89) above.

[0175] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XV), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Q is as defined in paragraph (90) above.

[0176] Certain compounds of the present invention include any of the compounds exemplified in this application, or a pharmaceutically acceptable salt or solvate thereof, particularly any of the following: 4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((14-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((17-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-(2-(2-(2-(2-(4-((2-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((14-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((17-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 5-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 3-(4-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-((2-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 4-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 3-[4-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethylamino]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 5-[4-[2-[2-[2-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]oxy]ethoxy]ethoxy]ethyl]piperazin-1-yl]-2-(2,6-dioxo-3-piperidyl)-6-fluoro-isoindoline-1,3-dione 5-[2-[2-[2-[2-[2-[2-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 3-[5-[4-[2-[1-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]-4-piperidyl]acetyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 3-[5-[4-[1-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperidine-4-carbonyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 3-[5-[4-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 5-[4-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]methyl]piperazin-1-yl]-2-(2,6-dioxo-3-piperidyl)-6-fluoro-isoindoline-1,3-dione (2S,4R)-1-[(2S)-2-[[11-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]-11-oxo-undecanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[8-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]-8-oxo-octanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[7-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-7-oxo-heptanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[8-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-8-oxo-octanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[9-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-9-oxo-nonanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[10-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-10-oxo-decanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[11-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-11-oxo-undecanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

[0177] The various functional groups and substituents that make up the compounds of formula (I) or sub-formulae (II) to (I-XV) are typically chosen so that the molecular weight of the compounds of formula (I) does not exceed 1000. More typically, the molecular weight of the compounds is less than 900. More preferably, the molecular weight is less than 800. Even more preferably, the molecular weight is less than 700.

[0178] Suitable pharmaceutically acceptable salts of the compounds of the present invention are, for example, sufficiently basic, e.g., acid-addition salts of the compounds of the present invention, e.g., acid-addition salts with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid, methane sulfonate, or maleic acid. Furthermore, suitable pharmaceutically acceptable salts of the compounds of the present invention that are sufficiently acidic are alkali metal salts, e.g., sodium or potassium salts, alkaline earth metal salts, e.g., calcium or magnesium salts, ammonium salts, or salts with organic bases that form pharmaceutically acceptable cations, e.g., salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine, or tris-(2-hydroxyethyl)amine.

[0179] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of one another are called "diastereomers," and those that are non-superimposable mirror images of one another are called "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates plane-polarized light and can be designated as dextrorotatory or levorotatory (i.e., (+)- or (-)-isomer, respectively). Chiral compounds can exist as either enantiomer or a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0180] The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds can be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in this specification and claims is intended to include both individual enantiomers and their mixtures, racemic or otherwise. Methods for determining stereochemistry and separating stereoisomers are well known in the art, for example, by synthesis from optically active starting materials or by resolution of racemates (see Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001). Some compounds of the present invention may have geometric isomeric centers (E- and Z-isomers).

[0181] It is to be understood that the present invention embraces all optical, diastereomeric, and geometric isomers and mixtures thereof that possess activity.

[0182] The present invention also encompasses compounds of the present invention as defined herein that contain one or more isotopic substitutions. For example, H can be in any isotopic form, including 1H, 2H (D), and 3H (T); C can be in any isotopic form, including 12C, 13C, and 14C; O can be in any isotopic form, including 16O and 18O, etc.

[0183] It is also to be understood that some compounds of formula (I) or subformulas (II) to (I-XV) can exist in solvated as well as unsolvated forms, such as, for example, hydrated forms, etc. It is to be understood that the present invention encompasses all such solvated forms that possess activity.

[0184] It is also to be understood that some compounds of formula (I) or subformulas (II) to (I-XV) may exhibit polymorphism, and that the present invention encompasses all such forms that possess activity.

[0185] Compounds of formula (I) or subformulas (II) to (I-XV) can exist in many different tautomeric forms, and reference to a compound of formula (I) or subformulas (II) to (I-XV) includes all such forms. For the avoidance of doubt, a compound may exist in one of several tautomeric forms, and only one will be described or shown in detail, while all others are encompassed by formula (I) or subformulas (II) to (I-XV). Examples of tautomeric forms include, for example, the keto, enol, and enolate forms for the following tautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.

[0186] [ka]

[0187] Compounds of formula (I) or subformulas (II) to (I-XV) containing an amine functional group can also form N-oxides. References herein to compounds of formula (I) or subformulas (II) to (I-XV) containing an amine functional group also include N-oxides. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Particular examples of N-oxides are the N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent, such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid); see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience. More specifically, the N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), in which the amine compounds are reacted with m-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0188] The compounds of formula (I) or subformulas (II) to (I-XV) can be administered in the form of prodrugs that are broken down in the human or animal body to release the compounds of the present invention. Prodrugs can be used to modify the physical and / or pharmacokinetic properties of the compounds of the present invention. Prodrugs can be formed when the compounds of the present invention contain a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include in vivo cleavable ester derivatives that can be formed at a carboxy or hydroxy group in the compounds of formula (I) or subformulas (II) to (I-XV) and in vivo cleavable amide derivatives that can be formed at a carboxy or amino group in the compounds of formula (I) or subformulas (II) to (I-XV).

[0189] The present invention therefore includes compounds of formula (I) or sub-formulas (II) to (I-XV), as defined above, when available by organic synthesis and when available in the human or animal body as cleavage of a prodrug thereof. The present invention therefore includes compounds of formula (I) or sub-formulas (II) to (I-XV) produced by organic synthetic means, and also compounds produced in the human or animal body as metabolism of precursor compounds that are compounds of formula (I) or sub-formulas (II) to (I-XV), such compounds may be synthetically produced compounds or metabolically produced compounds.

[0190] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or subformulas (II) to (I-XV) are those based on sound medical judgment, such that they are free from undesirable pharmacological activity and are free from undue toxicity and are suitable for administration to the human or animal body.

[0191] Various forms of prodrugs are described, for example, in the following documents: a)Methods in Enzymology, Vol.42, p.309-396, edited by K.Widder, et al.(Academic Press, 1985); b)Design of Pro-drugs, edited by H.Bundgaard,(Elsevier, 1985); c)A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H.Bundgaard p.113-191(1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285(1988); f) N.Kakeya, et al., Chem.Pharm.Bull., 32, 692(1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACSSymposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0192] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or sub-formulas (II) to (I-XV) having a carboxy group are, for example, in vivo cleavable esters thereof. In vivo cleavable esters of compounds of formula I or sub-formulas (II) to (I-XV) containing a carboxy group are, for example, pharmaceutically acceptable esters which are cleaved in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include (1-6C)alkyl esters such as methyl, ethyl and tert-butyl, (1-6C)alkoxymethyl esters such as methoxymethyl ester, (1-6C)alkanoyloxymethyl esters such as pivaloyloxymethyl ester, 3-phthalidyl ester, (3-8C)cycloalkylcarbonyloxy-(1-6C)alkyl esters such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl ester, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester and (1-6C)alkoxycarbonyloxy-(1-6C)alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl ester.

[0193] Suitable pharmaceutically acceptable prodrugs of the compounds of Formula (I) or sub-formulas (II) to (I-XV) having a hydroxy group include, for example, in vivo cleavable esters or ethers thereof. In vivo cleavable esters or ethers of the compounds of Formula (I) or sub-formulas (II) to (I-XV) containing a hydroxy group include, for example, pharmaceutically acceptable esters or ethers that are cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable ester-forming groups for hydroxy groups include inorganic esters, such as phosphate esters (including phosphoramidate cyclic esters). Further suitable pharmaceutically acceptable ester-forming groups for hydroxy groups include (1-10C)alkanoyl groups, such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups, and (1-10C)alkoxycarbonyl groups, such as ethoxycarbonyl, N,N-(1-6C)2carbamoyl, 2-dialkylaminoacetyl, and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(1-4C)alkylpiperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether forming groups for hydroxy groups include α-acyloxyalkyl groups, such as acetoxymethyl and pivaloyloxymethyl groups.

[0194] Suitable pharmaceutically acceptable prodrugs of the compounds of formula (I) or sub-formulae (II) to (I-XV) having a carboxy group are, for example, in vivo cleavable amides thereof, such as amides formed with amines, such as ammonia, (1-4C)alkylamines, such as methylamine, [(1-4C)alkyl]2amines, such as dimethylamine, N-ethyl-N-methylamine or diethylamine, (1-4C)alkoxy-(2-4C)alkylamines, such as 2-methoxyethylamine, phenyl-(1-4C)alkylamines, such as benzylamine and amino acids, such as glycine or its esters.

[0195] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or subformulae (II) to (I-XV) having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides derived from an amino group include, for example, amides formed with (1-10C)alkanoyl groups, such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(1-4C)alkyl)piperazin-1-ylmethyl.

[0196] The in vivo effects of the compounds of formula (I) or sub-formulas (II) to (I-XV) may be exerted in part by one or more metabolic products formed in the human or animal body following administration of the compounds of formula (I) or sub-formulas (II) to (I-XV). As described below, the in vivo effects of the compounds of formula (I) or sub-formulas (II) to (I-XV) may also be exerted as a result of metabolism of precursor compounds (prodrugs).

[0197] While the invention may relate to any compound or particular group of compounds defined herein as an optional, preferred or suitable feature or otherwise in relation to certain particular embodiments, the invention may relate to any compound or particular group of compounds that specifically excludes said optional, preferred or suitable feature or certain particular embodiment.

[0198] Suitably, the present invention excludes any individual compound that does not have biological activity as defined herein.

[0199] synthesis The compounds of the present invention can be prepared by any suitable technique known in the art. Certain methods for the preparation of these compounds are further described in the accompanying examples.

[0200] In the descriptions of synthetic methods described herein and in any referenced synthetic methods used to prepare starting materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedure, can be selected by one skilled in the art.

[0201] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.

[0202] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined herein, or of some of the starting materials, it may be desirable to protect some of the substituents to prevent their undesired reactions. The skilled chemist will understand when such protection is required and how such protecting groups can be introduced and subsequently removed.

[0203] For examples of protecting groups, see one of the many general texts on the subject, such as 'Protective Groups in Organic Synthesis' by Theodora Green (published by John Wiley & Sons, Inc.) Protecting groups can be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such method being chosen to effect removal of the protecting group with minimal disturbance to other groups in the molecule.

[0204] Thus, for example, if the reactants contain groups such as amino, carboxy or hydroxy, it may be desirable to protect the group in some of the reactions mentioned herein.

[0205] For example, suitable protecting groups for amino or alkylamino groups include, for example, acyl groups, such as alkanoyl groups, for example, acetyl, alkoxycarbonyl groups, for example, methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl groups, arylmethoxycarbonyl groups, for example, benzyloxycarbonyl, or aroyl groups, for example, benzoyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or alkoxycarbonyl groups, or aroyl groups, can be removed, for example, by hydrolysis with a suitable base, for example, an alkali metal hydroxide, for example, lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups may be removed by treatment with a suitable acid, for example, hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups such as benzyloxycarbonyl groups may be removed, for example, by hydrogenation over a catalyst, for example, palladium-on-carbon, or by treatment with a Lewis acid, for example, boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example, dimethylaminopropylamine, or with hydrazine.

[0206] Suitable protecting groups for hydroxy groups include, for example, acyl groups, such as alkanoyl groups, for example, acetyl, aroyl groups, for example, benzoyl, or arylmethyl groups, for example, benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or aroyl groups, can be removed, for example, by hydrolysis with a suitable base, for example, an alkali metal hydroxide, such as lithium, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups, such as benzyl groups, can be removed, for example, by hydrogenation over a catalyst, for example, palladium on carbon.

[0207] A suitable protecting group for a carboxy group is, for example, an esterifying group, a methyl or ethyl group which may be removed, for example, by hydrolysis with a base such as, for example, sodium hydroxide, or a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid, such as trifluoroacetic acid, or a benzyl group which may be removed, for example, by hydrogenation over a catalyst, for example palladium on carbon.

[0208] Resins can also be used as protecting groups.

[0209] The methodology used to synthesize compounds of formula (I), or sub-formulas (II) to (I-XV), is 2 , R 4 , R 6 , A1, A2, A4, L and Q and the nature of any substituents or associated subgroups thereof. Suitable methods for their preparation are further described in the accompanying examples.

[0210] After a compound of formula (I), or sub-formulas (II) to (I-XV), has been synthesized by any one of the methods defined herein, the methods may then proceed to the following further step: (i) removing any protecting groups present; (ii) converting a compound of formula (I) into another compound of formula (I); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or (iv) forming a prodrug thereof It may further include:

[0211] An example of (ii) above is where a compound of formula (I) is synthesized and then R 2 , R 4 , R 6 , where one or more of the A1, A2, A4, L and Q groups can be further reacted to change the nature of that group to provide alternative compounds of formula (I).

[0212] The resulting compounds of formula (I), or subformulas (II) to (I-XV), can be isolated and purified using techniques well known in the art.

[0213] Compounds of formula (I) can be synthesized by the synthetic routes shown in the Examples section below.

[0214] biological activity The pharmacological effects of the compounds of the present invention can be determined using the biological assays described in the Examples section herein.

[0215] Although the pharmacological properties of compounds of formula (I) vary with structural variation, as expected, compounds of the invention were found to be active in the assays described in the Examples section.

[0216] Pharmaceutical Composition According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the invention as hereinbefore defined, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0217] Compositions of the invention may be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as a finely divided powder or liquid aerosol), administration by insufflation (e.g., as a finely divided powder) or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration or as a suppository for rectal administration).

[0218] The compositions of the present invention can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use can contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.

[0219] An effective amount of a compound of the invention for use in therapy is an amount sufficient to treat or prevent, slow the progression of and / or alleviate the symptoms associated with the proliferative conditions referred to herein.

[0220] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending on the individual treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain from 0.5 mg to 0.5 g (more suitably, 0.5 to 100 mg, e.g., 1 to 30 mg) of active agent, combined with an appropriate and convenient amount of excipients, which may vary, for example, from about 5 to about 98 weight percent of the total composition.

[0221] The size of an administered dose of a compound of formula I for therapeutic or prophylactic purposes will, of course, vary with the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration, according to well-known principles of medicine.

[0222] When using the compounds of the present invention for therapeutic or prophylactic purposes, they are generally administered in a daily dose range, for example, 0.1 mg / kg to 75 mg / kg body weight, taking into account the need for divided doses. Generally, lower doses are administered when parenteral routes are used. Thus, for example, for intravenous or intraperitoneal administration, a dose range, for example, 0.1 mg to 30 mg / kg body weight, is generally used. Similarly, for administration by inhalation, a dose range, for example, 0.05 mg to 25 mg / kg body weight, is used. Oral administration may also be appropriate, particularly in tablet form. Typically, a unit dosage form contains about 0.5 mg to 0.5 g of the compounds of the present invention.

[0223] Therapeutic Uses and Applications The present invention provides compounds that function to reduce PMS2 protein levels and / or as inhibitors of PMS2 activity.

[0224] Thus, the compounds of formula (I), or pharmaceutically acceptable salts thereof, have potential therapeutic use in a variety of disease states in which reducing PMS2 protein levels and / or inhibiting PMS2 activity is beneficial.

[0225] Accordingly, the present invention provides a method of treating a disease or disorder in which reducing PMS2 protein levels and / or inhibiting PMS2 activity would be beneficial in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0226] The present invention provides a method for reducing PMS2 protein levels and / or inhibiting PMS2 activity in vitro or in vivo, said method comprising the step of contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0227] The present invention provides a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0228] The present invention provides a method of treating cancer in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0229] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.

[0230] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use as a pharmaceutical.

[0231] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative disorder.

[0232] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use in the treatment of cancer. In a particular embodiment, the cancer is a human cancer. In a particular embodiment, the cancer is a human cancer, particularly an estrogen-positive cancer, such as breast cancer, or an androgen receptor-positive cancer, such as prostate cancer.

[0233] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in reducing PMS2 protein levels and / or inhibiting PMS2 activity.

[0234] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder in which reduction of PMS2 protein levels and / or inhibition of PMS2 activity is beneficial.

[0235] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0236] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of cancer.

[0237] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for reducing PMS2 protein levels and / or inhibiting PMS2 activity.

[0238] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a disease or disorder in which reduction of PMS2 protein levels and / or inhibition of PMS2 activity is beneficial.

[0239] The terms "proliferative disorder," "proliferative condition," and "proliferative disease" are used interchangeably herein and relate to unwanted or uncontrolled cell proliferation of excessive or abnormal cells, either in vitro or in vivo, that is unwanted, e.g., neoplastic or hyperplastic growth.

[0240] In the above-outlined aspect of the invention, the proliferative disorder is suitably cancer, and the cancer is suitably a human cancer. In particular, the compounds of the invention are useful in the treatment of any cancer in which mismatch repair inhibition is beneficial.Any suitable cancer can be targeted (e.g., adenoid cystic carcinoma, adrenal tumor, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer (cholangiocarcinoma), Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, Carney complex, central nervous system tumor, cervical cancer, colorectal cancer, Cowden disease, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing's sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, etc.). Chromoma, familial non-VHL clear cell renal cell carcinoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary mixed polyposis syndrome, hereditary pancreatitis, hereditary papillary renal cell carcinoma, juvenile polyposis syndrome, kidney cancer, lacrimal gland tumors, laryngeal and hypopharyngeal cancer, leukemia (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, hairy cell leukemia, chronic lymphocytic leukemia (CLL), chronic myeloblastic leukemia (CRL), Myeloid leukemia (CML), chronic T-cell lymphocytic leukemia, eosinophilic leukemia), Li-Fraumeni syndrome, liver cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (Hodgkin, non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, melanoma, meningioma, mesothelioma, multiple endocrine neoplasia type 1 and type 2, multiple myeloma, MUTYH (or MYH)-associated polyposis, myelodysplastic syndrome (MDS), cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, neuroendocrine tumors (e.g., of the gastrointestinal tract, lung, or pancreas), neurofibromatosis type 1 and type 2, nevoid basal cell carcinoma syndrome , oral or oropharyngeal cancer, osteosarcoma, ovarian / fallopian tube / peritoneal cancer, pancreatic cancer, parathyroid cancer, penile cancer, Peutz-Jeghers syndrome, pheochromocytoma, paraganglioma, pituitary tumors, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas (e.g., Kaposi or soft tissue), skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, tuberous sclerosis, uterine cancer, vaginal cancer, von Hippel-Lindau syndrome, vulvar cancer, Waldenström's macroglobulinemia, Werner's syndrome, Wilms' tumor, and xeroderma pigmentosum).Particular cancers of interest include hematological cancers, such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma (BL), and angioimmunoblastic T-cell lymphoma (AITL)), leukemias (including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, endometrial cancer, gastro-esophageal cancer, neuroendocrine cancer, osteosarcoma, prostate cancer, pancreatic cancer, small intestine cancer, bladder cancer, rectal cancer, cholangiocarcinoma, CNS cancer, thyroid cancer, head and neck cancer, esophageal cancer, and ovarian cancer.

[0241] The compounds of the invention may also be used to treat triplet repeat disorders.

[0242] Thus, a further aspect of the present invention provides a method of treating a triplet repeat disorder (e.g., Huntington's disease (HD), myotonic dystrophy type 1 (DM1), Fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs)) in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0243] According to a further aspect of the present invention, there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in treating a triplet repeat disorder. In particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0244] According to a further aspect of the present invention, there is provided use of a compound defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition defined herein, in the manufacture of a medicament for the treatment of a triplet repeat disorder. In particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0245] Administration route The compounds of the invention or pharmaceutical compositions containing these compounds can be administered to a subject by any convenient route of administration, whether systemic, peripheral, or local (i.e., at the desired site of action).

[0246] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., patches, plasters, etc.); transmucosally (including, e.g., patches, plasters, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, e.g., via aerosol, e.g., through the mouth or nose, using); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); by injection, including, e.g., intratumoral, subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intraarticular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; parenterally, e.g., by a depot or reservoir placement, subcutaneously or intramuscularly.

[0247] Combination therapy The compounds of the present invention can be administered as a monotherapy, or the compounds of the present invention can be used in addition to conventional surgery or radiation therapy or chemotherapy or targeted agents. Such chemotherapy or targeted agents can include one or more of the following categories: (i) As used in medical oncology, antiproliferative / antineoplastic agents and combinations thereof, for example, but not limited to, alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolamide, and nitrosoureas); antimetabolites (e.g., gemcitabine and antifolates, e.g., fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor agents Biologics (e.g., anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); mitotic inhibitors (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, and taxoids such as taxol and taxotere, and polo kinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, amsacrine, camptothecins including topotecan and irinotecan); (ii) Cytostatic agents, such as, but not limited to, antiestrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene, and iodoxyfene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or agonists (e.g., goserelin, leuprolide, and buserelin), progestogens (e.g., megestrol acetate), and corticosteroids (e.g., dexamethasone, prednisone, and prednisolone), steroid hormones, including aromatase inhibitors (such as anastrozole, letrozole, vorazole, and exemestane), and inhibitors of 5α-reductase, such as finasteride; (iii) anti-invasion agents, such as, but not limited to, the c-Src kinase family inhibitor 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application Publication No. WO 01 / 94341), N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658-6661), bosutinib (SKI-606), and metalloproteinase inhibitors, such as marimastat, inhibitors of urokinase-type plasminogen activator receptor function or antibodies against heparanase; (iv) inhibitors of growth factor function, including, but not limited to, growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225], and the antibody described by Stern et al. (Critical reviews in oncology / haematology, 2005, Vol. 54, and any growth factor or growth factor receptor antibody disclosed by I. M. Schmidt, M ... inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors, such as farnesyltransferase inhibitors, e.g., sorafenib (BAY43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signaling via MEK and / or AKT kinase, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Aurora kinase inhibitors and cyclin-dependent kinase inhibitors, such as CDK2 and / or CDK4 inhibitors; (v) antiangiogenic agents, including, but not limited to, those that inhibit the effects of vascular endothelial growth factor [e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), and pazopanib (GW786034); (vi) vascular damaging agents, such as, but not limited to, combretastatin A4 and compounds disclosed in International Patent Application Publications WO99 / 02166, WO00 / 40529, WO00 / 41669, WO01 / 92224, WO02 / 04434 and WO02 / 08213; (vii) endothelin receptor antagonists, such as zibotentan (ZD4054) or atrasentan; (viii) antisense therapy, including but not limited to those directed to the targets set forth above, e.g., ISIS2503, anti-ras antisense, etc.; (ix) Immunotherapeutic approaches, including, for example, cancer vaccines, antibodies, viruses (oncolytic viruses), and small molecule or cell therapy approaches to increase the immunogenicity of a patient's tumor cells and / or facilitate a cell-mediated anti-tumor response. Such therapies may include, but are not limited to, OX40 agonists, cGAS-STING agonists, ENPP1 inhibitors, CD38 inhibitors, TBK1 inhibitors, A2a receptor antagonists, PI3 kinase inhibitors, TLR7 / 8 agonists, IDO inhibitors, arginase inhibitors, BTK inhibitors, and bromodomain inhibitors; transduction of cancer antigens by microbial vectors, direct transduction of cancer antigens into antigen-presenting cells, treatment with cancer antigen-specific immune cells (e.g., CAR-T), treatment with antibodies, antibody fragments, and antibody-drug conjugates that enable the immune system to recognize tumor cells.

[0248] Such conjoint treatment may be achieved by the simultaneous, sequential or separate administration of the individual components of the treatment. Such combination products utilize the compounds of this invention within the dosage ranges described hereinabove and the other pharmaceutically active agent(s) within their approved dosage ranges.

[0249] According to this aspect of the invention there is provided a combination for use in the treatment of cancer (e.g. cancer involving a solid tumour) comprising a compound of the invention as hereinbefore defined, or a pharmaceutically acceptable salt or solvate thereof, and an anti-tumour agent.

[0250] According to this aspect of the invention there is provided a combination for use in the treatment of a proliferative condition, such as cancer (e.g. a cancer involving a solid tumor), comprising a compound of the invention as defined hereinabove, or a pharmaceutically acceptable salt or solvate thereof, and any one of the anti-tumour agents set out in the specification above.

[0251] In a further aspect of the present invention, there is provided a compound of the present invention or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of cancer, in combination with another anti-tumour agent, optionally selected from those set out in the specification above.

[0252] In a further aspect of the present invention, there is provided a compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer, in combination with a tyrosine kinase inhibitor, optionally selected from those set out in the specification above.

[0253] When the term "combination" is used herein, it is understood to mean simultaneous, separate or sequential administration. In one aspect of the present invention, "combination" means simultaneous administration. In another aspect of the present invention, "combination" means separate administration. In a further aspect of the present invention, "combination" means sequential administration. When administration is sequential or separate, the delay in administering the second component should not, for example, cause the beneficial effect of the combination to be lost.

[0254] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, in combination with an anti-tumour agent (optionally selected from those set out in the specification above), in association with a pharmaceutically acceptable diluent or carrier.

[0255] Combination therapy with immune modulation therapy Immune checkpoint inhibitors Immune checkpoint proteins present in immune cells and / or cancer cells (e.g., CTLA4 (also known as cytotoxic T-lymphocyte-associated protein 4 and CD152), LAG3 (also known as lymphocyte-activation gene 3 and CD223), PD1 (also known as programmed cell death protein 1 and CD279), PD-L1 (also known as programmed death-ligand 1 and CD274), TIM-3 (also known as T-cell immunoglobulin mucin-3), and TIGIT (also known as T-cell immunoreceptor with Ig and ITIM domains) are molecular targets that have been found to play an important role in regulating anti-tumor immune responses. Inhibitors of these immune checkpoint proteins (e.g., CTLA4, LAG3, PD1, PD-L1, TIM-3, and / or TIGIT inhibitors) promote anti-tumor immune responses that can be used to effectively treat some forms of cancer.

[0256] immunostimulants Monoclonal antibodies, bispecific antibodies, recombinant ligands, and small molecule therapeutics that bind to stimulatory receptors on immune cells can facilitate effective anti-tumor responses. Such receptors may be involved in cell-to-cell contact, for example, contact between tumor cells and immune cells or contact between two types of immune cells, while other receptors may bind to soluble factors that stimulate an immune response. In one such embodiment, the antibody, bispecific antibody, recombinant protein, or small molecule therapeutic can activate stimulatory receptors, including, but not limited to, 4-1BB, OX40, cGAS-STING, CD27, CD40, and DR3, which enhance anti-tumor immunity.

[0257] A modulator of antigen processing can facilitate the presentation of neoantigenic peptides on the cell surface to enhance effective anti-tumor responses. In one such embodiment, an inhibitor of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 can stimulate anti-tumor immunity.

[0258] In one aspect, the invention relates to a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder.

[0259] In another aspect, the invention relates to the use of a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0260] In another aspect, the present invention relates to a method of treating a proliferative disorder in a subject in need thereof, comprising the step of administering to said subject a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein.

[0261] In another aspect, the invention relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a proliferative disorder, wherein the compound, or a pharmaceutically acceptable salt thereof, is for simultaneous, separate or sequential administration with an immune checkpoint inhibitor, or an immunostimulant, or a pharmaceutically acceptable salt thereof.

[0262] In another aspect, the present invention relates to an immune checkpoint inhibitor or immunostimulant, or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder, wherein the immune checkpoint inhibitor is in the case of simultaneous, separate or sequential administration with a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein.

[0263] In another aspect, the invention relates to the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with an immune checkpoint inhibitor or an immunostimulant, or a pharmaceutically acceptable salt thereof.

[0264] In another aspect, the invention relates to the use of an immune checkpoint inhibitor or immunostimulant, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with a compound as defined herein, or a pharmaceutically acceptable salt thereof.

[0265] In another aspect, the present invention relates to a method of treating a proliferative disorder comprising the step of sequentially, separately or simultaneously administering therapeutically effective amounts of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

[0266] Any immune checkpoint inhibitor or immunostimulatory agent can be used in the combination therapy defined herein.

[0267] In one aspect, the immune stimulator is selected from a 4-1BB stimulator, an OX40 stimulator, a CD27 stimulator, a CD40 stimulator, and a DR3 stimulator. In another embodiment, the immune checkpoint inhibitor is selected from a PD1 inhibitor, a PD-L1 inhibitor, a LAG3 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, and / or a TIGIT inhibitor. In a detailed embodiment, the immune checkpoint inhibitor is a PD1 or PD-L1 inhibitor.

[0268] PD-1 is a cell surface receptor protein present on immune cells, such as T cells. PD-1 plays an important role in promoting self-tolerance by downregulating the immune system and suppressing T cell activation. PD-1 protein is an immune checkpoint that monitors autoimmunity through a dual mechanism: it promotes apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes, while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory suppressor T cells).

[0269] PD-1 therefore suppresses the immune system, which prevents autoimmune diseases but can also prevent the immune system from killing cancer cells.

[0270] PD1 binds to two ligands, PD-L1 and PD-L2. PD-L1 is of particular interest because it is highly expressed in several cancers, and its role in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 to boost the immune system have been approved or are being developed for the treatment of cancer. Many tumor cells express PD-L1, the immunosuppressive PD-1 ligand; inhibiting the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate pro-oncogenic antitumor activity. This is known as immune checkpoint blockade.

[0271] Examples of drugs that target PD-1 include pembrolizumab (Keytruda) and nivolumab (Opdivo). These drugs have been shown to be effective in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer, renal cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. They are also being investigated for use against many other types of cancer. Examples of drugs in development include BMS-936559 (Bristol Myers Squibb), MGA012 (MacroGenics), and MEDI-0680 (MedImmune).

[0272] Examples of drugs that block PD-L1 include atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). These drugs have also been shown to help treat different types of cancer, including bladder cancer, non-small cell lung cancer, and Merkel cell skin cancer (Merkel cell carcinoma). They are also being studied for use in other types of cancer.

[0273] Examples of LAG3 inhibitors include BMS-986016 / Relatlimab, TSR-033, REGN3767, MGD013 (a bispecific DART combining PD-1 and LAG-3), GSK2831781, and LAG525.

[0274] Examples of CTLA-4 inhibitors include MDX-010 / ipilimumab, AGEN1884, and CP-675,206 / tremelimumab.

[0275] Examples of TIM-3 inhibitors include MBG453 (Novartis), TSR-022 (Tesaro), and LY3321367 (Lilly).

[0276] Examples of TIGIT inhibitors include tiragolumab (MTIG7192A; RG6058; Genentech / Roche), AB154 (Arcus Bioscience), MK-7684 (Merck), BMS-986207 (Bristol-Myers Squibb), and ASP8374 (Astellas Pharma; Potenza Therapeutics).

[0277] In one embodiment, the immune checkpoint inhibitor is selected from BMS-986016 / leratolimab, TSR-033, REGN3767, MGD013 (bispecific DART combining PD-1 and LAG-3), GSK2831781, LAG525, MDX-010 / ipilimumab, AGEN1884, and CP-675,206 / tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, MBG453, TSR-022, LY3321367, tiragolumab (MTIG7192A; RG6058), AB154, MK-7684, BMS-986207, and / or ASP8374 or a pharmaceutically acceptable salt or solvate thereof.

[0278] Combination therapy with DNA damage response modulators The compounds of the invention are particularly suitable for use in combination with agents that act as DNA damage response modulators, for example PARP inhibitors, ATM inhibitors and ATR inhibitors.

[0279] In one aspect, the invention relates to a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder.

[0280] In another aspect, the invention relates to the use of a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a proliferative disorder.

[0281] In another aspect, the present invention relates to a method of treating a proliferative disorder in a subject in need thereof, comprising the step of administering to said subject a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, as defined herein.

[0282] In another aspect, the present invention relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a proliferative disorder, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0283] In another aspect, the invention relates to the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, in the manufacture of a medicament for treating a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0284] In another aspect, the present invention relates to a method of treating a proliferative disorder comprising the step of sequentially, separately or simultaneously administering to a subject in need thereof therapeutically effective amounts of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, and a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0285] Any DNA damage response modulator (eg, a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor) can be used in the combination therapy defined herein. [Example]

[0286] While specific embodiments of the present invention have been described herein for purposes of reference and example, various modifications will become apparent to those skilled in the art without departing from the scope of the invention as defined by the appended claims. Abbreviation Boc is tert-butyloxycarbonyl DAST is diethylaminosulfur trifluoride DBU is 1,8-diazabicyclo(5.4.0)undec-7-ene DCC is dicyclohexylcarbodiimide DCE is 1,1-dichloroethane DCM is dichloromethane DEA is diethanolamine DEAD is diethyl azodicarboxylate DIAD is diisopropyl azodicarboxylate DIBAL is diisobutylaluminum hydride DIPEA is N,N-diisopropylethylamine, Hunig's base DMA is N,N-dimethylacetamide DMAP is 4-(dimethylamino)pyridine DMF is N,N-dimethylformamide DMSO is dimethyl sulfoxide. EDC is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EtOAc is ethyl acetate h is the time HATU is N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide HBTU is (1H-benzotriazol-1-yloxy)(dimethylamino)-N,N-dimethylmethaniminium hexafluorophosphate HOBT is N-hydroxybenzotriazole HPLC is high pressure liquid chromatography. IBX is 2-iodoxybenzoic acid IPA is isopropyl alcohol LAH is lithium aluminum hydride LCMS is liquid chromatography-mass spectrometry LDA is lithium diisopropylamide LiHMDS is lithium bis(trimethylsilyl)amide mCPBA is meta-chloroperbenzoic acid MI is the molecular ion Min is minutes MgSO4 Anhydrous Magnesium Sulfate MW is microwave NBS is N-bromosuccinamide NCS is N-chlorosuccinamide NFOBS is N-fluoro-o-benzenedisulfonimide NFSI is N-fluorobenzenesulfonimide NHS is N-hydroxysuccinimide NIS is N-iodosuccinamide NMM is N-methylmorpholine NMP is 1-methyl-2-pyrrolidinone NMR is nuclear magnetic resonance. PdCl2(PPh3)2 is bis(triphenylphosphine)palladium chloride Pd(dppf)2Cl2 is [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). Pd(dppf)2Cl2.DCM is the [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (Pd(dba)2) is bis(dibenzylideneacetone)palladium Rbf is a round bottom flask RT is retention time. SCX-2 is a silica-based sorbent with chemically bonded propylsulfonic acid functional groups. SFC stands for supercritical fluid chromatography STAB Sodium triacetoxyborohydride TBAF is tetra-n-butylammonium fluoride TBDMS is tert-butyldimethylsilyl TFAA is trifluoroacetic anhydride TFA is trifluoroacetic acid THF is tetrahydrofuran T3P is propylphosphonic anhydride Ts is toluenesulfonyl XPhos-Pd-G1 is 2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) chloride XPhos-Pd-G2 is chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II).

[0287] Analysis method Commercially available starting materials, reagents, and dry solvents were used as supplied. Flash or glass column chromatography was performed using Merck silica gel 230-400 mesh size. Flash chromatography was also performed on a combi-flash RF Teledyne Isco instrument. Preparative TLC was performed on Merck plates.

[0288] Unless otherwise stated, the solvents listed were used at room temperature. 1 For H NMR, 400 MHz or 13 C NMR was performed using a Bruker Avance-400 instrument operating at 100 MHz. 1 H nuclear magnetic resonance (NMR) spectroscopy was performed. Samples were prepared as solutions in suitable deuterated solvents and referenced to the appropriate internal non-deuterated solvent peak or to tetramethylsilane. Chemical shifts were reported in ppm (δ) downfield from tetramethylsilane. In all cases, the NMR data were consistent with the proposed structures. Characteristic chemical shifts (δ) are indicated in parts per million using conventional abbreviations for the major peak designations: e.g., s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; and br, broad.

[0289] Liquid chromatography-mass spectrometry Method A Waters Acquity UPLC with binary solvent manager, PDA detector, and Acquity QDA performance mass detector; Column: X-Bridge BEH C18, 50 × 2.1 mm, 2.5 micron; Column temperature: 35 °C; Autosampler temperature: 5 °C; Mobile phase A: 0.1% (v / v) formic acid in water (pH = 2.70); Mobile phase B: 0.1% formic acid in water (v / v):acetonitrile (10:90); Mobile phase gradient details: t = 0 min (97% A, 3% B) flow rate: 0.8 mL / min; t = 0.75 min (97% A, 3% B) flow rate: 0.8 mL / min; Gradient to t = 2.7 min (2% A, 98% B) flow rate: 0.8 mL / min; Gradient to t = 3 min (0% A, 100% B) flow rate: 1 mL / min; t = 3.5 min (0% A, 100% B) flow rate: 1 mL / min B) Flow rate: 1 mL / min; gradient (97% A, 3% B) until t = 3.51 min; flow rate: 0.8 mL / min; run ended at t = 4 min (97% A, 3% B), flow rate: 0.8 mL / min, analysis time 4 min. Mass detector parameters: ionization mode cycled in positive and negative modes with cone voltages of 10 V and 30 V and capillary voltage of 0.8 kV; source and probe temperatures were 120 °C and 600 °C, respectively.

[0290] Method B Waters 996 Photodiode Array Detector with Waters Micromass ZQ detector. Column: Xtimate C18 4.6 × 150 mm 5 μm. Column temperature: 35 °C. Autosampler temperature: 15 °C. Mobile phase A: 0.1% ammonia in Milli-Q Water. Mobile phase B: CAN. Mobile phase gradient details: T = 0 min (95% A, 5% B); T = 7.0 min (60% A, 40% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (95% A, 5% B); run end: T = 17 min (95% A, 5% B). Flow rate: 1.0 mL / min. Run time: 17 min. UV detection method: PDA. Mass detector parameters: Probe: ESI, mode of ionization: positive and negative, cone voltage: 30 and 10 V, capillary voltage: 3.0 KV, extractor voltage: 2 V, Rf lens: 0.1 V, source temperature: 120 °C, probe temperature: 400 °C, cone gas flow: 100 L / Hr, desolvation gas flow: 800 L / Hr.

[0291] Method T1 Infinity 1220 DAD LC G4294B and 6120 Quadrupole LC / MS G6120B, Column: Agilent Zorbax SB-C18. Mobile phase gradient details: 10% MeCN + formic acid (0.1% v / v) to 100% HO + formic acid (0.1% v / v) over 5 min at a flow rate of 0.5 mL / min.

[0292] Method T2 1260 Quat Pump G7111B, 1260 Multisampler G7167A, 1290 MCT G7116B (column chamber), 1260 DAD WR G7115A, and LC / MSD XT G6135B. Column: Agilent Zorbax SB-C18. Mobile phase: 10% MeCN + formic acid (0.1% v / v) to 100% HO + formic acid (0.1% v / v) over 5 min at a flow rate of 0.5 mL / min.

[0293] Analytical HPLC method Method A Agilent 1100 Series with PDA detector, column: SUNFIRE C18 150 × 4.6 mm, 3.5 μm, column temperature: 25 °C, autosampler temperature: 25 °C, mobile phase A: 0.05% trifluoroacetic acid in Milli-Q water (pH = 2.1), mobile phase B: 100% acetonitrile. Mobile phase gradient details: T = 0 min (90% A, 10% B); T = 7.0 min (10% A, 90% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (90% A, 10% B); run end: T = 17 min (90% A, 10% B); flow rate: 1.0 mL / min; run time: 17 min; UV detection method: PDA.

[0294] Method B The Agilent 1260 series was equipped with a PDA detector. Column: SUNFIRE C18 (150 mm × 4.6 mm), 3.5 μm. Column temperature: 25°C. Autosampler temperature: 25°C. Mobile phase A: 0.05% trifluoroacetic acid in Milli-Q water (pH = 2.1). Mobile phase B: 100% acetonitrile. Mobile phase gradient details: T = 0 min (90% A, 10% B); T = 7.0 min (10% A, 90% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (90% A, 10% B); run termination at T = 17 min (90% A, 10% B). Flow rate: 1.0 mL / min. Run time: 17 min. UV detection method: PDA.

[0295] Method C Waters Alliance e2695 with 2998 PDA detector, column: ATLANTIS C18 (150 mm × 4.6 mm), 5 μm; column temperature: 25 °C; autosampler temperature: 25 °C; mobile phase A: 0.1% ammonium hydroxide solution in HPLC water; mobile phase B: 100% acetonitrile. Mobile phase gradient details: T = 0 min (90% A, 10% B); T = 7.0 min (10% A, 90% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (90% A, 10% B); run end: T = 17 min (90% A, 10% B); flow rate: 1.0 mL / min; run time: 17 min; UV detection method: PDA.

[0296] Analytical HPLC method Method A WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation were performed using a Waters 2545 purification system equipped with a UV detector. Column: X-bridge prep, C18, OBD (250 × 19) mm, 5 μm. The compounds were eluted with mobile phase A: 5 mM ammonium bicarbonate + 0.05% ammonium hydroxide solution in Milli-Q water; mobile phase B (acetonitrile) (100%). The gradient was T = 0 min (75% A, 25% B); T = 2.0 min (65% A, 35% B); T = 17.0 min (53% A, 47% B); gradient T = 17.01 min (2% A, 98% B) to T = 20.0 min (2% A, 98% B); gradient T = 20.01 min (75% A, 25% B) to T = 23.0 min (75% A, 25% B); flow rate = 22 ml / min; analysis time 23 min.

[0297] Method B WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation were performed using a Waters 2545 purification system equipped with a UV detector, column: YMC-Actus Triart Prep C18-s, 250 × 20 mm, S-5 μm, 12 nm. The compounds were separated using mobile phase A: 5 mM ammonium bicarbonate in Milli Q water, mobile phase B: (acetonitrile:isopropyl alcohol) (90:10) with a gradient of T = 0 min (52% A, 48% B); flow rate = 8 ml / min with a gradient of T = 32.0 min (52% A, 48% B); T = 32.01 min (2% A, 98% B); flow rate = 15 ml / min with a gradient of T = 36.00 min (2% A, 98% B); T = 36.01 min (52% A, 48% B); and T = 40.0 min (50% A, 48% B). B); flow rate = 0.8 ml / min; analysis time = 40 min.

[0298] Method C WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation were performed using a Waters 2545 purification system equipped with a UV detector. Column: X-bridge prep, C18, OBD (250 × 19) mm, 5 μm. Compounds were purified using mobile phase A: 5 mM ammonium bicarbonate + 0.05% ammonium hydroxide solution in Milli Q water. Mobile phase B: 10% mobile phase A in (acetonitrile:tetrahydrofuran) (90:10). Gradient: T = 0 min (80% A, 20% B); gradient to T = 2.0 min (67% A, 33% B); gradient T = 22.01 min (2% A, 98% B) to T = 24.0 min (2% A, 98% B); gradient T = 24.01 min (80% A, 20% B) to T = 25.0 min (80% A, 20% B). B); Flow rate = 23 ml / min; Analysis time = 25 min.

[0299] Method D WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation were performed using a Waters 2545 purification system equipped with a UV detector. Column: X-bridge prep, C18, OBD (250 × 19) mm, 5 μm. Compounds were purified using mobile phase A: 5 mM ammonium bicarbonate + 0.05% ammonium hydroxide solution in Milli Q water. Mobile phase B: (acetonitrile) (100%) with a gradient of T = 0 min (80% A, 20% B); gradient to T = 2.0 min (70% A, 30% B); flow rate = 20-21 ml / min with a gradient of T = 17.0 min (65% A, 35% B); flow rate = 24 ml / min with a gradient of T = 17.01 min (2% A, 98% B) to T = 20.0 min (2% A, 98% B); gradient of T = 20.01 min (80% A, 20% B) to T = 23.0 min (80% A, 20% B). B); Flow rate = 20 ml / min; Analysis time = 23 min.

[0300] Method E WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation was performed using a Waters 2545 purification system equipped with a UV detector. Column: X-bridge Prep C18, OBD, 250 × 19 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonia in Milli Q water, mobile phase B: (20% A line in acetonitrile:MEOH:IPA) (65:25:10) with a gradient of T = 0 min (53% A, 47% B); T = 17.0 min (42% A, 58% B); T = 17.01 min (0.2% A, 98% B); T = 19.00 min (2% A, 98% B); T = 19.01 min (53% A, 47% B); T = 22.00 min (53% A, 47% B); flow rate = 23 ml / min; analysis time 22 min.

[0301] Method F WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation was performed using a Waters 2545 purification system equipped with a UV detector. Column: X-bridge Prep C10BD, 250 × 19 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonia in Milli Q water, mobile phase B: (20% A line: acetonitrile) (20:80) with a gradient of T = 0 min (60% A, 40% B); T = 20.0 min (52% A, 48% B); T = 22.01 min (0.2% A, 98% B); T = 24.00 min (2% A, 98% B); T = 24.01 min (60% A, 40% B); T = 27.00 min (60% A, 40% B); flow rate = 13 ml / min; analysis time 27 min.

[0302] Method G WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation was performed using a Waters 2545 purification system equipped with a UV detector, column: C18-s, 250 × 21.2 mm, 5 μm; compounds were separated using mobile phase A: 5 mM ammonium bicarbonate in 0.05% ammonia solution in Milli Q water, mobile phase B: (20% A line: acetonitrile) (20:80) with a gradient of T = 0 min (70% A, 30% B); gradient to T = 2.0 min (55% A, 45% B); gradient to T = 20.01 min (55% A, 45% B); gradient to T = 20.01 min (2% A, 98% B); gradient to T = 22.00 min (02% A, 98% B); gradient to T = 22.01 min (70% A, 30% B); gradient to T = 25.00 min (70% A, 30% B); B); flow rate = 24 ml / min; analysis time = 25 min.

[0303] Method H WATERS 2545 Quaternary system with WATERS 2489 UV detector. Chromatographic separation and isolation was performed using a Waters 2545 purification system equipped with a UV detector. Column: Repack C18-s, 250 × 21.2 mm, 5 μm; compounds were eluted with mobile phase A: 5 mM ammonium bicarbonate in 0.05% ammonia solution in Milli Q water, mobile phase B: (20% A line: acetonitrile) (20:80) with a gradient of T = 0 min (66% A, 34% B); gradient (66% A, 34% B) to T = 20.0 min; gradient (0.2% A, 98% B) to T = 20.01 min; gradient (2% A, 98% B) to T = 22.00 min; gradient (66% A, 34% B) to T = 25.00 min; flow rate = 24 ml / min; analysis time 25 min.

[0304] Method I A WATERS 2545 Quaternary System equipped with a WATERS 2489 UV Detector was used. Column: X-bridge Prep, C18, OBD (250 × 19) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (65% A, 35% B), T = 14.00 min (65% A, 35% B), T = 14.01 min (02% A, 98% B), T = 16.00 min (02% A, 98% B), T = 16.01 min (65% A, 35% B), T = 19.00 min (65% A, 35% B), T = 23 ml / min, T = 16.01 min (65% A, 35% B), T = 19.00 min (65% A, 35% B), T = 20 ml / min, and run time: 19 min.

[0305] Method J The Shimadzu LC20AP purification system was equipped with a UV detector. Column: Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (95% A, 0.5% B), T = 02.00 min (65% A, 35% B), T = 02.00 min (65% A, 35% B), T = 20.00 min (60% A, 40% B), T = 20.01 min (0.2% A, 98% B), T = 22.00 min (0.2% A, 98% B), T = 22.01 min (95% A, 0.5% B), T = 24.00 min (95% A, 0.5% B), T = 23 ml / min, and run time: 24 min.

[0306] Method K The Shimadzu LC20AP purification system was equipped with a UV detector. Column: Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.1% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (61% A, 39% B), T = 19.00 min (61% A, 39% B), T = 19.01 min (02% A, 98% B), T = 21.00 min (02% A, 98% B), T = 21.01 min (61% A, 39% B), and T = 24.00 min (61% A, 39% B). Flow rate: 20 ml / min. Analysis time: 24 min.

[0307] Method L Chromatographic separation and isolation were performed using a WATERS 2545 quaternary purification system equipped with a 2489 UV detector. The compounds were eluted on a NEW XBRIDGE 250 × 19 mm, 5 μm column with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (70% A, 30% B), T = 17.00 min (53% A, 47% B), T = 17.01 min (02% A, 98% B), T = 19.00 min (02% A, 98% B), T = 19.01 min (70% A, 30% B), and T = 22.00 min (70% A, 30% B). Flow rate: 22 ml / min. Analysis time: 22 min.

[0308] Method M Chromatographic separation and isolation were performed using a WATERS 2545 Quaternary Purification System equipped with a 2489 UV detector. Column: Xtimate, C18, OBD (250 × 21.2) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile: mobile phase-A:THF (70:20:10) with a gradient of T = 0 min (60% A, 40% B), T = 27.00 min (58% A, 42% B), T = 27.01 min (02% A, 98% B), T = 29.00 min (02% A, 98% B), T = 29.01 min (60% A, 40% B), T = 32.00 min (60% A, 40% B), flow rate = 20 ml / min, and run time 32 min.

[0309] Method N Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: Xtimate C18 (250 mm × 21.2 mm), 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water + 5 mM ammonium bicarbonate, mobile phase B: acetonitrile: mobile phase-A:THF (70:20:10) with a gradient of T = 0 min (49% A, 51% B), T = 21.00 min (48% A, 52% B), T = 21.01 min (02% A, 98% B), T = 24.00 min (02% A, 98% B), T = 24.01 min (49% A, 51% B), T = 28.00 min (49% A, 51% B), flow rate = 21 ml / min, and run time 28 min.

[0310] Method O Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. The compounds were eluted on an Xtimate C18 column (250 mm × 21.2 mm × 5 μm) with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile: mobile phase-A:THF (70:20:10) with a gradient of T = 0 min (56% A, 44% B), T = 18.00 min (52% A, 48% B), T = 18.01 min (02% A, 98% B), T = 21.00 min (02% A, 98% B), T = 21.01 min (56% A, 44% B), T = 25.00 min (56% A, 44% B), flow rate = 22 ml / min, and run time 25 min.

[0311] Method P Chromatographic separation and isolation was performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: Xtimate C18 (250 mm × 21.2 mm × 5 μm). Compounds were analyzed with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile:THF (90:10) with a gradient of T = 0 min (80% A, 20% B); T = 02.00 min (58% A, 42% B); T = 02.00 min (58% A, 42% B); T = 15.00 min (53% A, 47% B); T = 15.00 min (53% A, 47% B); T = 21.00 min (53% A, 47% B); T = 21.01 min (02% A, 98% B); T = 24.00 min (02% A, 98% B); T = 24.01 min (80% A, 20% B). Elution was performed with a gradient (80% A, 20% B) up to T=30.00 min; flow rate=20 ml / min; analysis time 30 min.

[0312] Method Q Chromatographic separation and isolation was performed using a Waters 2545 purification system equipped with a 2489 UV detector. Column: Xtimate, C18, OBD (250 × 21.2) mm, 5 μm. Compounds were analyzed with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile: mobile phase-A:THF (70:20:10) with gradients of T = 0 min (90% A, 10% B); T = 02.00 min (57% A, 43% B); T = 02.00 min (57% A, 43% B); T = 20.00 min (57% A, 43% B); T = 20.01 min (02% A, 98% B); T = 22.00 min (02% A, 98% B); T = 22.01 min (90% A, 10% B); T = 24.00 min (90% A, 10% B). B); Flow rate = 22 ml / min; Analysis time = 24 min.

[0313] Method R Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column NEW Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (65% A, 35% B), T = 25.00 min (55% A, 45% B), T = 25.01 min (02% A, 98% B), T = 27.00 min (02% A, 98% B), T = 27.01 min (65% A, 35% B), T = 31.00 min (65% A, 35% B), flow rate = 17 ml / min, and run time 31 min.

[0314] Method S Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. The column used was an XTIMATE, C18, OBD 19 × 250 mm, 5 μm column. The compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (59% A, 41% B), T = 17.00 min (59% A, 41% B), T = 17.01 min (02% A, 98% B), T = 19.00 min (02% A, 98% B), T = 19.01 min (59% A, 41% B), T = 22.00 min (59% A, 41% B), flow rate = 20 ml / min, and run time 22 min.

[0315] Method T Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. The column used was a NEW Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm column. The compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (55% A, 45% B), T = 22.00 min (52% A, 48% B), T = 22.01 min (02% A, 98% B), T = 24.00 min (02% A, 98% B), T = 24.01 min (55% A, 45% B), T = 27.00 min (55% A, 45% B), T = 27.00 min (55% A, 45% B), flow rate = 17 ml / min, and run time = 27 min.

[0316] Method U Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water + 5 mM ammonium bicarbonate, mobile phase B: acetonitrile, with a gradient of T = 0 min (58% A, 42% B), T = 22.00 min (50% A, 50% B), T = 22.01 min (02% A, 98% B), T = 24.00 min (02% A, 98% B), T = 24.01 min (58% A, 42% B), T = 27.00 min (58% A, 42% B), T = 27.00 min (58% A, 42% B), flow rate = 20 ml / min, run time 27 min.

[0317] Method V Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: NEW Xbridge Prep, C18, OBD 19 × 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile:THF (95:05) with a gradient of T = 0 min (54% A, 46% B), T = 25.00 min (54% A, 46% B), T = 25.01 min (02% A, 98% B), T = 27.00 min (02% A, 98% B), T = 27.01 min (54% A, 46% B), T = 30.00 min (54% A, 46% B), flow rate = 20 ml / min, run time 30 min.

[0318] Method W Chromatographic separation and isolation was performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: NEW X-bridge Prep, C18, OBD (250 × 19) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water + 5 mM ammonium bicarbonate, mobile phase B: acetonitrile, with a gradient of T = 0 min (80% A, 20% B); T = 02.00 min (70% A, 30% B); T = 02.00 min (70% A, 30% B); T = 21.00 min (70% A, 30% B); T = 21.01 min (02% A, 98% B); T = 23.00 min (02% A, 98% B); T = 23.01 min (80% A, 20% B) T = 25.00 min (80% A, 20% B); flow rate = 21 ml / min; run time 25 min.

[0319] Method X Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: C18, OBD (250 × 212) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (64% A, 36% B), T = 19.00 min (59% A, 41% B), T = 19.01 min (02% A, 98% B), T = 21.00 min (02% A, 98% B), T = 21.01 min (64% A, 36% B), T = 24.00 min (64% A, 36% B), flow rate = 22 ml / min, and run time 24 min.

[0320] Method Y Chromatographic separation and isolation were performed using a WATERS 2545 purification system equipped with a 2489 UV detector. Column: XTIMATE, C18, OBD (250 × 21.2) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile: mobile phase-A:THF (70:20:10) with a gradient of T = 0 min (58% A, 42% B), T = 27.00 min (57% A, 43% B), T = 27.01 min (02% A, 98% B), T = 29.00 min (02% A, 98% B), T = 29.01 min (58% A, 42% B), T = 32.00 min (58% A, 42% B), flow rate = 20 ml / min, and run time 32 min.

[0321] Method Z Chromatographic separation and isolation was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: XTIMATE, C18, OBD 19 x 250 mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water, mobile phase B: acetonitrile with a gradient of T = 0 min (85% A, 15% B); T = 02.00 min (68% A, 32% B); T = 02.00 min (68% A, 32% B); T = 21.00 min (68% A, 32% B); T = 21.01 min (02% A, 98% B); T = 23.00 min (02% A, 98% B); T = 23.01 min (85% A, 15% B) T = 25.00 min (85% A, 15% B); flow rate = 22 ml / min; run time 25 min.

[0322] Preparation of compounds 4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: Example 1 [ka]

[0323] 5-(benzyloxy)-4-(5-((4-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl)piperazin-1-yl)methyl)isoindoline-2-carbonyl)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 5-(benzyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (Intermediate 1) (1.7 g, 2.17 mmol, 1.0 eq) in DMF (17 mL) at room temperature under a nitrogen atmosphere was treated with KCO (1.5 g, 10.88 mmol, 5.0 eq) and stirred for 15 min. t-Butyl (2-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)ethyl)carbamate (CAS 1076199-21-7) (1.54 g, 4.35 mmol, 2.0 eq) was added and the resulting reaction mixture was allowed to stir at room temperature for 20 h, then diluted with ethyl acetate (80 mL) and washed with cold brine solution (5 x 80 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material (2.5 g) was purified by flash chromatography (the product was eluted with 0.8% methanol in DCM) to give the title compound (1.51 g, yield: 66%).

[0324] LCMS (Method A): 2.066 min, 2.108 min, MS: ES+ 1057.7 (M+1).

[0325] t-Butyl (2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)carbamate The procedure was carried out in two parallel batches on a 0.7 g scale. A stirred solution of 5-(benzyloxy)-4-(5-((4-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl)piperazin-1-yl)methyl)isoindoline-2-carbonyl)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (0.7 g, 0.66 mmol, 1.0 eq.) in EtOH:water (1:1) (7 mL) at room temperature was treated with a solution of potassium hydroxide (1.48 g, 26.51 mmol, 40 eq.) in water (1 mL). The reaction mixture was heated to 60 °C and stirred for 2 h. The resulting reaction mixture was slowly cooled to room temperature, poured into water (75 mL), neutralized with dilute HCl (pH = 6-7), and extracted with ethyl acetate (3 x 75 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material (0.91 g) was purified by flash chromatography (product was eluted with 5.8% methanol in DCM) to give the title compound (0.26 g, yield: 26%).

[0326] 1 H NMR (DMSO-d6, 400 MHz): 1.36 (s, 9H), 1.96 (s, 3H), 2.35 - 2.50 (m, 8H), 2.55 - 2.56 (m, 2H), 3.03 - 3.04 (m, 2H), 3.33 - 3.38 (m, 2H), 3.39 - 3.42 (m, 2H), 3.46 - 3.50 (m, 10H), 4.39 - 4.55 (m, 2H), 4.67 - 4.73 (m, 3H), 4.90 (d, J= 10.4 Hz, 1H), 6.29 (s, 1H), 6.76 (s, br, 1H), 7.13 - 7.21 (m, 2H), 7.24 - 7.30 (m, 4H), 7.34 (d, J= 7.2 Hz, 2H), 9.48 - 9.53 (m, 2H). LCMS (Method A): 1.472 min, MS: ES+ 749.4 (M+1). Analytical HPLC (Method C): 5.776 minutes.

[0327] (5-((4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)isoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone hydrochloride A stirred solution of t-butyl (2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)carbamate (0.23 g, 0.30 mmol, 1.0 eq.) in DCM (2.3 mL) at 0° C. was treated dropwise with 4 N HCl in dioxane (1.15 mL). The resulting reaction mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and the crude material (0.23 g) was triturated with diethyl ether (50 mL) to give the title compound (0.22 g, yield: 26%).

[0328] 1 H NMR (DMSO-d6, 400 MHz, D2O shake): 1.96 - 1.97 (m, 3H), 2.95 (m, br, 2H), 3.30 - 3.34 (m, br, 2H), 3.35 - 3.40 (m, br, 2H), 3.54 - 3.61 (m, 18H), 3.73 (m, br, 2H), 4.27 - 4.31 (m, 2H), 4.41 - 4.59 (m, 2H), 4.71 - 4.81 (m, 3H), 4.91 (d, J= 10.4 Hz, 1H), 6.35 (m, 1H), 7.24 - 7.37 (m, 5H), 7.45 - 7.60 (m, 3H) LCMS (Method A): 1.104 min, MS: ES+ 649.3 (M+1). Analytical HPLC (Method A): 4.555 min.

[0329] 4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: Example 1 A stirred solution of (5-((4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)isoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone hydrochloride (0.2 g, 0.29 mmol, 1.0 eq) in DMF (2 mL) at room temperature under nitrogen atmosphere was treated with DIPEA (0.3 g, 2.33 mmol, 8.0 eq.) and stirred for 15 min. 2-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (CAS: 835616-60-9) (0.096 g, 0.35 mmol, 1.2 eq.) was added and the resulting reaction mixture was heated to 120° C. for 1 h. The resulting reaction mixture was concentrated under vacuum at 45° C. in a genevac. The crude material (0.51 g) was purified by preparative HPLC (Method F) to give the title compound (0.021 g, yield: 7.5%).

[0330] 1H NMR (DMSO-d6, 400 MHz) Four aliphatic protons are hidden under the solvent peaks: 1.96 (s, 3H), 1.99 - 2.02 (m, 1H), 2.32 - 2.42 (m, 8H), 2.55 - 2.59 (m, 2H), 2.84 - 2.90 (m, 1H), 3.35 - 3.48 (m, 9H), 3.52 - 3.54 (m, 3H), 3.60 - 3.61 (m, 2H), 4.39 - 4.55 (m, 2H), 4.71 - 4.73 (m, 3H), 4.89 - 4.91 (m, 1H), 5.03 - 5.07 (m, 1H), 6.30 (s, 1H), 6.59 (s, br, 1H), 7.03 (d, J= 7.2 Hz, 1H), 7.12 - 7.19 (m, 3H), 7.24 - 7.35 (m, 5H), 7.54 - 7.59 (m, 1H), 9.51 - 9.56 (m, 2H), 11.11 (s, 1H). LCMS (Method A): 1.464 min, MS: ES+ 905.1 (M+1). Analytical HPLC (Method A): 7.552 min, 95%.

[0331] The following compounds were prepared using a procedure similar to Example 1 using Intermediate 1, 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (CAS: 835616-60-9) and the listed intermediates (Table 1):

[0332] JPEG2024541578000036.jpg255170JPEG2024541578000037.jpg255170JPEG2024541578000038.jpg255162JPEG2024541578000039.jpg100170

[0333] 4-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: Example 9 [ka]

[0334] A stirred solution of (2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone (Intermediate 3) (0.370 g, 0.78 mmol, 1 eq) and 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)acetaldehyde (Intermediate 4) (0.455 g, 1.01 mmol, 1.3 eq) in DCM (3.7 mL) at room temperature was treated with TEA (0.474 g, 4.70 mmol, 6.0 eq.) and NaCNBH (0.098 g, 1.56 mmol, 2 eq). The resulting reaction mixture was allowed to stir at room temperature for 2 hours and then concentrated in vacuo. The crude material was purified by preparative HPLC (Method B) to give the title compound (0.045 g, 6.4% yield) as an off-white solid.

[0335] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.96 (s, 3H), 1.97- 2.00 (m, 1H), 2.30 - 2.50 (m, 7H), 2.48 - 2.52 (m, 4H), 2.83 - 2.92 (m, 2H), 3.34 - 3.35 (m, 2H), 3.42 - 3.53 (m, 6H), 3.51 - 3.59 (m, 4H), 3.61 - 3.78 (m, 2H), 4.31 - 4.32 (m, 2H), 4.37 - 4.40 (m, 1H), 4.49 - 4.53 (m, 1H), 4.65 - 4.75 (m, 3H), 4.86 - 4.89 (m, 1H), 5.0 - 5.13 (m, 1H), 6.28 (s, 1H), 7.1 - 7.2 (m, 2H), 7.24 - 7.33 (m, 5H), 7.42 - 7.51 (m, 2H), 7.76 - 7.80 (m, 1H), 9.49 (s, 1H, D2O exchangeable), 9.55 (s, 1H, D2O exchangeable), 11.13 (s, 1H, D2O exchangeable). LCMS (Method A): 1.423 min, MS: ES+ 466.4 (M+1). Analytical HPLC (Method-C) 6.393 minutes., 95%.

[0336] The following compounds were prepared using procedures similar to Example 9 using the intermediates listed (Table 2):

[0337] JPEG2024541578000041.jpg255167JPEG2024541578000042.jpg255170

[0338] 5-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: Example 13 [ka]

[0339] A stirred solution of 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (Intermediate 5) (1 eq.) and (2-benzyloxy-4,6-dihydroxy-3-methyl-phenyl)-[5-(piperazin-1-ylmethyl)isoindolin-2-yl]methanone (Intermediate 3) (1 eq.) in NMP (5 mL per 100 mg of alkylating agent) at room temperature was treated with KHCO (2 eq.) and KI (1 eq.), and the mixture was heated to 50° C. overnight. The solution was cooled to ambient temperature, added to brine, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. Purification by column chromatography (DCM to DCM / 20% MeOH / 2% NH4OH) afforded the title compound (13% yield) as a yellow solid.

[0340] 1 H NMR (d6-DMSO) δ: 11.06 (1H, s), 9.54 (1H, s), 9.48 (1H, s), 7.56 (1H, dd, J = 8.3, 1.4), 7.41 -7.07 (9H, m), 7.01 (1H, s), 6.89 (1H, m), 6.30 (1H, s), 5.03 (1H, dd, J = 12.8, 5.1), 4.91 (1H, d, J = 10.6), 4.81 - 4.67 (3H, m), 4.55 (1H, d, J = 14.6), 4.42 (1H, d, J = 14.4), 3.66 - 3.21 (18H, m), 2.87 (1H, m), 2.65 - 2.18 (10H, m), 2.04 - 1.88 (4H, m). 13C NMR (d6-DMSO) δ: 172.82, 170.16, 167.69, 167.16, 165.88, 157.00, 154.68, 154.44, 152.05, 137.67, 137.47, 136.82, 136.27, 135.47, 134.91, 134.16, 128.21, 127.95, 127.78, 125.05, 123.38, 123.21, 122.72, 122.60, 116.17, 108.24, 98.72, 75.03, 69.80, 68.73, 68.23, 61.96, 57.21, 53.11, 52.60, 52.30, 51.23, 51.12, 48.63, 42.46, 30.99, 22.25, 8.68. LCMS (Method T2) m / z (ES+): 905.4 [M+1].

[0341] 3-(4-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 14 [ka]

[0342] A stirred solution of 3-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 6) (1 eq.) in acetone (10 mL / 100 mg relative to alcohol) at room temperature was treated with IBX (3 eq.) and the mixture was heated to reflux for 6 h. After cooling to ambient temperature, the solid was removed by filtration and washed with acetone. The filtrate was concentrated, DCM (10 mL / 100 mg relative to alcohol) was added and the solid was removed by filtration and washed with DCM. To this DCM solution, with vigorous stirring, was added (2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone (Intermediate 3) (1 eq.), followed by triethylamine (1.5 eq.) and sodium triacetoxyborohydride (1.5 eq.). The mixture was then stirred at ambient temperature overnight. The solution was washed with NaHCO3 solution (saturated aqueous), and the aqueous phase was further extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Purification by column chromatography (DCM / MeOH, 0-20% MeOH) followed by preparative HPLC afforded the title compound (10.1% yield).

[0343] 1H NMR (d6-DMSO) δ: 10.92 (1H, s), 9.61 - 9.37 (2H, br, s), 7.40 (1H, td, J = 7.9, 2.0), 7.37 - 7.02 (9H, m), 6.23 (1H, s), 5.04 (1H, ddd, J = 13.3, 5.1, 1.6), 4.84 (1H, d, J = 10.6), 4.74 - 4.58 (3H, m), 4.52 - 4.24 (3H, m), 4.21 - 4.10 (3H, m), 3.71 - 3.64 (2H, m), 3.54 - 3.21 (13H, m), 2.84 (1H, m), 2.51 (1H, m), 2.41 - 2.14 (10H, m), 1.97 - 1.85 (4H, m), 1.76 (1H, s). LCMS (Method T2) m / z (ES+): 892.41 [M+H + ] + .

[0344] 3-(4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 15 [ka]

[0345] Prepared according to the method described for Example 14 using 3-(4-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 7) (4.5% yield).

[0346] 1H NMR (d6-DMSO) δ: 11.01 (1H, s), 9.55 (1H, s), 9.50 (1H, s), 7.38 -7.12 (9H, m), 6.95 (1H, d, J = 7.5), 6.80 (1H, dd, J = 8.0, 2.7), 6.30 (1H, s), 5.59 - 5.53 (2H, m), 5.12 (1H, dd, J = 13.2, 5.0), 4.92 (1H, d, J = 10.6), 4.80 - 4.65 (3H, m), 4.55 (1H, d, J = 14.8), 4.42 (1H, d, J = 14.8), 4.23 (1H, d, J = 17.1), 4.12 (1H, d, J = 17.1), 3.61 - 3.36 (15H, m), 2.92 (1H, m), 2.63 (1H, m), 2.46 - 2.21 (11H, m), 2.07 - 1.94 (4H, m). LCMS (Method T2) m / z (ES+): 861.41 [M+H + ] + .

[0347] 3-(5-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 16 [ka]

[0348] Prepared according to the method described for Example 14 using 3-(5-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 8) (9.5% yield).

[0349] 1H NMR (d6-DMSO) δ: 10.85 (1H, s), 9.46 (1H, s), 9.41 (1H, s), 7.34 - 7.14 (7H, m), 7.13 - 7.04 (2H, m), 6.66 - 6.56 (2H, m), 6.28 (1H, m), 6.23 (1H, s), 4.94 (1H, dd, J = 13.3, 5.1), 4.84 (1H, d, J = 10.7), 4.74 - 4.56 (3H, m), 4.47 (1H, d, J = 15.0), 4.35 (1H, d, J = 15.0), 4.19 (1H, d, J = 16.6), 4.06 (1H, d, J = 16.6), 3.55 - 3.27 (14H, m), 3.22 - 3.14 (2H, m), 2.82 (1H, m), 2.51 (1H, m), 2.39 - 2.16 (10H, m), 2.00 - 1.78 (5H, m). LCMS (Method T2): m / z (ES+): 891.31 [M+H + ] + .

[0350] 3-(4-((2-(2-(2-(2-(4-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 17 [ka]

[0351] Prepared according to the method described for the last step of Example 14 using 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetaldehyde (Intermediate 9) and (2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone (Intermediate 10) and preparative HPLC purification (Method Y).

[0352] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 0.87 - 0.96 (m, 2H), 1.65 - 1.09 (m, 2H), 1.55 - 1.62 (m, 6H), 1.91 (s, 2H), 2.00 - 2.03 (m, 1H), 2.32 - 2.33 (m, 2H), 2.40 - 2.41 (m, 2H), 2.61 (s, 2H), 2.91 (m, 1H), 3.47 - 3.59 (m, 10H), 4.09 - 4.25 (m, 2H), 4.47 (s, 2H), 4.64 - 4.69 (m, 2H), 5.08 - 5.11 (dd, J = 4.8, 13.2 Hz, 1H), 5.59 (s, br, 1H), 6.24 (s, 1H), 6.79 (d, J = 6.4 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 7.16 - 7.31 (m, 3H), 8.54 (s, 1H), 9.37 (bs, 2H), 10.83 (bs, 1H). Aliphatic protons are hidden under the solvent peak. LCMS (Method I): 1.925 min, MS: ES+ 897.4 (M+1). HPLC (Method C): 5.85 min. 96.2%.

[0353] 5-(4-(2-(2-(2-((1-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carbonyl)piperidin-4-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione: Example 18 [ka]

[0354] t-Butyl-4-(2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)piperidine-1-carboxylate A solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)isoindoline-1,3-dione hydrochloride (CAS: 2222114-23-8) (0.7 g, 1.77 mmol, 1.0 eq.), t-butyl 4-(2-(2-(2-oxoethoxy)ethoxy)ethoxy)piperidine-1-carboxylate (Intermediate 11) (0.7 g, 2.12 mmol, 1.2 eq.) in THF (7 mL) at 0° C. was treated with STAB (0.75, 3.54 mmol, 2 eq.) and acetic acid (catalytic amount). The resulting reaction mixture was stirred at room temperature for 3 hours, then filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (product was eluted with 6% MeOH in DCM) to give the title compound (0.6 g, 0.88 mmol, yield: 50.1%).

[0355] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.24 (s, 2H),1.26 - 1.34 (m, 2H), 1.37 - 1.39 (m, 9H), 1.76 - 1.79 (m, 2H), 1.99 - 2.09 (m, 1H), 2.57 - 2.68 (m, 5H), 2.99 (m, 3H), 3.24 - 3.27 (m, 3H), 3.47 - 3.52 (m, 11H), 3.53 - 5.57 (m, 3H), 7.45 (d, J= 7.6 Hz, 1H), 7.72 (d, J= 11.2 Hz, 1H), 11.11 (s, 1H). LCMS (Method A): 1.432 min, MS: ES+ 676.3 (M+1).

[0356] 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(2-(2-(2-(piperidin-4-yloxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)isoindoline-1,3-dione A stirred solution of t-butyl 4-(2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)piperidine-1-carboxylate (0.57 g, 0.84 mmol, 1.0 eq.) in DCM (5.7 mL) at 0° C. under a nitrogen atmosphere was treated with 4 M HCl in dioxane (5.7 mL). The resulting reaction mixture was allowed to stir at room temperature for 30 minutes and then concentrated under reduced pressure. The crude material was triturated with diethyl ether (3×10 mL) followed by n-pentane (3×10 mL) to afford the title compound (0.5 g, quantitative yield) as a yellow solid.

[0357] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.64 - 1.71 (m, 4H), 1.91 - 1.96 (m, 4H), 2.03 - 2.06 (m, 1H), 2.60 - 2.99 (m, 5H), 3.15 (s, 3H), 3.30 - 3.48 (m, 7H), 3.50 - 3.58 (m, 10H), 3.61 - 3.87 (m, 3H), 3.88 - 3.98 (m, 2H) 5.11 - 5.15 (m, 1H), 7.59 (d, J= 7.2 Hz, 1H), 7.82 (d, J= 11.2 Hz, 1H) 11.13 (s, 2H). HCl salt. LCMS (Method A): 0.793 min, MS: ES+ 576.0 (M+1)

[0358] 5-(4-(2-(2-(2-((1-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carbonyl)piperidin-4-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione A stirred solution of 2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carboxylic acid (Intermediate 12) (0.3 g, 0.71 mmol, 1 eq.) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(2-(2-(2-(piperidin-4-yloxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)isoindoline-1,3-dione hydrochloride (0.43 g, 0.71 mmol, 1 eq.) in DMF (3 mL) at room temperature was treated with DCC (0.29 g, 1.43 mmol, 2 eq.). The reaction mixture was heated to 150° C. under microwave irradiation for 15 min. The reaction mixture was diluted with water (50 mL) and washed with EtOAc (3×30 mL). The desired product was found to be water soluble, therefore the aqueous layer was lyophilized and the crude material was purified by preparative HPLC (Method Z) followed by lyophilization of the pure fractions to give the title compound (0.030 g, yield: 5.9%) as a white solid.

[0359] 1 H NMR (DMSO-d6, 400 MHz, D2O exchange): δ ppm 1.1 -1.43(m, 3H), 1.75 - 1.85 (m, 4H), 2.07 (s, 3H), 3.16 - 3.17 (m, 3H), 3.22 - 3.26 (m, 4H), 3.50 (s, br, 11H), 4.35 - 4.38 (m, 2H), 4.44 - 4.46 (m, 2H), 4.71 - 4.76 (m, 3H), 4.90 - 4.93 (m, 1H), 5.10 - 5.12 (m, 1H), 6.31 (s, 1H), 7.24 - 7.45 (m, 9H), 7.71 (d, J= 11.6 Hz, 1H). Aliphatic protons are hidden under the solvent peak. LCMS (Method A): 7.346 min, MS: ES+ 978.5 (M+1). Analytical HPLC (Method C): 5.654 min. 98.7%.

[0360] 5-[2-[2-[2-[2-[2-[2-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione: Example 19 [ka]

[0361] A stirred solution of DMSO (0.83 g, 10.64 mmol, 3.5 eq.) in DCM (3 mL) was treated with oxalyl chloride (1.15 g, 9.13 mmol, 3.0 eq.) in DCM (3 mL) at −78° C. and stirred for 10 min. 2-(2,6-Dioxopiperidin-3-yl)-5-((14-hydroxy-3,6,9,12-tetraoxatetradecyl)amino)isoindoline-1,3-dione (Intermediate 13) (1.5 g, 3.04 mmol, 1 eq.) in DCM (6 mL) was added, followed by dropwise addition of TEA (1.84 g, 3.74 mmol, 6 eq.) at −78° C. The reaction mixture was stirred for 1 h, poured into ice-cold water (50 mL), and extracted with DCM (3 × 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material (2.0 g) was purified by flash chromatography (eluting the product with 4.0% MeOH in DCM) to give 14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxa-tetradecanal (0.4 g, yield: 26.7%) as a yellow oil, which was used directly in the next step. LCMS (Method H): 6.755 min, MS: ES+ 492.3 (M+1).

[0362] A stirred solution of (2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone (Intermediate 3) (0.280 g, 0.59 mmol, 1 eq.), 14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxatetradecanal (0.349 g, 0.70 mmol, 1.2 eq.) in THF (2.8 mL) was treated with acetic acid (2 drops, catalytic) and NaBH(OAc) at 0 °C. The resulting reaction mixture was stirred at room temperature for 1 h, concentrated in vacuo, and the crude material was purified by preparative HPLC (Method M), followed by lyophilization of the pure fractions to give the title compound (0.030 g, 5.3% yield) as an off-white solid.

[0363] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.96 (s, 3H), 2.13 - 2.18 (m, 3H), 2.33 (m, br, 5H), 2.67 - 2.89 (m, 2H), 3.41 - 3.58 (m, 16H), 4.41 (d, J= 14.8 Hz, 1H), 4.54 - 4.58 (m, 1H), 4.71 - 4.73 (m, br, 3H), 4.92 - 4.99 (m, 1H), 5.01 - 5.04 (m, br, 1H), 6.29 (s, 1H), 6.89 (d, J= 8.5 Hz, 1H), 7.00 (s, 1H), 7.13 - 7.22 (m, 3H), 7.24 - 7.35 (m, 5H), 7.55 (d, J = 8.0 Hz, 1H), 9.4 (brs, 2H), 11.1 (brs, 1H). Aliphatic protons are hidden under the water peak. LCMS (Method A): 1.435 min, MS: ES+ 950 (M+1). Analytical HPLC (Method C): 5.263 min. 95.1 %)

[0364] 3-(5-(4-(2-(1-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 20 [ka]

[0365] t-Butyl-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)-2-oxoethyl)piperidine-1-carboxylate A stirred solution of 1-(t-butoxycarbonyl)piperidine-4-carboxylic acid (CAS 157688-46-5) (1.45 g, 5.97 mmol, 1.0 eq.) in DMF (14.5 mL) was cooled to 0 °C and treated with EDC.HCl (1.37 g, 7.13 mmol, 1.2 eq.), HOAt (0.081 g, 0.59 mmol, 0.1 eq.), Intermediate 14 (2.4 g, 6.57 mmol, 1.1 eq.), and NMM (0.723 g, 7.16 mmol, 1.2 eq.). The resulting reaction mixture was stirred at room temperature for 1 h, poured into ice-cold water (200 mL), and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with ice-cold water (3 x 100 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give the title compound (3.0 g, 82%) as an off-white solid, which was used in the next step without purification. LCMS (Method A): 1.595 min, MS: ES+ 454.1 (M-100).

[0366] 3-(1-oxo-5-(4-(2-(piperidin-4-yl)acetyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride A stirred solution of tert-butyl 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)-2-oxoethyl)piperidine-1-carboxylate (3 g, 5.42 mmol, 1 eq.) in DCM (30 mL) was cooled to 0° C. 4 M HCl in dioxane (30 mL) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo and the crude material was triturated with diethyl ether (20 mL) followed by n-pentane (20 mL) and the resulting material was dried under high vacuum to give an off-white solid (3.0 g, quantitative, 6.13 mmol).

[0367] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.36 - 1.39 (m, 2H), 1.81 - 1.84 (m, 2H), 1.95 - 1.98 (m, 2H), 2.34 - 2.39 (m, 3H), 2.71 - 2.75 (m, 1H), 2.84 - 2.90 (m, 3H), 2.99 - 3.1 (m, 1H), 3.20 - 3.34 (m, 6H), 3.62 (s, br, 4H), 4.20 - 4.24 (m, 1H), 4.33 - 4.36 (m, 1H), 5.07 - 5.08 (m, 1H), 7.08 - 7.11 (m, 2H), 7.55 (d, J= 8.4 Hz, 1H), 8.72 - 8.74 (m, 1H), 8.91 - 8.93 (m, 1H), 10.97 (s, 1H). LCMS (Method A): 0.881 min, MS: ES+ 454.0 (M+1).

[0368] t-Butyl 5-((4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)-2-oxoethyl)piperidin-1-yl)methyl)isoindoline-2-carboxylate Three parallel batches were carried out as follows: A stirred solution of 3-(1-oxo-5-(4-(2-(piperidin-4-yl)acetyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride (1 g, 2.04 mmol, 1 eq.) in DMF (10 mL) at room temperature was treated with DIPEA (0.79 g, 6.13 mmol, 3 eq.) and t-butyl 5-(bromomethyl)isoindoline-2-carboxylate (described in the preparation of Intermediate 1). The reaction mixture was heated to 70° C. and stirred for 1 h. The reaction mixture was poured into ice-cold water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with ice-cold water (3×50 mL), dried over NaSO, filtered, and concentrated in vacuo to give the title compound (2.5 g, 60%) as an off-white solid.

[0369] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.16 - 1.22 (m, 2H), 1.45 (s, 9H), 1.63 - 1.66 (m, 3H), 1.91 - 1.99 (m, 3H), 2.28 - 2.32 (m, 2H), 2.35 - 2.39 (m, 1H), 2.56 (s, 1H), 2.73 - 2.77 (m, 2H), 2.86 - 2.94 (m, 1H), 3.26 - 3.31 (m, 4H), 3.36 - 3.43 (m, 2H), 3.61 (s, br, 4H), 4.21 (d, J= 16.8 Hz, 1H), 4.34 (d, J= 16.8 Hz, 1H), 4.55 - 4.57 (m, br, 4H), 5.06 (q, J= 5.2 Hz, 13.2 Hz, 1H), 7.07 - 7.09 (m, 2H), 7.21 - 7.26 (m, 3H), 7.54 (d, J= 8.4 Hz, 1H), 10.97 (s, 1H). LCMS (Method A): 1.409 min, MS: ES+ 685.3 (M+1).

[0370] 3-(5-(4-(2-(1-(isoindolin-5-ylmethyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride A stirred solution of t-butyl 5-((4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)-2-oxoethyl)piperidin-1-yl)methyl)isoindoline-2-carboxylate (2.5 g, 3.65 mmol, 1 eq.) in DCM (25 mL) was cooled to 0° C. and treated dropwise with 4 M HCl in dioxane (25 mL), and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo, and the crude material was triturated with diethyl ether (20 mL) followed by n-pentane (20 mL); the resulting material was dried under high vacuum to give the title compound (2.5 g, quantitative, 4.03 mmol) as an off-white solid.

[0371] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.54 - 1.60 (m, 2H), 1.67 - 1.8 (m, 1H), 1.84 - 1.97 (m, 4H), 2.32 - 2.39 (m, 2H), 2.56 - 2.67 (m, 1H), 2.87 - 2.95 (m, 3H), 2.95 (s, 1H), 3.27 - 3.32 (m, 5H), 3.60 (s, br, 4H), 4.19 - 4.37 (m, 4H), 4.51 - 4.52 (m, br, 4H), 5.06 (q, J= 4.8 Hz, 13.2 Hz, 1H), 7.07 - 7.09 (m, 2H), 7.47 -7.62 (m, 4H), 10.03 (s, 2H), 10.97 (s, 1H). LCMS (Method A): 0.826 min, MS: ES+ 585.1 (M+1).

[0372] 3-(5-(4-(2-(1-((2-(2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione A stirred solution of 2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoic acid (Intermediate 15) (1.5 g, 4.07 mmol, 1 eq.) in DMF (15 mL) at 0° C. was treated with HATU (2.32 g, 6.10 mmol, 1.5 eq.) and DIPEA (1.05 g, 8.14 mmol, 2 eq.). 3-(5-(4-(2-(1-(isoindolin-5-ylmethyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (2.78 g, 4.48 mmol, 1.1 eq.) was added at 0° C., and the resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into ice-cold water (100 mL) and extracted with ethyl acetate (3×100 mL). A sticky solid material precipitated, which was dissolved by adding DMF (100 mL). The combined organics were then dried over NaSO, filtered, and concentrated in vacuo to give an off-white solid (1.2 g, 43%), which was used in the next step without purification. LCMS (Method A): 1.754 min, 1.808 min, MS: ES+ 935.3 (M+1).

[0373] 3-(5-(4-(2-(1-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 20 A stirred solution of 3-(5-(4-(2-(1-((2-(2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidin-4-yl)acetyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (1 g, 1.07 mmol, 1 eq.) in EtOH (10 mL) at 0° C. was treated dropwise with 4 M HCl in dioxane (10 mL). The resulting reaction mixture was stirred at 0° C. for 7 h. The reaction mixture was concentrated under reduced pressure and the crude material was purified by preparative HPLC (Method N) followed by lyophilization of the pure fractions to afford the title compound (0.430 g, yield: 47%) as a white solid.

[0374] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 0.89 - 0.96 (m, 2H), 1.03 - 1.21 (m, 5H), 1.54 (s, br, 3H), 1.61 - 1.63 (m, 6H), 1.87 (s, 1H), 1.91 (s, 3H), 1.87 - 1.96 (m, 2H), 2.28 (t, J= 6.0 Hz, 2H), 2.3 - 2.4 (m, 1H), 2.56 (s, 1H), 2.75 - 2.76 (m, 2H), 2.85 - 2.96 (m, 1H), 3.25 - 3.26 (m, 2H), 3.29 - 3.42 (m, 4H), 3.46 - 3.49 (m, 1H), 3.61 - 3.64 (m, 5H), 4.27 (q, J= 16.8 Hz, 51.2 Hz, 2H), 4.47 - 4.48 (m, br, 2H), 4.69 (s, br, 2H), 5.06 (dd, J= 5.2 Hz, 13.2 Hz, 1H), 6.24 (s, 1H), 7.06 - 7.08 (m, 2H), 7.16 - 7.21 (m, 2H), 7.29 - 7.32 (m, 1H), 7.54 (d, J= 8.4 Hz, 1H), 9.37 (s, 1H), 9.47 (s, 1H), 10.97 (s, 1H). LCMS (Method I): 1.778 min, MS: ES+ 847.5 (M+1). Analytical HPLC (Method D): 6.34 min 98.9%.

[0375] 3-(5-(4-(1-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 21 [ka]

[0376] t-Butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carbonyl)piperidine-1-carboxylate A stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1.4 g, 6.11 mmol, 1.0 eq.) in DMF (14 mL) was cooled to 0 °C. EDC.HCl (1.41 g, 7.34 mmol, 1.2 eq.), HOAt (0.083 g, 0.61 mmol, 0.1 eq.), (Intermediate 14) (2.4 g, 6.57 mmol, 1.1 eq.), and NMM (0.741 g, 7.34 mmol, 1.2 eq.) were added, and the resulting reaction mixture was stirred at room temperature for 1 h. The reaction mixture was poured into ice-cold water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with ice-cold water (3 × 50 mL), dried over NaSO, filtered, and concentrated in vacuo. The isolated crude material was purified by reverse phase column chromatography (product was eluted with 34% ACN in water) to give the title compound (2.4 g, yield: 67%) as an off-white solid, which was used directly in the next step. LCMS (Method A): 1.541 min, MS: ES+ 440.0 (M-100).

[0377] 3-(1-oxo-5-(4-(piperidine-4-carbonyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride A stirred solution of t-butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carbonyl)piperidine-1-carboxylate (2.4 g, 4.45 mmol, 1 eq.) in DCM (24 mL) was cooled to 0° C. 4 M HCl in dioxane (24 mL) was added dropwise and the reaction was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo and the crude material was triturated with diethyl ether (20 mL) followed by n-pentane (20 mL) and dried under high vacuum to give the title compound (2.28 g, quantitative) as an off-white solid.

[0378] 1H NMR (DMSO-d6, 400 MHz, D2O exchange): δ ppm 1.73 - 1.82 (m, 4H), 1.95 - 1.98 (m, 1H), 2.33 - 2.40 (m, 1H), 2.54 - 2.61 (m, 1H), 2.86 - 3.1 (m, 4H), 3.20 - 3.40 (m, 6H), 3.58 (s, br, 4H), 4.25 (m, 1H), 4.32 (m, 1H), 5.04 - 5.08 (m, 1H), 7.10 - 7.16 (m, 2H), 7.55 - 7.59 (m, 1H). LCMS (Method A): 0.823 min, MS: ES+ 440.1 (M+1).

[0379] t-Butyl 5-((4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carbonyl)piperidin-1-yl)methyl)isoindoline-2-carboxylate A stirred solution of 3-(1-oxo-5-(4-(piperidine-4-carbonyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.7 g, 1.47 mmol, 1 eq.) in DMF (0.75 mL) at room temperature was treated with DIPEA (0.38 g, 2.94 mmol, 2 eq.) followed by t-butyl 5-(bromomethyl)isoindoline-2-carboxylate (previously described in the preparation of Intermediate 1) (0.472 g, 1.91 mmol, 1.3 eq.). The resulting reaction mixture was heated to 70° C. and stirred for 1 h. The reaction mixture was poured into ice-cold water (100 mL) and extracted using ethyl acetate (3×100 mL). The combined organic layers were washed with ice-cold water (3 x 50 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (1.9 g, yield: 58%) as an off-white solid, which was used directly in the next step. LCMS (Method A): 1.36 min, 85.16 %, 210 nm MS: ES+ 671.3

[0380] 3-(5-(4-(1-(isoindolin-5-ylmethyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride A stirred solution of t-butyl 5-((4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carbonyl)piperidin-1-yl)methyl)isoindoline-2-carboxylate (1.9 g, 2.83 mmol, 1 eq.) in DCM (19 mL) was cooled to 0° C. and treated dropwise with 4 M HCl in dioxane (19 mL). The reaction mixture was stirred at room temperature for 1 h, concentrated in vacuo, and the crude material was triturated with diethyl ether (20 mL) followed by n-pentane (20 mL). The resulting solid material was dried under high vacuum to give the title compound (1.8 g, quantitative) as an off-white solid.

[0381] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.82 - 1.96 (m, 4H), 2.89 - 2.96 (m, 3H), 3.17 - 3.47 (m, 5H), 3.56 - 3.67 (m, 6H), 4.20 - 4.4 (m, 3H), 4.45 - 4.54 (m, 6H), 5.04 - 5.08 (m, 1H), 5.77 (s, 2H), 7.15 - 7.16 (m, 1H), 7.4 - 7.66 (m, 5H), 9.80 (s, 1H), 9.98 - 10.06 (m, 2H), 10.61 (s, 1H), 10.96 (s, 1H). LCMS (Method A): 0.756 min, MS: ES+ 571.2 (M+1).

[0382] 3-(5-(4-(1-((2-(2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione A stirred solution of 2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoic acid (Intermediate 15) (0.850 g, 2.31 mmol, 1 eq.) in DMF (8.5 mL) at 0° C. was treated with HATU (1.32 g, 3.47 mmol, 1.5 eq.) and DIPEA (0.59 g, 4.61 mmol, 2 eq.). 3-(5-(4-(1-(isoindolin-5-ylmethyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.82 g, 2.99 mmol, 1.3 eq.) was added, and the resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo to give crude material (2.0 g) which was purified by flash chromatography (product eluted with 10% MeOH:DCM) to give the title compound (0.8 g, 38% yield) as an off-white solid. LCMS (Method A): 1.669 min, 1.718 min, MS: ES+ 921.3 (M+1).

[0383] 3-(5-(4-(1-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 21 A stirred solution of 3-(5-(4-(1-((2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.8 g, 0.86 mmol, 1 eq.) in EtOH (8 mL) at 0° C. was treated dropwise with 4 M HCl in dioxane (8 mL). The resulting reaction mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure and the resulting crude material was purified by preparative HPLC (Method O) followed by lyophilization of the pure fractions to give the title compound (0.114 g, 16% yield) as a white solid.

[0384] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.88 - 1.02 (m, 2H), 1.07 - 1.24 (m, 3H), 1.56 - 1.59 (m, 9H), 1.91 (s, 3H), 1.94 - 1.97 (m, 2H), 2.81 - 2.87 (m, 2H), 2.90 - 2.94 (m, 1H), 3.26 - 3.27 (m, 4H), 3.43 - 3.50 (m, 3H), 3.60 - 3.65 (m, 4H), 4.19 - 4.25 (m, 1H), 4.32 - 4.36 (m, 1H), 4.49 (m, br, 2H), 4.70 (m, br, 2H), 5.03 - 5.08 (m, 1H), 6.24 (s, 1H), 7.06 - 7.09 (m, 2H), 7.17 - 7.23 (m, 2H), 7.31 - 7.33 (m, 1H), 7.54 (d, J = 8.4 Hz, 1H), 9.42 (d, J = 37.2 Hz, 2H), 10.97 (s, 1H). Aliphatic protons are hidden under the solvent peak. LCMS (Method A): 1.464 min, MS: ES+ 833.3 (M+1). Analytical HPLC (Method C): 6.22 min. 97.1%.

[0385] 3-(5-(4-((1-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Example 22 [ka]

[0386] t-Butyl 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate A stirred solution of 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride (Intermediate 14) (0.9 g, 2.74 mmol, 1.0 eq.) in THF (10 mL) at 0 ° C. was treated with t-butyl 4-formylpiperidine-1-carboxylate (0.7 g, 3.29 mmol, 1.2 eq.) (CAS: 137076-22-3), STAB (1.16 g, 5.48 mmol, 2.0 eq.), and acetic acid (catalytic) at 0 ° C. The resulting reaction mixture was stirred at room temperature for 4 hours, concentrated under reduced pressure, and the crude material was purified by flash chromatography (the product was eluted with 5.0% MeOH in DCM) to give the title compound (0.9 g, 1.71 mmol, yield: 62%) as an off-white solid.

[0387] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 0.94 - 1.00 (m, 2H), 1.38 (s, 9H), 1.69 (d, J= 11.2 Hz, 2H), 1.91 - 1.97 (m, 1H), 2.17 (d, J= 6.4 Hz, 2H), 2.34 - 2.39 (m, 1H), 2.67 - 2.70 (m, 2H), 2.87 - 2.91 (m, 1H), 3.33 (s, 4H), 3.91 - 3.94 (m, 2H), 4.18 - 4.35 (m, 2H), 5.03 - 5.07 (m, 1H), 7.05 (d, J= 8.4 Hz, 2H), 7.52 (d, J= 8.4 Hz, 1H), 10.95 (s, 1H). Aliphatic protons are hidden under the solvent peak. LCMS (Method A): 1.134 min, MS: ES+ 426.12 (M-100).

[0388] 3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride A stirred solution of t-butyl 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate (0.9 g, 1.71 mmol, 1.0 eq.) in DCM (10 mL) at 0° C. was treated dropwise with 4 M HCl in dioxane (5 mL). The resulting reaction mixture was stirred at room temperature for 2 hours. The resulting reaction mixture was concentrated under reduced pressure, and the crude material was triturated with diethyl ether (10 mL) to afford the title compound (0.9 g, 2.11 mmol, yield: quantitative) as an off-white solid.

[0389] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.44 - 1.47 (m, 2H), 1.91 - 2.05 (m, 3H), 2.20 (m, br, 1H), 2.37 - 2.41 (m, 1H), 2.56 - 2.61 (m, 1H), 2.81 - 2.90 (m, 3H), 3.08 - 3.12 (m, 4H), 3.24 - 3.27 (m, 3H), 3.47 - 3.61 (m, 2H), 3.96 - 3.99 (m, 2H), 4.21 - 4.38 (m, 2H), 5.04 - 5.09 (m, 1H), 7.16 (t, J= HCl salt. LCMS (Method A): 0.574 min, MS: ES+ 426.02 (M+1).

[0390] 3-(5-(4-((1-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Example 22) A stirred solution of 3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.4 g, 0.94 mmol, 1.0 eq.) in DMF (2 mL) at room temperature was treated with 2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carboxylic acid (Intermediate 12) (0.39 g, 0.94 mmol, 1.0 eq.) and DCC (0.38 g, 1.88 mmol, 2.0 eq.). The resulting reaction mixture was heated to 150 °C under microwave irradiation and stirred for 15 min. The reaction mixture was diluted with ice-cold water (30 mL) and extracted with ethyl acetate (30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The desired product was found to be water soluble, therefore the aqueous layer was lyophilized and washed with 10% MeOH:DCM solution. The resulting filtrate was concentrated under high vacuum to give the crude material, which was purified by preparative HPLC to give the title compound (0.105 g, 15% yield) as an off-white solid.

[0391] high temperature 1 H NMR (DMSO-d6, 400 MHz, 348.5K): δ ppm 1.20 (s, br, 3H), 1.86 (s, br, 2H), 1.99 (s, 3H), 2.35 (s, br, 1H), 2.60 - 2.70 (m, 2H), 2.98 (s, 2H), 3.52 (s, br, 4H), 3.99 (s, br, 4H), 4.25 - 4.38 (m, 2H), 4.56 (s, br, 2H), 4.78 - 5.03 (m, 5H), 4.99 - 5.04 (m, 1H), 6.38 (s, 1H), 7.10 (s, br, 2H), 7.24 - 7.42 (m, 8H), 7.55 (d, br, J = 8Hz, 1H), 9.31 - 9.36 (m, 2H), 10.70 (s, 1H). Aliphatic protons are hidden under the solvent peak. LCMS (Method A): 1.298 min, MS: ES+ 827.27 (M+1). Analytical HPLC (Method C): 5.182 min. 95.9%

[0392] 5-(4-((1-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione: Example 23 Prepared using a method similar to Example 22 from 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)isoindoline-1,3-dione hydrochloride and t-butyl 4-formylpiperidine-1-carboxylate (CAS: 137076-22-3) and preparative HPLC purification (Method X).

[0393] high temperature 1 H NMR (DMSO-d6, 400 MHz, 348K): δ ppm 1.12 - 1.14 (m, 2H), 1.75 - 1.78 (m, 2H), 1.85 (m, br, 1H), 1.99 (s, 3H), 2.07 - 2.08 (m, 1H), 2.25 - 2.33 (m, 2H), 2.60 - 2.68 (m, 5H), 2.85 - 2.93 (m, 2H), 3.28 (s, br, 4H), 4.00 (s, br, 4H), 4.56 (s, br, 2H), 4.77 (s, br, 2H), 4.79 - 4.9 (m, 2H), 5.04 - 5.08 (m, 1H), 6.38 (s, 1H), 7.22 -7.42 (m, 7H), 7.43 (d, J= 7.6 Hz, 2H), 7.64 (d, J= 11.6 Hz, 1H), 9.52 (bs, 2H). LCMS (Method A): 1.419 min, MS: ES+ 859.2 (M+1). Analytical HPLC (Method B): 5.240 min. 97.9%.

[0394] (2S,4R)-1-((S)-2-(11-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-11-oxoundecanamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide: Example 24 [ka]

[0395] 11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoic acid A stirred solution of undecanedioic acid (3.77 g, 17.45 mmol, 5.0 eq.) (CAS: 1852-04-6) in DCM:THF (1:1) (37.5 mL) at 0 °C was treated with EDC.HCl (0.8 g, 4.17 mmol, 1.2 eq.) and HOAt (0.57 g, 4.19 mmol, 1.2 eq.). Then, (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CAS 2137142-47-1) (1.5 g, 3.49 mmol, 1.0 eq.) (CAS: 1448297-52-6) and TEA (1.23 g, 12.18 mmol, 3.5 eq.) were added, and the resulting reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and the crude material was purified by column chromatography (the product was eluted in 8% MeOH in DCM) to obtain the title compound (2.5 g, quantitative, 3.97 mmol) as a sticky solid.

[0396] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.93 (s, 6H), 1.18 (t, J= 18 Hz, 10H), 1.24 (s, br, 6H), 1.46 - 1.47 (m, 3H), 1.88 - 1.89 (m, 1H), 2.03 - 2.18 (m, 2H), 2.18 (t, J= 18 Hz, 2H), 2.22 - 2.28 (m, 1H), 2.45 (s, 3H), 3.04 - 3.09 (m, 6H), 3.16 (d, J= 4.8 Hz, 1H), 3.65 - 3.66 (m, 1H), 4.23 - 4.24 (m, 1H), 4.35 (s, br, 1H), 4.40 - 4.44 (m, 1H), 4.54 (d, J= 9.2 Hz, 1H), 7.37 - 7.43 (m, 3H), 7.86 (d, J= 9.2 Hz, 1H), 8.57 - 8.60 (m, 1H), 8.99 (s, 1H), 9.72 - 9.73 (m, 1H), 11.9 - 12.1 (m, 1H). LCMS (Method A): 1.737 min, MS: ES+ 629.3 (M+1).

[0397] (2S,4R)-1-((S)-2-(11-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-11-oxoundecanamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide: Example 24 A solution of 11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoic acid (1.43 g, 2.28 mmol, 1 eq.) in DMF (14.3 mL) at room temperature was treated with EDC.HCl (0.53 g, 2.76 mmol, 1.22 eq.) and HOAt (0.031 g, 0.23 mmol, 0.1 eq.). (2-(Benzyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone (Intermediate 3) (2.15 g, 4.54 mmol, 2.0 eq.) and NMM (0.55 g, 2.72 mmol, 1.2 eq.) were added and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 × 200 mL). The organic layer was washed with ice-cold water (3 × 100 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material was purified by preparative HPLC (Method P) followed by lyophilization of the pure fractions to give the title compound (0.289 g, 14% yield) as a white solid.

[0398] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.93 (s, 8H), 1.23 (s, 10H), 1.86 (s, 5H), 1.86 - 1.93 (m, 1H), 1.97 (s, 3H), 2.01 - 2.06 (m, 1H), 2.08 - 2.12 (m, 1H), 2.24 - 2.33 (m, 5H), 2.44 (s, 3H), 3.43 - 3.47 (m, 4H), 3.62 - 3.65 (m, 2H), 4.18 - 4.24 (m, 1H), 4.35 (s, 1H), 4.41 - 4.44 (m, 3H), 4.53 - 4.56 (m, 2H), 4.68 - 4.72 (m, 3H), 4.74 - 4.90 (m, 1H), 5.15 (s, 1H), 6.30 (s, 1H), 7.17 (d, J= 8 Hz, 1H), 7.21 - 7.36 (m, 5H), 7.37 - 7.43 (m, 6H), 7.86 (d, J= 9.2 Hz, 1H), 8.58 (t, J= 5.6 Hz, 1H), 8.99 (s, 1H), 9.53 (s, br, 2H). LCMS (Method A): 1.636 min, MS: ES+ 1084.5 (M+1). Analytical HPLC (Method C): 7.42 minutes, 98.4%.

[0399] The following compounds were prepared using procedures similar to Example 24 using the intermediates listed (Table 3):

[0400] JPEG2024541578000054.jpg248170JPEG2024541578000055.jpg245170JPEG2024541578000056.jpg235170

[0401] Preparation of intermediates 5-(Benzyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate): Intermediate 1 [ka]

[0402] 2-(t-butyl) 5-methylisoindoline-2,5-dicarboxylate A solution of tert-butyl 5-bromoisoindoline-2-carboxylate (CAS: 201940-08-1) (36 g, 120.8 mmol, 1 eq.) in MeOH:DMF (324:36 mL) at room temperature in an autoclave was treated with TEA (48.8 mL, 362.4 mmol, 3.0 eq.) and degassed using N for 10-15 min; then, PdCl(dppf) (17.67 g, 24.16 mmol, 0.2 eq.) was added. The reaction mixture was pressurized at 20 kg / cm. 2 The resulting reaction mixture was heated to 120° C. and stirred for 16 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude material was diluted with water (800 mL) and extracted into EtOAc (2×900 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, eluting with 20% ethyl acetate in hexanes) to give the title compound (28 g).

[0403] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.45 (s, 9H), 3.84 (s, 3H), 4.62 (s, br, 4H), 7.46 (t, J= 4.8 Hz, 1H), 7.88 - 7.91 (dd, J= 8.8 Hz, 12.8 Hz, 2H). LCMS (Method A): 2.096 min, MS: ES+ 222.09 (M-56).

[0404] t-Butyl 5-(hydroxymethyl)isoindoline-2-carboxylate A stirred solution of 2-(t-butyl) 5-methylisoindoline-2,5-dicarboxylate (31 g, 111.8 mmol) in THF (310 mL) at 0 °C was treated dropwise with LiAlH solution (1 M in THF) (111 mL, 111.8 mmol, 1.0 eq.). The resulting reaction mixture was stirred at 0 °C for 3 h. The resulting reaction mixture was poured into cold saturated aqueous ammonium chloride solution (800 mL) and extracted into ethyl acetate (3 × 900 mL). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated in vacuo to give the title compound (15.0 g). This material was used in the next step without further purification.

[0405] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.45 (s, 9H), 4.48 (d, J= 5.6 Hz, 2H), 4.55 - 4.56 (m, 4H), 5.20 (t, J= 5.6 Hz, 1H), 7.19 - 7.26 (m, 3H). LCMS (Method A): 1.685 min, MS: ES+ 194.03 (M-56).

[0406] t-Butyl 5-(bromomethyl)isoindoline-2-carboxylate A stirred solution of t-butyl-5-(hydroxymethyl)isoindoline-2-carboxylate (12 g, 48.19 mmol, 1.0 eq.) in DCM (120 mL) at 0° C. was treated with T3P (15.15 g, 57.83 mmol, 1.2 eq.) and CBr4 (19.14 g, 57.83 mmol, 1.2 eq.). The resulting reaction mixture was stirred at room temperature for 30 minutes and concentrated under reduced pressure to give the crude material (45.0 g), which was purified by column chromatography (the product was eluted with 20% ethyl acetate in hexanes) to give the title compound (12.0 g, 80% yield) as a white solid.

[0407] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.45 (s, 9H), 4.56 (d, J= 8.4 Hz, 4H), 4.71 (s, 2H), 7.29 - 7.40 (m, 3H).

[0408] t-Butyl 5-((4-(((9H-fluoren-9-yl)methoxy)carbonyl)piperazin-1-yl)methyl)isoindoline-2-carboxylate A stirred solution of t-butyl 5-(bromomethyl)isoindoline-2-carboxylate (12 g, 38.46 mmol, 1.0 eq) in DMF (120 mL, 10 v) under a nitrogen atmosphere at room temperature was treated with K2CO3 (15.92 g, 15.38 mmol, 3.0 eq) and stirred for 15 min. Fmoc-piperazine.HCl (11.84 g, 38.46 mmol, 1.0 eq) (CAS: 215190-22-0) was added to the reaction mixture and stirred at rt for 2 h. The resulting reaction mixture was diluted with ethyl acetate (250 mL) and washed with cold brine solution (4 x 250 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the title compound (12 g, yield: 60%).

[0409] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.45 (s, 9H), 3.33 (s, 1H), 2.21 (s, br, 4H), 3.26 - 3.42 (s, br, 4H), 3.44 (s, 2H), 4.23 - 4.26 (m, LCMS (Method A): 1.806 minutes, MS: ES+ 540.3 (M+1).

[0410] (9H-Fluoren-9-yl)methyl 4-(isoindolin-5-ylmethyl)piperazine-1-carboxylate dihydrochloride A stirred solution of 5-((4-(((9H-fluoren-9-yl)methoxy)carbonyl)piperazin-1-yl)methyl)isoindoline-2-carboxylate (8.0 g, 14.83 mmol, 1.0 eq.) in DCM (80 mL) at 0° C. was treated dropwise with 4 N HCl in dioxane (40 mL) and then stirred at rt for 1 h. The resulting reaction mixture was concentrated under reduced pressure. The crude material was triturated with diethyl ether (3×40 mL) to give the title compound (8 g, quantitative).

[0411] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 2.92 - 2.95 (m, 2H), 3.27 (d, J= 12 Hz, 2H), 3.74 (s, br, 2H), 3.96 - 3.98 (m, 2H), 4.26 - 4.37 (m, 5H), 4.52 (t, J= 5.2 Hz, 4H), 7.34 (t, J= 7.2 Hz, 2H), 7.42 (t, J= 7.2 Hz, 2H), 7.49 (d, J= 7.6 Hz, 1H), 7.63 (d, J= 6.8 Hz, 4H), 7.90 (d, J= 7.6 Hz, 2H), 10.16 (bs, 2H), 11.67 (bs, 1H) 2.HCl salt. LCMS (Method A): 1.184 min, MS: ES+ 440.2 (M+1).

[0412] (9H-Fluoren-9-yl)methyl 4-((2-(2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate A stirred solution of 2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid (Intermediate 16) (7 g, 12.02 mmol, 1.0 eq.) in DMF (70 mL) at 0 °C under a nitrogen atmosphere was treated with HATU (6.85 g, 18.04 mmol, 1.5 eq.) and DIPEA (4.65 g, 36.08 mmol, 3.0 eq.) and stirred for 15 min. (9H-Fluoren-9-yl)methyl 4-(isoindolin-5-ylmethyl)piperazine-1-carboxylate dihydrochloride (6.3 g, 13.23 mmol, 1.1 eq.) was added, and the reaction mixture was stirred at 0 °C for 1 h. The resulting reaction mixture was diluted with ethyl acetate (250 mL) and washed with cold brine solution (4 × 250 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (product eluted in 52% ethyl acetate in hexanes) to give the title compound, which was used directly in the next step (6.3 g, yield: 52%). LCMS (Method A): 2.317 min, 2.346 min, MS: ES+ 1004.6 (M+1).

[0413] 5-(Benzyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate): Intermediate 1 A stirred solution of (9H-fluoren-9-yl)methyl 4-((2-(2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)-benzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate (3.3 g, 3.29 mmol, 1.0 eq) in THF (33 mL) at 0° C. under a nitrogen atmosphere was treated with DBU (1.0 g, 6.58 mmol, 2.0 eq.). The resulting reaction mixture was allowed to stir at 0° C. for 5 minutes. The resulting reaction mixture was poured into water (120 mL) and extracted with ethyl acetate (6×100 mL), followed by 10% MeOH in DCM (3×100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (the product was eluted with 15% methanol in DCM) to give the title compound (1.72 g, yield: 67%).

[0414] 1 H NMR (DMSO-d6, 400 MHz): 1.87 (s, 3H), 2.19 (s, 3H), 2.46 (m, br, 7H), 2.91 - 2.95 (m, 4H), 3.47 - 3.83 (m, 2H), 3.80 (d, J= 14.4 Hz, 1H), 4.33 - 4.38 (m, 1H), 4.65 (s, 2H), 4.79 (s, 2H), 6.87 (d, J= 6.8 Hz, 1H), 7.09 - 7.13 (m, 1H), 7.19 - 7.28 (m, 6H), 7.30 - 7.34 (m, 3H), 7.54 (d, J= 7.6 Hz, 2H), 7.69 (d, J= 6.8 Hz, 2H), 7.78 (d, J= 7.6 Hz, 2H). LCMS (Method A): 1.847 min, 1.878 min, MS: ES+ 782.1 (M+1).

[0415] 5-(Cyclohexyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate): Intermediate 2 [ka]

[0416] A stirred solution of 2-(cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid (Intermediate 17) (20 g, 34.0 mmol, 1.0 eq.) in DMF (200 mL) under a nitrogen atmosphere at 0° C. was treated with HATU (19.3 g, 51.02 mmol, 1.5 eq.) and DIPEA (8.7 g, 68.02 mmol, 2.0 eq.) and stirred for 15 min. (9H-Fluoren-9-yl)methyl 4-(isoindolin-5-ylmethyl)piperazine-1-carboxylate hydrochloride (described in the preparation of Intermediate 1) (21 g, 44.21 mmol, 1.1 eq.) was added to the reaction mixture, which was then stirred at 0° C. for 16 h. The resulting reaction mixture was diluted with water (100 mL) and extracted using EtOAc (3 × 100 mL), and the organic layer was washed with cold brine solution (3 × 200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (product eluted with 2% MeOH in DCM) to give (9H-fluoren-9-yl)methyl 4-((2-(2-(cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate (15.5 g, yield: 57.00%) as a yellow solid. LCMS (Method A): 2.465 min, 2.508 min, MS: ES+ 1010.69 (M+1).

[0417] A solution of ((9H-fluoren-9-yl)methyl 4-((2-(2-(cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate (15.5 g, 15.3 mmol, 1.0 eq) in THF (150 mL) at room temperature was treated with DEA ​​(30.9 g, 306.9 mmol, 20 eq.) and stirred at room temperature for 16 hours. The resulting reaction mixture was concentrated under reduced pressure and the crude material was purified by flash column chromatography (product was eluted with 10% methanol in DCM) to give the title compound (7 g, yield: 58.3%) as a yellow solid.

[0418] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.81 - 0.88 (m, 2H), 0.99 - 1.07(m, 3H), 1.50 (s, br, 6H), 1.83 (s, 3H), 2.18 (d, J= 3.2 Hz, 3H), 2.33 (s, 3H), 2.56 (s, br, 4H), 3.05 (s, br, 4H), 3.17 (m, 1H), 3.51 (m, 2H), 4.40 (d, J= 14.4 Hz, 2H), 4.65 (d, J= 6.8 Hz, 2H), 6.69 (d, J= 39.2 Hz, 1H), 7.15 - 7.30 LCMS (Method A): 2.039 minutes, 2.090 minutes, MS: ES+ 788.3 (M+1).

[0419] (2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone: Intermediate 3 [ka]

[0420] A stirred solution of 5-(benzyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)-isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (0.3 g, 0.38 mmol, 1.0 eq.) in EtOH:HO (2:1) (7.5 mL) at room temperature was treated with KOH (0.860 g, 15.35 mmol, 40 eq.), and the reaction mixture was heated to 60 °C and stirred for 2 h. The resulting reaction mixture was slowly cooled to room temperature, poured into ice-cold water (50 mL), acidified using KHSO solution, and extracted with 20% MeOH:DCM (2 × 100 mL). The aqueous layer was then basified using saturated NaHCO solution and extracted with 20% MeOH:DCM (3 × 100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (0.2 g, quantitative yield) as an off-white solid.

[0421] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.57 - 1.58, m, 1H), 1.90 - 2.00 (m, 1H), 1.95 (s, 3H), 2.23 - 2.32 (m, 4H), 2.64 (s, br, 4H), 4.44 - 4.49 (m, 1H), 4.71 (bs, 4H), 4.87 - 4.89 (m, 1H), 6.24 (s, 1H), 7.15 - 7.16 (m, 2H), 7.22 - 7.31 (m, 4H), 7.34 - 7.36 (m, 2H), 9.75 (s, br, 2H). LCMS (Method A): 1.122 min, MS: ES+ 474.2.

[0422] 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)acetaldehyde: Intermediate 4 [ka]

[0423] 2-(2,6-dioxopiperidin-3-yl)-4-((1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)oxy)isoindoline-1,3-dione Five parallel reactions were carried out, each on a 1.0 g scale. 2-(2,6-Dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (1 g, 3.65 mmol, 1.0 eq.) (CAS: 5054-59-1), 1-phenyl-2,5,8,11-tetraoxatridecan-13-ol (1.14 g, 4.01 mmol, 1.1 eq.) (CAS: 86259-87-2), and triphenylphosphine (1.05 g, 4.00 mmol, 1.1 eq.) were taken in THF (10 mL) under a nitrogen atmosphere at room temperature. DIAD (98%) (0.96 g, 4.75 mmol, 1.3 eq.) was added dropwise, and the reaction mixture was stirred at room temperature for 16 h. The resulting reaction mixture was concentrated under reduced pressure and the crude material was purified by column chromatography (product was eluted in 1% methanol in DCM) to afford the title compound (7.0 g, yield: 70.9%).

[0424] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 2.00 - 2.03 (m, 1H), 2.55 - 2.67 (m, 1H), 2.84 - 2.89 (m, 1H), 3.39 - 3.41 (m, 1H), 3.46 - 3.52 (m, 4H), 3.53 - 3.55 (m, 6H), 3.62 - 3.65 (m, 2H), 3.78 - 3.80 (m, 2H), 4.32 - 4.34 (m, 2H), 4.47 - 4.48 (m, 2H), 5.06 - 5.10 (m, 1H), 7.26 - 7.35 (m, 6H), 7.45 (d, J= 7.2 Hz, 1H), 7.52 (d, J= 8.4 Hz, 1H), 7.78 - 7.80 (m, 1H), 11.10 (s, 1H). LCMS (Method A): 1.717 min, MS: ES+ 541.2 (M+1).

[0425] 2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)isoindoline-1,3-dione A stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-((1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)oxy)isoindoline-1,3-dione (7.0 g, 12.94 mmol, 1.0 eq.) in MeOH (70 mL) at room temperature was treated with 10% Pd / C (50% water) (7.0 g) and stirred under an atmosphere of H (g) for 2 h. The resulting reaction mixture was filtered through a bed of Celite using MeOH:DCM (1:1) (500 mL) and concentrated under reduced pressure. The resulting crude material (5.5 g) was purified by flash chromatography (4.4% methanol in DCM) to give the title compound (4.8 g, yield: 82.4%).

[0426] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 2.00 - 2.03 (m, 1H), 2.55 - 2.67 (m, 2H), 2.84 - 2.89 (m, 1H), 3.38 - 3.42 (m, 4H), 3.45 - 3.54 (m, 6H), 3.63 - 3.65 (m, 2H), 3.80 (s, br, 2H), 4.09 - 4.10 (m, 1H), 4.34 (s, br, 2H), 4.55 - 4.59 (m, 2H), 5.06 - 5.11 (m, 1H), 7.45 (d, J= 7.2 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.81 (t, J= 8.0 Hz, 1H), 11.10 (s, 1H). LCMS (Method A): 1.129 min, MS: ES+ 451.1 (M+1).

[0427] 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)acetaldehyde: Intermediate 4 A stirred solution of DMSO (0.607 g, 7.7 mmol, 3.5 eq) in DCM (3 mL) at −78° C. was treated dropwise with oxalyl chloride (0.6 g, 4.4 mmol, 1.0 eq.) in DCM (3 mL). The reaction mixture was allowed to stir at −78° C. for 10 minutes. 2-(2,6-Dioxopiperidin-3-yl)-4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)isoindoline-1,3-dione (1.0 g, 2.22 mmol, 1 eq) in DCM (3 mL) was added to the reaction mixture, which was stirred at −78° C. for 1 hour. TEA (1.34 g, 13.26 mmol, 6 eq) was added to the reaction mixture at −78° C. and stirred for an additional 1.5 hours. The resulting reaction mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction mixture was poured into ice-cold water (100 mL) and extracted with DCM (3 x 300 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (silica gel, eluting the product with 4.8% MeOH in DCM) to give the title compound (0.5 g, yield: 50.2%).

[0428] 1 H NMR (CDCl3, 400 MHz): δ ppm 2.13 - 2.16 (m, 1H), 2.72 - 2.93 (m, 3H), 3.68 - 3.75 (m, 6H), 3.80 - 3.82 (m, 2H), 3.95 - 3.97 (m, 2H), 4.17 - 4.18 (m, 2H), 4.36 - 4.38 (m, 2H), 4.94 - 4.99 (m, 1H), 7.28 (d, J= 7.2 Hz, 1H), 7.48 (d, J= 7.2 Hz, 1H), 7.69 (t, J= 8.4 Hz, 1H), 8.08 (s, 1H), 9.73 (s, 1H). LCMS (Method B: 6.884 min, MS: ES+ 466.4 (M+1).

[0429] 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate: Intermediate 5 [ka]

[0430] 2-(2,6-dioxopiperidin-3-yl)-5-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione 2-(2,6-Dioxo-3-piperidyl)-5-fluoro-isoindoline-1,3-dione (CAS: 835616-61-0; 1 eq.), 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol (CAS: 86770-74-3; 1.1 eq.), and DIPEA (3 eq.) in NMP (5 mL / g) were heated to 100 °C for 1 h. The mixture was cooled to ambient temperature and added to a 5% aqueous citric acid solution. The product was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. Purification by column chromatography (DCM / MeOH, 0–20% MeOH) afforded the title compound (30% yield) as a pale green solid.

[0431] 1 H NMR (CDCl3) δ: 8.02 (1H, s), 7.63 (1H, d, J = 8.3), 7.04 (1H, d, J = 2.1), 6.83 (1H, dd, J = 8.3, 2.1), 4.95 (1H, dd, J = 12.4, 5.2), 3.81 - 3.66 (15H, m), 3.42 (2H, t, J = 4.7), 2.96 - 2.67 (4H, m), 2.15 (1H, m). LCMS (Method T2) m / z (ES+): 450.3 [M+H + ] + , 472.3 [M+Na + ] + .

[0432] 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate: Intermediate 5 A stirred solution of 2-(2,6-dioxopiperidin-3-yl)-5-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-ethyl)amino)isoindoline-1,3-dione, TEA (3 eq), and DMAP (0.1 eq) in DCM (20 mL / mmol) at room temperature was treated with TsCl (1.2 eq), and the resulting mixture was stirred at room temperature overnight. Additional TsCl (0.6 eq), TEA (1.5 eq), and DMAP (0.1 eq) were added, and the mixture was stirred for 4 h. The mixture was washed with water, the aqueous extracted with DCM, the organic layers combined, washed with saturated aqueous NaHCO3 solution and brine, dried over anhydrous magnesium sulfate, and the solvent removed in vacuo. Purification by column chromatography (hexane / ethyl acetate 0–100% ethyl acetate) afforded the title compound (73% yield) as a clear oil.

[0433] 1 H NMR (CDCl3) δ: 7.98 (1H, s), 7.81 (2H, d, J = 8.5), 7.62 (1H, d, J = 8.4), 7.35 (2H, d, J = 8.5), 7.00 (1H, d, J = 2.1), 6.80 (1H, dd, J = 8.4, 2.1), 4.95 (1H, dd, J = 12.2, 5.2), 4.21 - 4.15 (2H, m), 3.80 - 3.60 (12H, m), 3.43 (2H, t, J = 5.3), 2.95 - 2.69 (4H, m), 2.46 (3H, s), 2.115 (1H, m). LCMS (Method T2) m / z (ES+): 604.2 [M+H + ] + , 626.2 [M+Na + ] + .

[0434] 3-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 6 [ka]

[0435] 3-[4-[2-[2-[2-(2-benzyloxyethoxy)ethoxy]ethoxy]ethoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione A stirred solution of 3-(4-hydroxy-1-oxo-isoindolin-2-yl)piperidine-2,6-dione (CAS: 1061604-41-8; 1 eq) in NMP (5.5 mL / mmol) was treated with 1-phenyl-2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (CAS: 89346-82-7; 1.2 eq), KHCO (2 eq), and KI (1 eq). The mixture was stirred at 110 °C overnight, then cooled to ambient temperature and added to saturated aqueous brine solution, and the product was extracted with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous magnesium sulfate, and the solvent removed in vacuo. Purification by column chromatography (DCM / acetone, 0–100% acetone) afforded the title compound (43% yield) as a yellow oil.

[0436] 1 H NMR (d6-DMSO) δ: 10.97 (1H, br, s), 7.48 (1H, t, J = 7.8), 7.38 - 7.23 (7H, m), 5.11 (1H, dd, J = 13.2, 5.1), 4.47 (2H, s), 4.36 (1H, d, J = 17.4), 4.26 - 4.16 (2H, m), 3.78 - 3.48 (13H, m), 2.94 (1H, m), 2.58 (1H, m), 2.43 (1H, m), 2.00 (1H, m). LCMS (Method T1) m / z (ES+): 527.3 [M+H + ] + , 549.3 [M+Na+ ] + .

[0437] 3-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 6 3-[4-[2-[2-[2-(2-benzyloxyethoxy)ethoxy]ethoxy]ethoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione was dissolved in ethanol (10 mL / mmol), degassed under vacuum, and the atmosphere was replaced with nitrogen. 10% Pd / C (10% wt / wt on a wet support) was added, degassed repeatedly, and the atmosphere was switched to hydrogen. The suspension was then stirred overnight at ambient temperature. The catalyst was removed by filtration, and the filtrate was concentrated to give the title compound (56% yield).

[0438] 1 H NMR (d6-DMSO) δ: 10.97 (1H, s), 7.49 (1H, d, J = 7.8), 7.32 (1H, d, J = 7.0), 7.27 (1H, d, J = 8.0), 5.12 (1H, dd, J = 13.2, 5.1), 4.56 (1H, t, J = 5.5), 4.38 (1H, d, J = 17.4), 4.30 - 4.20 (3H, m), 3.81 - 3.75 (2H, m), 3.63 - 3.57 (2H, m), 3.57 - 3.44 (8H, m), 3.42 - 3.37 (2H, m), 2.92 (1H, m), 2.59 (1H, m), 2.45 (1H, m), 2.00 (1H, m) LCMS (Method T1) m / z (ES+): 437.1 [M+H + ] + , 459.1 [M+Na + ] + .

[0439] 3-(4-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 7 [ka]

[0440] 3-(1-oxo-4-((1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)amino)isoindolin-2-yl)piperidine-2,6-dione 1-Phenyl-2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (CAS: 89346-82-7; 2.8 g), lenalidomide (CAS: 191732-72-6; 1.5 g), KI (0.96 g), and DIPEA (1.5 mL) in NMP (40 mL) were heated to 100 °C overnight. The solution was cooled and added to brine, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. Purification by column chromatography (DCM / MeOH, 0-10% MeOH) afforded the title compound (2.7 g) as a gray oil.

[0441] 1 H NMR (d6-DMSO) δ: 11.01 (1H, s), 7.41 - 7.26 (7H, m), 6.95 (1H, d, J = 7.7), 6.80 (1H, d, J = 7.7), 5.58 (1H, t, J = 5.7), 5.11 (1H, dd, J = 13.2, 5.1), 4.48 (2H, s), 4.23 (1H, d, J = 17.1), 4.12 (1H, d, J = 17.1), 3.65 - 3.27 (15H, m), 2.92 (1H, ddd, 18.9, 13.6, 5.4), 2.62 (1H, m), 2.30 (1H, ddd, 26.3, 8.8, 4.4) 2.03 (1H, m). LCMS (Method T1) m / z (ES+): 526.3 [M+H + ] + .

[0442] 3-(4-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 7 3-(1-Oxo-4-((1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)amino)isoindolin-2-yl)piperidine-2,6-dione was dissolved in ethanol (10 mL / mmol), degassed under vacuum, and the atmosphere replaced with nitrogen. 10% Pd / C (10% wt / wt on a wet support) was added, degassing repeated, and the atmosphere switched to hydrogen. The suspension was then stirred overnight at ambient temperature. The catalyst was removed by filtration, and the filtrate was concentrated to give the title compound (100% yield).

[0443] 1 H NMR (CDCl3) δ: 8.18 (1H, s), 7.36 (1H, t, J = 7.7), 7.28 (1H, m), 6.80 (1H, d, J = 7.7), 5.24 (1H, dd, J = 13.2, 5.2), 4.38 (1H, d, J = 15.9), 4.24 (1H, d, J = 15.9), 3.74 (2H, t, J = 5.0), 3.71 - 3.58 (12H, m), 3.46 - 3.34 (2H, m), 2.96 - 2.76 (2H, m), 2.37 (1H, m), 2.20 (1H, m). LCMS (Method T1) m / z (ES+): 436.2 [M+H + ] + .

[0444] 3-(5-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 8 [ka]

[0445] 3-(1-oxo-5-((1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)amino)isoindolin-2-yl)piperidine-2,6-dione A mixture of 1-phenyl-2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (CAS: 89346-82-7; 2.0 g), 3-(5-amino-1-oxo-isoindolin-2-yl)piperidine-2,6-dione (CAS 191732-70-4; 1.0 g), KI (0.64 g), and DIPEA (1 mL) in NMP (20 mL) was heated to 100 °C overnight. The solution was cooled and added to brine. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. Purification by column chromatography (DCM / MeOH, 0–10% MeOH) afforded the title compound (0.98 g, 48%) as a gray oil.

[0446] 1 H NMR (CDCl3) δ: 7.96 (1H, br, s), 7.66 (1H, d, J = 8.4), 7.38 - 7.29 (5H, s), 6.69 (1H, dd, J = 8.4, 2.0), 6.60 (1H, s), 5.20 (1H, dd, J = 13.6, 5.2), 4.58 (2H, s), 4.37 (1H, d, J = 15.6), 4.22 (1H, d, J = 15.6), 3.78 - 3.57 (15H, m), 3.36 (1H, t, J = 5.3), 2.96 - 2.76 (2H, m), 2.40 - 2.14 (2H, m). LCMS (Method T1) m / z (ES+): 526.3 [M+H + ] + .

[0447] 3-(5-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Intermediate 8 3-[5-[2-[2-[2-(2-benzyloxyethoxy)ethoxy]ethoxy]ethylamino]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione was dissolved in ethanol (10 mL / mmol), degassed under vacuum, and the atmosphere was replaced with nitrogen. 10% Pd / C (10% wt / wt on a wet support) was added, degassed repeatedly, and the atmosphere was switched to hydrogen. The suspension was then stirred overnight at ambient temperature. The catalyst was removed by filtration, and the filtrate was concentrated to give the title compound (86% yield).

[0448] 1 H NMR (CDCl3) δ: 8.31 (1H, s), 7.65 (1H, d, J = 8.4), 6.69 (1H, dd, J = 8.4, 2.0), 6.60 (1H m), 5.27 (1H, m), 5.19 (1H, dd, J = 13.2, 5.2), 4.36 (1H, d, J = 15.7), 4.22 (1H, d, J = 15.7), 3.79 - 3.62 (14H, m), 3.36 (2H, q, J = 4.7), 3.28 (1H, br, s), 2.94 - 2.76 (2H, m), 2.30 (1H, qd, J = 13.2, 5.2), 2.18 (1H, m). LCMS (Method T1) m / z (ES+): 436.3 [M+H + ] + , 458.2 [M+Na + ] + .

[0449] 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetaldehyde: Intermediate 9 Two parallel batches were carried out as follows: A stirred solution of DMSO (0.13 g, 1.72 mmol, 3.0 eq.) and DCM (1.5 mL) was treated dropwise with oxalyl chloride over a period of 15 minutes under a nitrogen atmosphere at −78° C. 3-(4-((2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 7) (0.25 g, 0.57 mmol, 1.0 eq.) and TEA (0.34 g, 3.44 mmol, 6.0 eq.) in DCM (1 mL) were added dropwise to the reaction mixture under a nitrogen atmosphere at −78° C. The resulting reaction mixture was stirred at room temperature for 1 hour. The resulting reaction mixture was concentrated under reduced pressure to give the title compound (0.2 g, 0.46 mmol), which was used without purification. LCMS (Method A): 1.042 min, 1.120 min, MS: ES+ 433.9 (M+1).

[0450] (2-(cyclohexyloxy)-4,6-dihydroxy-3-methylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone: Intermediate 10 [ka]

[0451] A stirred solution of 5-(cyclohexyloxy)-4-methyl-6-(5-(piperazin-1-ylmethyl)isoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (Intermediate 2) (1.1 g, 1.39 mmol, 1.0 eq.) in EtOH:water (11 mL) at room temperature was treated with aqueous KOH (3.13 g, 55.90 mmol, 40 eq. in minimal water). The resulting reaction mixture was heated to 60 °C, stirred for 2 h, cooled to room temperature, neutralized with dilute HCl (pH = 7), and extracted with ethyl acetate (3 × 150 mL) and 10% MeOH in DCM (3 × 150 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give the title compound (2.1 g, 80% yield).

[0452] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.94 - 0.98 (m, 2H), 1.07 -1.28 (m, 3H), 1.56 (s, br, 6H), 1.96 (s, 3H), 2.28 - 2.29 (m, 4H), 2.67 - 2.69 (m, 4H), 3.46 - 3.50 (m, 2H unclear due to water peak), 3.48 (m, 1H), 3.63 (t, J= 8.4 Hz, 1H), 4.47 - 4.48 (m, 2H), 4.69 (s, 2H), 6.24 (s, 1H), 7.18 (m, 3H), 7.19 -7.23 (m, 1H), 9.40 - 9.50 (m, 2H). LCMS (Method A): 1.303 min, MS: ES+ 480.1 (M+1).

[0453] t-Butyl 4-(2-(2-(2-oxoethoxy)ethoxy)ethoxy)piperidine-1-carboxylate: Intermediate 11 [ka]

[0454] 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate A solution of 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethan-1-ol (CAS: 55489-58-2) (10 g, 41.6 mmol, 1.0 eq.) in DCM (100 mL) at room temperature was treated with TEA (8.4 g, 83.3 mmol, 2 eq.), DMAP (0.5 g, 4.16 mmol, 0.1 eq.) and p-toluenesulfonyl chloride (7.9 g, 41.6 mmol, 1 eq.). The resulting reaction mixture was allowed to stir at room temperature for 2 hours, then filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (the product was eluted with 12% EtOAc in hexane) to give the title compound (12 g, yield: 73.1%) as a white solid.

[0455] 1H NMR (DMSO-d6, 400 MHz): δ ppm 2.41 (s, 3H), 3.45 - 3.47 (m, 4H), 3.53 (s, 4H), 3.55 - 3.58 (m, 2H), 4.09 - 4.12 (m, 2H), 4.48 - 4.49 (m, 2H), 7.28 - 7.36 (m, 5H), 7.47 (d, J= 8 Hz, 2H), 7.78 (d, J= 6.8 Hz, 2H). LCMS (Method A): 2.182 min, MS: ES+ 394.9 (M+1)

[0456] t-Butyl 4-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)piperidine-1-carboxylate A solution of t-butyl 4-hydroxypiperidine-1-carboxylate (5.6 g, 27.9 mmol, 1.1 eq.) (CAS: 108489-19-2) in DMF (100 mL) at 0 °C was treated with NaH (60% in mineral oil) (1.52 g, 38.0 mmol, 1.5 eq.) and stirred for 45 min. 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (10 g, 25.3 mmol, 1.0 eq.) was added, and the resulting reaction mixture was heated to 60 °C and stirred for 16 h. The resulting reaction mixture was poured into ice-cold water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with cold brine solution (3 × 200 mL), dried over Na SO , filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (product was eluted with 20% EtOAc in hexanes) to give the title compound (7 g, yield: 65.2%).

[0457] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.25 - 1.34 (m, 2H), 1.38 (s, 9H), 1.74 - 1.79 (m, 2H), 2.98 (s, br, 2H), 3.42 - 3.47 (m, 1H), 3.50 - 3.53 (m, 8H), 3.61 - 3.64 (m, 6H), 4.49 (s, 2H), 7.26 - 7.37 (m, 5H). LCMS (Method A): 2.142 min, MS: ES+ 323.8 (M-100).

[0458] t-Butyl 4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)piperidine-1-carboxylate A solution of tert-butyl 4-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)piperidine-1-carboxylate (6.8 g, 16.07 mmol, 1.0 eq.) in MeOH (70 mL) in an autoclave at room temperature was treated with Pd / C (6.8 g) (W / W)). 3 A pressure of H gas was added at room temperature, and the resulting reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through a bed of Celite, which was washed with 20% MeOH in DCM (400 mL). The resulting filtrate was concentrated under reduced pressure to give the title compound (4 g, yield: 74.7%) as a colorless liquid.

[0459] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.28 - 1.34 (m, 2H), 1.39 (s, 9H), 1.75 - 1.79 (m, 2H), 2.98 (s, br, 2H), 3.34 - 3.41 (m, 3H), 3.43 - 3.49 (m, 3H), 3.51 - 3.54 (m, 7H), 3.49 - 3.65 (m, 2H), 4.58 (t, J= 5.2 Hz, 1H, D2O exchangeable).

[0460] t-Butyl 4-(2-(2-(2-oxoethoxy)ethoxy)ethoxy)piperidine-1-carboxylate: Intermediate 11 A stirred solution of DMSO (0.81 g, 10.5 mmol, 3.5 eq.) in DCM (7 mL) at −78° C. was treated dropwise with oxalyl chloride (1.13 g, 9.0 mmol, 3.0 eq.) in DCM (3 mL) and stirred for 10 min. t-Butyl 4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)piperidine-1-carboxylate (1.0 g, 3.0 mmol, 1 eq.) in DCM was slowly added to the reaction mixture, which was then stirred at −78° C. for 1 h. TEA (1.81 g, 18.0 mmol, 6 eq.) was added dropwise to the reaction mixture, which was then stirred at −78° C. for 3 h. The reaction mixture was diluted with water (80 mL) and extracted with DCM (3 × 80 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (product was eluted with 3% MeOH in DCM) to give the title compound (0.9 g, yield: 45.3% l) as a colorless sticky solid.

[0461] 1 H NMR (CDCl3, 400 MHz): δ ppm 1.46 (s, 9H), 1.49 - 1.53 (m, 3H), 1.83 - 1.85 (m, 2H), 3.06 (t, J= 4 Hz, 2H), 3.60 - 3.72 (m, 7H), 3.72 - 4.18 (m 5H), 9.74 (s, 1H).

[0462] 2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindoline-5-carboxylic acid: intermediate 12 [ka]

[0463] A stirred solution of 2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid (Intermediate 16) (1.2 g, 2.06 mmol, 1.0 eq.) in DMF (12 mL) under a nitrogen atmosphere at 0 °C was treated with HATU (1.17 g, 3.09 mmol, 1.5 eq.) and DIPEA (0.53 g, 4.12 mmol, 2.0 eq.) and stirred for 15 min. Methyl isoindoline-5-carboxylate hydrochloride (0.48 g, 0.22 mmol, 1.1 eq.) was added to the reaction mixture, which was then stirred at 0 °C for 1 h. The resulting reaction mixture was diluted with ethyl acetate (120 mL) and washed with cold brine solution (3 × 100 mL). The organic layer was dried over Na SO , filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (product eluted with 0.8% methanol in DCM) to give methyl 2-(2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoyl)isoindoline-5-carboxylate (0.95 g, yield: 62%), which was used directly in the next step. LCMS (Method A): 2.992 min, 3.014 min, MS: ES+ 742.2 (M+1).

[0464] A stirred solution of methyl 2-(2-(benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoyl)isoindoline-5-carboxylate (0.95 g, 1.28 mmol, 1.0 eq.) in EtOH:water (1:1) (9.5 mL) at room temperature was treated with aqueous NaOH (0.51 g, 12.82 mmol, 10 eq. in 0.5 mL of water). The resulting reaction mixture was heated to 90° C., stirred for 2 h, cooled to room temperature, poured into ice-cold water (125 mL), neutralized with dilute HCl (to pH 7), and extracted with ethyl acetate (4×100 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material was triturated with n-pentane (3×30 mL) followed by drying to give the title compound (0.45 g, yield: 84%). LCMS (Method A): 1.555 min, MS: ES+ 420.2 (M+1).

[0465] 2-(2,6-Dioxopiperidin-3-yl)-5-((14-hydroxy-3,6,9,12-tetraoxatetradecyl)amino)isoindoline-1,3-dione: Intermediate 13 [ka]

[0466] Two parallel batches were prepared as follows: A stirred solution of 1-phenyl-2,5,8,11,14-pentaoxahexadecan-16-amine (CAS 86770-77-6) (6.25 g, 19.08 mmol, 1 eq.), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (6.33 g, 22.93 mmol, 1.2 eq.) (CAS: 835616-61-0) in DMF (62.5 mL, 10 v) at room temperature was treated with DIPEA (24.65 g, 191.08 mmol, 10 eq.). The resulting reaction mixture was heated to 100 °C and stirred for 16 h, then cooled, poured into ice-cold water (500 mL), and extracted with ethyl acetate (3 × 1000 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (eluting the product with 1% MeOH in DCM) to give 2-(2,6-dioxopiperidin-3-yl)-5-((1-phenyl-2,5,8,11,14-pentaoxahexadecan-16-yl)amino)isoindoline-1,3-dione (14 g, yield: 62.7%, 23.98 mmol) as a pale green oil.

[0467] 1H NMR (DMSO-d6, 400 MHz): δ ppm 3.49 - 3.51 (m, 10H), 3.55 (s, 9H), 4.48 (d, J= 4.8 Hz, 2H), 5.02 - 5.04 (m, 1H), 6.89 (d, J= 8.4 Hz, 1H), 7.00 (s, 1H), 7.16 (d, J= 5.2 Hz, 1H), 7.27 - 7.36 (m, 6H), 7.56 (d, J= 8.4 Hz, 1H), 11.07 (s, 1H). LCMS (Method A): 1.767 min, MS: ES+ 584.0 (M+1).

[0468] A stirred solution of 2-(2,6-dioxopiperidin-3-yl)-5-((1-phenyl-2,5,8,11,14-pentaoxahexadecan-16-yl)amino)isoindoline-1,3-dione (11.0 g, 18.85 mmol, 1 eq.) in EtOH (100 mL) at room temperature was treated with Pd / C (10% water) (10 g, 100% w / w) and HCl (1 mL). The resulting reaction mixture was stirred under an atmosphere of H2(g) for 4 h. The reaction mixture was filtered through a bed of Celite using 10% MeOH / DCM (1000 mL) and concentrated under vacuum. The crude material was purified using flash chromatography (eluting the product with 3% MeOH / DCM) to afford the title compound (7.0 g, 75.38% yield) as a yellow oil.

[0469] 1H NMR (DMSO-d6, 400 MHz): δ ppm. 1.95 - 2.05 (m, 2H), 2.80 - 2.92 (m, 2H), 3.40 - 3.43 (m, 2H), 3.46 - 3.49 (m, 4H), 3.51 - 3.53 (m, 8H), 3.56 - 3.58 (m, 3H), 3.59 - 3.61 (m, 3H), 4.58 (t, J= 5.2 Hz, 1H), 5.01 - 5.05 (m, 1H), 6.88 - 6.91 (dd, J= 2 Hz 1H), 7.00 (d, J= 1.6 Hz, 1H), 7.17 (t, J= 5.6 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 11.07 (s, 1H). LCMS (Method A): 1.189 min, MS: ES+ 493.8 (M+1).

[0470] 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride: Intermediate 14 [ka]

[0471] 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione Methyl 4-bromo-2-(bromomethyl)benzoate (20.0 g, 64.93 mmol, 1.0 eq.) (CAS: 78471-43-9) and 3-aminopiperidine-2,6-dione hydrochloride (15.97 g, 97.40 mmol, 1.5 eq.) (CAS: 24666-56-6) in MeCN (160 mL) at room temperature were treated dropwise with DIPEA (25.2 g, 194.80 mmol, 3 eq.). The resulting reaction mixture was heated to 80 °C and stirred for 48 h. The reaction mixture was filtered, and the solid precipitate was washed with ACN (50 mL). The solid material was further dried under high vacuum to give the title compound (17.5 g, yield: 83.0%) as a light blue solid.

[0472] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.90 - 2.08 (m, 1H), 2.34 - 2.45 (m, 1H), 2.57 - 2.62 (m, 1H), 2.86 - 2.95 (m, 1H), 4.32 - 4.49 (m, 2H), 5.10 - 5.14 (m, 1H), 7.66 - 7.74 (m, 2H), 7.90 (s, 1H), 11.02 (s, 1H). LCMS (Method A): 1.357 min, MS: ES+ 322.9, 324.8 (M+2).

[0473] t-Butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate A stirred solution of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (13.0 g, 40.37 mmol, 1.0 eq.), t-butyl piperazine-1-carboxylate (9.76 g, 52.48 mmol, 1.3 eq.) (CAS: 57260-71-6) and CsCO (39.46 g, 121.12 mmol, 3.0 eq.) in dioxane (130 mL) was heated under N 2(g) The mixture was purged with HCl for 15 minutes. Pd-PEPPSI-Ipent (1.59 g, 2.02 mmol, 0.05 eq.) (CAS: 1158652-41-5) was added at room temperature, and the resulting reaction mixture was heated to 90° C. and stirred for 4.5 hours. The reaction mixture was cooled, poured into water (100 mL), and extracted with ethyl acetate (4×100 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude material was purified by flash followed by reverse-phase chromatography to give the title compound (6.4 g, yield: 37%) as an off-white solid.

[0474] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.46 (s, 9H), 1.95 - 1.97 (m, 1H), 2.33 - 2.42 (m, 1H), 2.56 - 2.60 (m, 1H), 2.86 - 2.95 (m, 1H), 3.27 - 3.40 (s, br, 4H), 3.41 - 3.47 (s, br, 4H), 4.19 - 4.36 (m, 2H), 5.03 - 5.08 (m, 1H), 7.06 - 7.09 (m, 2H), 7.54 (d, J= 8.4 Hz, 1H), 10.96 (s, 1H). LCMS (Method A): 1.616 minutes, MS: ES+ 429.1 (M+1).

[0475] 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride: Intermediate 14 A stirred solution of t-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (2.5 g, 5.84 mmol, 1 eq.) in DCM (25 mL) was cooled to 0° C. and treated dropwise with 4 M HCl in dioxane (25 mL). The reaction mixture was stirred at room temperature for 1 h, concentrated in vacuo, and the isolated crude material was triturated with diethyl ether (25 mL) followed by n-pentane (25 mL). The resulting solid material was dried under high vacuum to give the title compound (2.5 g, quantitative) as an off-white solid.

[0476] 1H NMR (DMSO-d6, 400 MHz, D2O exchange): δ ppm 1.95 - 1.99 (m, 1H), 2.33 - 2.36 (m, 1H), 2.51 - 2.56 (m, 1H), 2.86 - 2.95 (m, 1H), 3.21 (s, br, LCMS (Method A): 0.651 min, MS: ES+ 328.9 (M+1)

[0477] 2-(Cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzoic acid: Intermediate 15 [ka]

[0478] A stirred solution of 2-(cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde (Intermediate 18) (1.5 g, 4.26 mmol, 1 eq.) in THF:t-BuOH (1:3) (15 mL) at room temperature was treated with saturated aqueous NaClO (1.16 g, 12.78 mmol, 3 eq.) and NaHPO (3.07 g, 25.58 mmol, 6 eq.) and 2-methyl-2-butene (5.96 g, 85.14 mmol, 20 eq.). The reaction mixture was stirred at room temperature for 1 h, then poured into ice-cold water (100 mL) and extracted with diethyl ether (3 × 100 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give the title compound (2 g, 95%).

[0479] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.00 - 1.10 (m, 2H), 1.11 (s, 5H), 1.13 - 1.16 (m, 1H), 1.17 - 1.18 (m, 2H), 1.21 - 1.26 (m, 2H), 1.64 - 1.79 (m, 6H), 2.02 (s, 3H), 3.35 - 3.36 (m, 3H), 3.38 (s, 3H), 3.63 (d, J= 6.0 Hz, 2H), 5.15 (s, 2H), 5.21 (s, 2H), 6.67 (s, 1H), 12.78 (s, 1H)._LCMS (Method A): 2.252 minutes, MS: ES+ 369.0 (M+1).

[0480] 2-(Benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid: Intermediate 16 [ka]

[0481] 2-Methylbenzene-1,3,5-triol Six batches were run in parallel. A stirred solution of 2,4,6-trihydroxybenzaldehyde (CAS: 487-70-7; 40 g, 260 mmol, 1 eq) in THF (800 mL) at room temperature was treated with NaBHCN (81.61 g, 1298 mmol, 5 eq). The resulting reaction mixture was slowly cooled to 0 °C, and 2 N HCl solution (400 mL) was added dropwise to the reaction mixture at 0 °C. The resulting reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo; the crude material was poured into water (5 L) and extracted with ethyl acetate (3 × 4 L). The combined organic layers were dried over NaSO and concentrated in vacuo. The crude material was purified by column chromatography (the product was eluted in 5% MeOH in DCM) to give the title compound (112 g, yield: 51%) as an off-white solid.

[0482] 1H NMR (DMSO-d6, 400 MHz): δ ppm 1.81 (s, 3H), 5.77 (s, 2H), 8.69 (s, 1H), 8.81 (s, 2H). LCMS (Method A): 0.636 min, MS: ES+ 140.8 (M+1).

[0483] 2,4,6-trihydroxy-3-methylbenzaldehyde Two batches were carried out in parallel. A stirred solution of 2-methylbenzene-1,3,5-triol (25 g, 178.6 mmol, 1 eq) in DMF (250 mL) was cooled to 0 °C. POCl (30.11 g, 196.37 mmol, 1.1 eq) was added dropwise at 0 °C, and the resulting reaction mixture was stirred at room temperature for 2 h. The reaction mixture was poured into ice-cold water (2 L) and extracted with ethyl acetate (4 × 2.2 L). The combined organic layers were dried over Na SO and concentrated in vacuo; the crude material was purified by column chromatography (the product was eluted in 3% MeOH in DCM) to give the title compound (40 g, yield: 70%) as an off-white solid.

[0484] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.88 (s, 3H), 6.00 (s, 1H), 9.94 (s, 1H), 10.55 (s, 1H), 10.63 (s, 1H), 12.33 (s, 1H). LCMS (Method A): 1.285 minutes, MS: ES+ 168.8 (M+1).

[0485] 4-Formyl-5-hydroxy-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) Four parallel batches were run. A stirred solution of 2,4,6-trihydroxy-3-methylbenzaldehyde (10 g, 59.88 mmol, 1 eq) in acetone (200 mL) at room temperature was treated with K2CO3 (24.79 g, 179.37 mmol, 3 eq). The resulting reaction mixture was allowed to stir at room temperature for 15–20 min. p-Toluenesulfonyl chloride (17.10 g, 89.78 mmol, 1.5 eq) was then added at room temperature. The reaction mixture was heated to 60 °C and stirred for 5 h, then concentrated under reduced pressure, poured into water (2 L), and extracted with ethyl acetate (3 × 2.2 L). The combined organic layers were dried over Na2SO4 and concentrated under vacuum. The crude material was purified by column chromatography (the product was eluted in 10% EtOAc in hexanes) to give the title compound (16 g, 14% yield, 33.57 mmol) as a pale yellow solid.

[0486] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.76 (s, 3H), 2.43 (s, 3H), 2.45 (s, 3H), 6.44 (s, 1H), 7.50 - 7.52 (m, 4H), 7.75 (d, J= 8 Hz, 2H), 7.79 (d, J= 8 Hz, 2H), 9.85 (s, 1H), 11.8 (bs, 1H). LCMS (Method A): 2.591 min, MS: ES+ 476.5 (M+1).

[0487] 5-(benzyloxy)-4-formyl-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 4-formyl-5-hydroxy-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (16 g, 33.61 mmol, 1 eq) in DMF (160 mL) at 0 °C was treated with K2CO3 (13.93 g, 100.79 mmol, 3 eq) followed by benzyl bromide (6.33 g, 37.03 mmol, 1.10 eq). The resulting reaction mixture was stirred at room temperature for 16 h, then poured into water (800 mL) and extracted with ethyl acetate (3 × 500 mL). The combined organic layers were washed with brine (2 × 800 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (the product was eluted in 16% EtOAc in hexanes) to give the title compound (16 g, 84% yield) as an off-white solid.

[0488] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.82 (s, 3H), 2.44 (s, 3H), 2.46 (s, 3H), 4.81 (s, 2H), 6.76 (s, 1H), 7.31 - 7.38 (m, 5H), 7.52 (t, J= 8.8 Hz, 4H), 7.71 - 7.77 (m, 4H), 9.87 (m, 1H). LCMS (Method A): 2.699 min, MS: ES+ 588.9 (M+23).

[0489] 2-(Benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid: Intermediate 16 A stirred solution of 5-(benzyloxy)-4-formyl-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (16 g, 28.26 mmol, 1 eq) in MeCN:water (1:1) (160 mL) at room temperature was treated with NaClO (9.45 g, 104.47 mmol, 3.7 eq) and NaHPO (6.78 g, 56.5 mmol, 2 eq). The resulting reaction mixture was stirred at room temperature for 16 hours, then concentrated in vacuo, poured into water (500 mL), acidified with dilute HCl (pH 6.0), and extracted with ethyl acetate (3 × 350 mL). The combined organic layers were dried over NaSO and concentrated in vacuo; the crude material was purified by column chromatography (eluting the product in 30% EtOAc in hexane) to give the title compound (17 g, 97% yield) as an off-white solid.

[0490] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.85 (s, 3H), 2.45 (s, br, 6H), 4.81 (s, 2H), 6.75 (s, 1H), 7.33 - 7.40 (m, 5H), 7.50 - 7.53 (m, 4H), 7.72 - 7.75 (m, 4H), 13.75 (bs, 1H). LCMS (Method A): 2.43 min, MS: ES+ 582.6 (M+1).

[0491] 2-(Cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid: Intermediate 17 [ka]

[0492] 5-(cyclohexylmethoxy)-4-formyl-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 4-formyl-5-hydroxy-6-methyl-1,3-phenylene-bis(4-methylbenzenesulfonate) (described in the preparation of Intermediate 16) (2.0 g, 4.19 mmol, 1.0 eq.) in DMF (20 mL) at 0 °C was treated with KCO (2.89 g, 20.9 mmol, 5.0 eq.) and bromomethylcyclohexane (1.11 g, 6.29 mmol, 1.5 eq.) and stirred for 10 min. The reaction mixture was heated to 60 °C and stirred for 16 h. The reaction mixture was poured into ice-cold water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted with 12% ethyl acetate in hexane) to give the title compound (1.4 g, yield: 58.3%).

[0493] 1 H NMR (DMSO-d6, 400 MHz): The compound is a mixture of rotamers: δ 0.97 - 1.00 (m, 2H), 1.11 - 1.26 (m, 3H), 1.67 - 1.73 (m, 5H), 1.77 and 1.83 (singlet, 3H), 2.33 - 2.45 (singlet, 6H), 3.49 and 3.70 (m, 2H), 5.77 (s, 1H), 6.44 and 6.70 (singlet, 1H), 7.48 - 7.53 (m, 4H), 7.71 - 7.81 (m, 4H), 9.86 and 9.90 (singlet, 1H). LCMS (Method D): 3.250 min, MS: ES+ 573.13 (M+1).

[0494] 2-(Cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid: Intermediate 17 A solution of 5-(cyclohexylmethoxy)-4-formyl-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (1.4 g, 2.44 mmol, 1.0 eq.) in MeCN:water (1:1) (15 mL) at room temperature was treated with NaH2PO4 (1.02 g, 8.55 mmol, 3.5 eq.) and NaClO2 (1.10 g, 12.22 mmol, 5.0 eq.) and stirred for 16 h. The mixture was evaporated, and the crude material was diluted with water (30 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (eluting the product using 15% ethyl acetate in hexane) to give the title compound (0.950 g, yield: 66.4%).

[0495] 1 H NMR (DMSO-d6, 400 MHz): δ0.95 - 1.10 (m, 2H), 1.11- 1.22 (m, 3H), 1.61 - 1.69 (m, 6H), 1.82 (s, br, 3H), 2.44 (s, br, 6H), 3.54 (m, br, 2H), 4.03 (q, J= 6.8 Hz, 14.0 Hz, 2H), 6.69 (s, 1H), 7.49 - 7.52 (m, 4H), 7.70 - 7.73 (m, 4H), 13.59 (s, 1H). LCMS (Method E): 2.657 minutes, MS: ES+ 589.2 (M+1).

[0496] 2-(Cyclohexylmethoxy)-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde (Intermediate 18) [ka]

[0497] 2-Hydroxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde A stirred solution of 2,4,6-trihydroxy-3-methylbenzaldehyde (described in the preparation of Intermediate 16) (5 g, 29.76 mmol, 1 eq.) in DCM (50 mL) at 0 °C was treated with DIPEA (19.19 g, 148.76 mmol, 5 eq.) and stirred for 5 min. MOM-Cl (7.18 g, 89.18 mmol, 3 eq.) was added to the reaction mixture at 0 °C, and the reaction mixture was stirred at room temperature for 30 min. It was then poured into ice-cold water (100 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted in 100% hexane) to give the title compound (5.8 g, yield: 76.13%) as a yellow sticky solid.

[0498] 1 H NMR (DMSO-d6, 400 MHz, D2O exchange): δ ppm 1.95 (s, 3H), 3.44 (s, 3H), 3.48 (s, 3H), 5.31 - 5.33 (m, 4H), 6.43 (s, 1H), 10.1 (s, 1H) LCMS (Method A): 1.864 minutes, 1.972 minutes, MS: ES+ 256.8 (M+1).

[0499] 2-(Cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzaldehyde A stirred solution of 2-hydroxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde (5.0 g, 19.53 mmol, 1 eq.) in DMF (50 mL) at room temperature was treated with K2CO3 (13.47 g, 97.61 mmol, 5 eq.). The reaction mixture was stirred at room temperature for 5 minutes, and then bromomethylcyclohexane (CAS: 2550-36-8) (4.49 g, 25.36 mmol, 1.3 eq.) and KI (0.324 g, 1.95 mmol, 0.1 eq.) were added. The resulting reaction mixture was heated to 110 °C and stirred for 4 hours, then cooled, poured into ice-cold water (500 mL), extracted with ethyl acetate (3 × 500 mL), and the combined organic layers were washed with ice-cold water (3 × 100 mL). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (product was eluted with 40% ethyl acetate in hexane) to give the title compound (3 g, yield: 43.6%) as a red sticky solid.

[0500] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 1.12 - 1.28 (m, 5H), 1.64 - 1.84 (m, 6H), 2.03 (s, 3H), 3.44 (s, 6H), 3.46 (d, J= 5.6 Hz, 2H), 3.60 (d, LCMS (Method A): 2.577 min, 2.464 min, MS: ES+ 352.9 (M+1).

[0501] PROTAC screening protocol using SW620 human colorectal cancer cells SW620 cells (ATCC / CCL-2227) were cultured in T75 Falcon flasks in culture medium (F12 / DMEM 1:1 medium, 10% FCS, +LG supplement). Cells were split twice weekly for up to 6 weeks. The medium was aspirated and the cells were washed with 10 mL of sterile PBS. The PBS was aspirated and the cells were incubated with 1.5 mL of TrypLE at 37°C and 5% CO2 for up to 5 minutes. Once the cells detached, the TrypLE was neutralized with 10 mL of culture medium, and the cells were mixed 1:1 with trypan blue and quantified using a Luna cell counter. The cells were then transferred to a new T75 flask at 1 x 10 6 The cells were seeded with 10 mL culture medium.

[0502] Using SW620 cells cultured and counted as described above, 1.5 x 10 cells were plated in a 12-well plate. 5 Cells were seeded at a density of 1000 cells / well and incubated overnight at 37°C, 5% CO2. Test compounds were solubilized in DMSO to a stock concentration of 10 mM and serially diluted to their test concentrations in DMSO and medium; the final DMSO concentration was 0.1% (v / v). Each concentration was tested in triplicate. SW620 cells were incubated with the test compounds for 24 hours at 37°C, 5% CO2. The medium was aspirated from each well, and each well was washed with 1 mL of ice-cold PBS. The PBS was then aspirated, and 50 μL of cold lysis buffer (RIPA buffer supplemented with 1x protease inhibitors, benzonase, and MgCl2) was added to each well; the plate was then incubated on ice for 5 minutes. Cells were scraped using a pipette tip and transferred to a new Eppendorf tube. The samples were spun at maximum speed in a benchtop centrifuge at 4°C for 5 minutes, and the supernatant was then transferred to a new tube. Samples were stored at -80°C until analysis.

[0503] Bicinchoninic acid (BCA) protein assay standards (2–0.125 mg / mL BSA) were prepared in advance. 6 μL of each standard was pipetted in duplicate into rows A and B of a 384-well assay plate. Test samples were diluted in duplicate (1:3–1:10) into lysis buffer in the 384-well plate. BCA reagent was combined 50:1 (part A:part B) and 50 μL was added to each well. The plate was incubated at 37°C in a plate incubator for 30 minutes and then read using the BCA protein 384 protocol on an EnSpire plate reader. Protein concentrations were calculated from the standard curve.

[0504] JESS Western Blot Protocol Protein lysates were prepared using Protein Simple EZ standard pack reagents: 40 μL distilled HO was added to the DTT tube (clear), treated with 20 μL 10x sample buffer, 20 μL DTT was added to the 5x MM tube (pink), and 20 μL dHO was added to the biotinylated ladder tube (green).

[0505] Test samples were prepared by diluting them to the required concentration (0.1 mg / mL) in 0.1x sample buffer. 1.25 μL of 5x fluorescent master mix from the EZ standard pack was added to 5 μL of sample for each lane loaded (e.g., 2.5 μL + 10 μL if the same sample was loaded into two wells). Samples were vortexed, briefly spun down, heated to 95°C for 5 minutes in a PCR instrument, and then vortexed again, briefly spun down, and loaded onto a JESS cassette (catalog number: SM-W004) according to the manufacturer's instructions (https: / / www.proteinsimple.com / technical_library.html?product=simplewestern&def_list=list). Protein expression was determined by the peak area of ​​the target protein signal. The peak area of ​​the target protein was normalized to the peak area of ​​the loading control (actin) and to the DMSO control.

[0506] The data obtained in this assay are shown in Table A1 below:

[0507] JPEG2024541578000074.jpg252170JPEG2024541578000075.jpg255169JPEG2024541578 000076.jpg255165JPEG2024541578000077.jpg255168JPEG2024541578000078.jpg61170

[0508] Upon further testing, the assay yielded the following data, which are shown below in Table A2:

[0509] JPEG2024541578000079.jpg99170

Claims

1. The compound of formula (I) shown below: 【Chemistry 1】 [In the formula, R 2 is hydrogen or fluoro; R 4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl, (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl, said (1-6C)alkyl being selected from one or more R 5a and said (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b each R 5a is independently selected from halogen or (1-4C)alkoxy; 5b is independently selected from the group consisting of halogen, (1-4C)alkyl and (1-4C)alkoxy; R 6 is a (1-6C)alkyl, (3-8C)cycloalkyl, or a 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O or S; or a group having a structure according to formula (A) shown below: 【Chemistry 2】 (In the formula, R 7 is hydrogen or (1-3C)alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; A 1 is N, CH or CR 11 Selected from: A 2 is N, CH or CR 12 Selected from: A 4 is N, CH or CR 14 Selected from: However, A 1 , A 2 Or A 4 Only one or two of may be N; R 11 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 11 is -(CHR o ) h -Z 11 (In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 is -OR 15 , -NR 16 R 17 , -C(O)NR 16 R 17 Or -NR 18 C(O)R 19 and R 15 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-7C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-7C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, j is 0 or 1; Or R 16 and R 17 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 6-membered heterocyclic ring; R 18 is hydrogen or (1-2C)alkyl; R 19 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-7C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], R l is hydrogen or methyl, k is 0 or 1; R 15 , R 16 , R 17 , R 18 Or R 19 Or R 16 and R 17 Each of any rings formed when a and optionally substituted with R 12 is fluoro; R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 (In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 is -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 Or -NR 33 C(O)R 34 and R 30 is (1-4C)alkyl, (3-7C)cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1; Or R 31 and R 32 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C)alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when the are linked may be one or more R a and optionally substituted with Each R a is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, or (1-4C)alkyl; L is a linker; Q is an E3 ubiquitin ligase-binding moiety, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

2. 1. Compounds of formula I, I-II, I-III, I-IV, IV, I-VI I-VII, I-VIII, I-IX, I-X, I-XI, I-XII, I-XIII, I-XIV or I-XV, as shown below: 【Chemistry 3-1】 【Chemistry 3-2】 【Chemistry 3-3】 【Chemistry 3-4】 【Chemistry 3-5】 [In the formula, R 4 , R 6 , A 1 , A 2 , L and Q are each as defined in claim 1; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

3. R 6 is (1-6C)alkyl, (3-6C)cycloalkyl, or a 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O or S; or a group having a structure according to formula (A) shown below: 【Chemistry 4】 [In the formula, R 7 is hydrogen or (1-3C)alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.

4. R 6 is a (1-4C)alkyl, a 4- to 6-membered heterocyclyl ring or a group having a structure according to formula (A) shown below: 【Chemistry 5】 [In the formula, R 7 is hydrogen or (1-2C)alkyl; n is 1 or 2; R 8 is (3-6C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.

5. R 6 is a (1-3C)alkyl, a 4- to 6-membered heterocyclyl ring or a group having a structure according to formula (A) shown below: 【Chemistry 6】 [In the formula, R 7 is hydrogen or methyl; n is 1; R 8 is cyclohexyl, phenyl, 6-membered heterocyclyl, or 6-membered heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.

6. R 6 is a 4- to 6-membered heterocyclyl ring or a group having a structure according to formula (A) shown below: 【Chemistry 7】 [In the formula, R 7 is hydrogen or methyl; n is 1; R 8 is cyclohexyl, phenyl, 6-membered heterocyclyl, or pyridyl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.

7. R 6 is a group having a structure according to formula (A) shown below: 【Chemistry 8】 [In the formula, R 7 is hydrogen; n is 1; R 8 is cyclohexyl or phenyl; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

8. A 2 , A 3 Or A 4 but the following options: (i) A 1 is N, CH or CR 11 Selected from: A 2 is N, CH or CR 12 Selected from: A 4 is N, CH or CR 14 Selected from: However, A 1 , A 2 Or A 4 Only one of may be N. (ii) A 1 is N, CH or CR 11 Selected from: A 2 is N, CH or CR 12 Selected from: A 4 is selected from N or CH; However, A 1 , A 2 Or A 4 Only one of may be N; (iv) A 1 is selected from N or CH; A 2 is N, CH or CR 12 Selected from: A 4 is selected from N or CH; However, A 2 , A 3 Or A 4 Only one of may be N; (v) A 1 is N, CH or CR 11 Selected from: A 2 is selected from N or CH; A 4 is selected from N or CH; However, A 1 , A 2 Or A 4 Only one of may be N; (vi) A 1 is CH; A 2 is CH; A 4 is CH; (vi) A 1 is CH; A 2 is CH or CR 12 and A 4 is CH; (vii) A 1 is CH or CR 11 and A 2 is CH; A 4 is CH; or (viii) A 1 is CH; A 2 is CH; A 4 is CH or CR 14 is 8. The compound according to any one of claims 1 to 7, selected from one of:

9. A 1 , A 2 Or A 4 or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

10. 10. The compound of any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein Q is a small molecule or peptide E3 ubiquitin ligase-binding moiety.

11. Q: von Hippel-Lindau (VHL); cereblon, XIAP, E3A; MDM2; anaphase-promoting complex; EIBR5 (EDDI); SOCS / BC-box / eloBC / CUL5 / RING; LNXp80; CBX4; CBLL1; HACE1; HECTD1; HECTD2; HECTD3; HECW1; HECW2; HERC1; HERC2; HERC3; HERC4; HUWE1; ITCH; NEDD4; NEDD4L; PPIL2; PRPF19; PIAS1; PIAS2; PIAS3; PIAS4; RANBP2; RNF4; RBX1; SMURF 1;SMURF2;STUB1;TOPORS;TRIP 12;UBE3A;UBE3B;UBE3C;UBE4A;UBE4B;UBOXS;UBR5;WWP1;WWP2;Parkin;A20 / TNFAIP3;AMFR / gp78;ARA54;beta-TrCP1 / BTRC;BRCA1;CBL;CHIP / STUB 1;E6;E6AP / UBE3A;F-box protein 15 / FBX015;FBXW7 / Cdc4;GR AIL / RNF 128; HOIP / RNF31; cIAP-l / HIAP-2; cIAP-2 / HIAP-l; cIAP(pan); ITCH / AIP4; KAP1; MARCH8,, Mind Bomb 1 / MIB1; Mind Bomb 2 / MIB2; MuRF 11. The compound of any one of claims 1 to 10, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, which is an E3 ubiquitin ligase-binding moiety capable of binding an E3 ubiquitin ligase selected from the group consisting of: 1 / TRIM63; NDFIP1; NEDD4; NleL; Parkin; RNF2; RNF4; RNF8; RNF168; RNF43; SART1; Skp2; SMURF2; TRAF-1; TRAF-2; TRAF-3; TRAF-4; TRAF-5; TRAF-6; TRIMS; TRIM21; TRIM32; UBR5; and ZNRF3.

12. 12. The compound of any one of claims 1 to 11, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein Q is an E3 ubiquitin ligase-binding moiety capable of binding an E3 ubiquitin ligase selected from the group consisting of: von Hippel-Lindau (VHL); or cereblon.

13. 13. The compound of any one of claims 1 to 12, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein Q is selected from thalidomide, pomalidomide, lenalidomide, VHL ligand, methyl-bestatin, or nutlin.

14. 14. The compound of any one of claims 1 to 13, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein Q is selected from thalidomide, pomalidomide, lenalidomide or a VHL ligand.

15. Q: 【Chemistry 9-1】 【Chemistry 9-2】 [In the formula, 【Chemistry 10】 represents the point of attachment to L; R q is hydrogen or fluoro; R VHL is cyclopropyl optionally substituted with fluoro; X 2 is -CH 2 - or -C(O)-; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

16. 16. The compound of any one of claims 1 to 15, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker comprising from 5 to 30 chain atoms.

17. 17. The compound of any one of claims 1 to 16, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker comprising from 10 to 25 chain atoms.

18. L is of the formula: -X L1 -A L1 -R L1 -X L2 -A L2 -X L3 -R L2 -A L3 -X L4 - * [In the formula, * represents the point of connection with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-15C) alkylene, -(CH 2 ) a1 -[O-CH 2 CH 2 ] a2 - or -[O-CH 2 CH 2 ] a2 - (CH 2 ) a1 - and R L1 does not exist, or: 【Chemistry 11】 (In the formula, Y L1 is CH or N; R L3 and R L4 is selected from H or methyl, or R L3 and R L4 are linked to form a piperidinyl or piperazinyl ring, optionally substituted with halo; X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -; or Y L1 is CH, then X L2 is -O-, NR XL2 , -C(O)-, -C(O)NR XL2 Or -NR XL2 C(O)-; R XL2 is hydrogen or methyl; A L2 is absent, or (1-15C) alkylene, -(CH 2 ) a3 -[O-CH 2 CH 2 ] a4 - or -[O-CH 2 CH 2 ] a4 - (CH 2 ) a3 - and X L3 is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: 【Chemistry 12】 (In the formula, Y L2 and Y L3 are each independently CH or N; R L3 and R L4 is selected from H or methyl, or R L3 and R L4 are linked to form a piperidinyl or piperazinyl ring, optionally substituted with halo; A L3 is absent, or (1-15C) alkylene, -(CH 2 ) a5 -[O-CH 2 CH 2 ] a6 - or -[O-CH 2 CH 2 ] a6 - (CH 2 ) a5 - and X L4 is absent, or -O-, -C(O)-, -C(O)NR XL4 -or-NR XL4 C(O)- or (2-4C)alkynyl; R XL4 is hydrogen or methyl; Integers a1, a3 and a5 are each independently 1 to 4; and integers a2, a4 and a6 are each independently 1 to 7; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

19. L is of the formula: -X L1 -A L1 -R L1 -X L2 -A L2 -X L3 -R L2 -A L3 -X L4 - * [In the formula, * represents the point of connection with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-10C) alkylene, -(CH 2 ) a1 -[O-CH 2 CH 2 ] a2 - or -[O-CH 2 CH 2 ] a2 - (CH 2 ) a1 - and R L1 does not exist, or: 【Chemistry 13】 (In the formula, Y L1 is CH or N; X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -; or Y L1 is CH, then X L2 is -O-, NR XL2 , -C(O)-, -C(O)NR XL2 Or -NR XL2 C(O)-; R XL2 is hydrogen or methyl; A L2 is absent, or (1-10C) alkylene, -(CH 2 ) a3 -[O-CH 2 CH 2 ] a4 - or -[O-CH 2 CH 2 ] a4 - (CH 2 ) a3 - and X L3 is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: 【Chemistry 14】 (In the formula, Y L2 and Y L3 are each independently CH or N; A L3 is absent, or (1-10C) alkylene, -(CH 2 ) a5 -[O-CH 2 CH 2 ] a6 - or -[O-CH 2 CH 2 ] a6 - (CH 2 ) a5 - and X L4 is absent, or -O-, -C(O)-, -C(O)NR XL4 -or-NR XL4 C(O)- or (2-4C)alkynyl; R XL4 is hydrogen or methyl; Integers a1, a3 and a5 are each independently 1 to 3; and integers a2, a4 and a6 are each independently 1 to 6. [0034] A compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

20. L is of the formula: -X L1 -A L1 -R L1 -X L2 -A L2 -X L3 -R L2 - * [In the formula, * represents the point of connection with Q; X L1 is absent, or -O-, NR XL1 , -C(O)-, -C(O)NR XL1 -or-NR XL1 C(O)-; R XL1 is hydrogen or methyl; A L1 is absent, or (1-10C) alkylene, -(CH 2 ) a1 -[O-CH 2 CH 2 ] a2 - or -[O-CH 2 CH 2 ] a2 - (CH 2 ) a1 - and R L1 does not exist, or: 【Chemistry 15】 (In the formula, Y L1 is CH or N; X L2 does not exist or Y L1 If N, then X L2 is -C(O)- or -C(O)NR XL2 -; or Y L1 is CH, then X L2 is -O-, NR XL2 , -C(O)-, -C(O)NR XL2 Or -NR XL2 C(O)-; R XL2 is hydrogen or methyl; A L2 is absent, or (1-10C) alkylene, -(CH 2 ) a3 -[O-CH 2 CH 2 ] a4 - or -[O-CH 2 CH 2 ] a4 - (CH 2 ) a3 - and X L3 is absent, or -O-, NR XL3 , -C(O)-, -C(O)NR XL3 -or-NR XL3 C(O)- or (2-4C)alkynyl; R XL3 is hydrogen or methyl; R L2 does not exist, or: 【Chemistry 16】 (In the formula, Y L2 and Y L3 are each independently CH or N; Integers a1 and a3 are each independently 1 to 3; and integers a2 and a4 are each independently 1 to 6. The compound of any one of claims 1 to 19, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

21. R 11 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 11 But -(CHR o ) h -Z 11 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 11 is -OR 15 , -NR 16 R 17 or -C(O)NR 16 R 17 and R 15 is (1-4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR n ) i -[4- to 6-membered heterocyclyl], R n is hydrogen or methyl, and i is 0 or 1; R 16 and R 17 is hydrogen, (1-6C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, or -(CHR m ) j -[4- to 6-membered heterocyclyl]; R m is hydrogen or methyl, j is 0 or 1; Or R 16 and R 17 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 8-membered heterocyclic ring; R 15 , R 16 , R 17 Or R 16 and R 17 Each of any rings formed when a optionally substituted with; R a or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

22. (i) R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or (ii) R 14 But -(CHR k ) m -Z 14 [In the formula, R k is hydrogen; m is 0 or 1; Z 12 is -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 Or -NR 33 C(O)R 34 and R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, -(CHR j ) o -(3-7C)cycloalkyl, or -(CHR j ) o -[4- to 6-membered heterocyclyl], R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, -(CHR i ) p -(3-7C)cycloalkyl, or -(CHR i ) p -[4- to 6-membered heterocyclyl]; R i is hydrogen or methyl, and p is 0 or 1; Or R 31 and R 32 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen or methyl; R 34 is (1-6C) alkyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, -(CHR h ) q -(3-7C)cycloalkyl, or -(CHR h ) q -[4- to 6-membered heterocyclyl], R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 Or R 34 , or R 31 and R 32 Any ring formed when the are linked may be one or more R a optionally substituted with; R a is as defined in claim 1; or (ii) R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

23. The compound is selected from the group consisting of: 4-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((14-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((17-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((14-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-((17-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 5-((2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 3-(4-(2-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(4-((2-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-((2-(2-(2-(2-(2-(4-((2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 4-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 3-[4-[2-[2-[2-[2-[2-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethylamino]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 5-[4-[2-[2-[2-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]oxy]ethoxy]ethoxy]ethyl]piperazin-1-yl]-2-(2,6-dioxo-3-piperidyl)-6-fluoro-isoindoline-1,3-dione 5-[2-[2-[2-[2-[2-[2-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 3-[5-[4-[2-[1-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]-4-piperidyl]acetyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 3-[5-[4-[1-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperidine-4-carbonyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 3-[5-[4-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 5-[4-[[1-[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindoline-5-carbonyl]-4-piperidyl]methyl]piperazin-1-yl]-2-(2,6-dioxo-3-piperidyl)-6-fluoro-isoindoline-1,3-dione (2S,4R)-1-[(2S)-2-[[11-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]-11-oxo-undecanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[8-[4-[[2-(2-benzyloxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-5-yl]methyl]piperazin-1-yl]-8-oxo-octanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[7-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-7-oxo-heptanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[8-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-8-oxo-octanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[9-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-9-oxo-nonanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[10-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-10-oxo-decanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-[[11-[4-[[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]methyl]piperazin-1-yl]-11-oxo-undecanoyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide 23. The compound according to any one of claims 1 to 22, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, selected from any one of:

24. 24. A pharmaceutical composition comprising a compound, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, according to any one of claims 1 to 23 in admixture with a pharma- ceutically acceptable diluent or carrier.

25. (i) for use in therapy; (ii) for use in the treatment of cancer; (iii) for use in the treatment of cancer, wherein the compound or pharmaceutical composition is administered in combination with another anti-cancer agent (e.g. a chemotherapeutic agent, an immune checkpoint inhibitor, an immunostimulant, or a DNA damage repair modulator); (iv) for use in the treatment of a triplet repeat disorder, 25. A compound according to any one of claims 1 to 23, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 24.